University of California San Francisco

Surgical Oncology Research

surg-onc-banner-group
UCSF Surgical Oncology Research
surg-onc-banner-group
UCSF Surgical Oncology Research

The UCSF Division of Surgical Oncology spearheads a diverse portfolio of multidisciplinary research initiatives encompassing basic and translational science, surgical services improvements, and health outcomes research. The Surgical Oncology Division faculty and their research interests are highlighted below.

Mohamed Adam 144x192
Mohamed Abdelgadir Adam, MD

Assistant Professor of Surgery 
Division of Surgical Oncology

Section:
HPB-GISS
Research Interests

Leveraging translational artificial intelligence and machine learning algorithms to optimize treatment of gastrointestinal tumors

Research Type:
Basic Biomedical and Translational
Clinical Discovery and Health Services
Disease focus:
GI Tumors
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 8
  1. ASO Visual Abstract: Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy-A Data-Driven, Machine Learning Approach to Augment Clinical Judgement.
    Adam MA, Zhou H, Byrd J, Greenberg AL, Kelly YM, Hall L, Jones HL, Pingpank JF, Lipton ZC, Bartlett DL, Choudry HM| | PubMed
  2. Predicting Severe Complications from Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: A Data-Driven, Machine Learning Approach to Augment Clinical Judgment.
    Adam MA, Zhou H, Byrd J, Greenberg AL, Kelly YM, Hall L, Jones HL, Pingpank JF, Lipton ZC, Bartlett DL, Choudry HM| | PubMed
  3. Disparities in access to care among patients with appendiceal or colorectal cancer and peritoneal metastases: A medicare insurance-based study in the United States.
    Aquina CT, Brown ZJ, Beane JD, Ejaz A, Cloyd JM, Eng OS, Monson JRT, Ruff SM, Kasumova GG, Adam MO, Obeng-Gyasi S, Pawlik TM, Kim AC| | PubMed
  4. Disparities in Care Access to Liver-Directed Therapy Among Medicare Beneficiaries with Colorectal Cancer Liver Metastasis.
    Aquina CT, Brown ZJ, Beane JD, Ejaz A, Cloyd JM, Tsung A, Adam MO, Pawlik TM, Kim AC| | PubMed
  5. Neoadjuvant Therapy Versus Upfront Resection for Nonpancreatic Periampullary Adenocarcinoma.
    Adam MA, Glencer A, AlMasri S, Winters S, Bahary N, Singhi A, Lee KK, Paniccia A, Zureikat AH| | PubMed
  6. ASO Author Reflections: Neoadjuvant Therapy for Nonpancreatic Periampullary Adenocarcinoma.
    Adam MA, Glencer AC, Zureikat AH| | PubMed
  7. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
    Adam MA, Paniccia A| | PubMed
  8. Development of stability-indicating methods for cefquinome sulphate.
    Shantier SW, Gadkariem EA, Adam MO, Mohamed MA| | PubMed
Kimberly Badal headshot 144x192
Kimberly Badal, PhD

Assistant Professor of Surgery
Division of Surgical Oncology

Section:
Breast Surgery
Research Interests

Computational biology, machine learning, and patient navigation

Research Type:
Basic Biomedical and Translational
Disease focus:
Breast oncology
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 13
  1. National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling.
    Badal K, Staib J, Tice JA, Kim MO, Eklund M, Wilson L, Dacosta Byfield S, Catlett K, Maffey L, Soonavala R, Shieh Y, Esserman LJ| | PubMed
  2. Guiding principles for the responsible development of artificial intelligence tools for healthcare.
    Badal K, Lee CM, Esserman LJ| | PubMed
  3. Falling down the biological rabbit hole: Epstein-Barr virus, biography, and multiple sclerosis.
    Horwitz RI, Hayes-Conroy A, Singer BH, Cullen MR, Badal K, Sim I| | PubMed
  4. The Repository for Caribbean Cancer Publications (ReCCaP): Database Development and Publication Trends 2004-2019.
    Badal K, Moore M, Thomas M| | PubMed
  5. Factors associated with breast cancer recurrence and survival at Sangre Grande Hospital, Trinidad.
    Badal K, Ali R, Warner WA, Maniam A, Carrington A, Foster JE, Haraksingh R| | PubMed
  6. Developing a patient navigation training program for the Caribbean context
    Badal K, Marcelline E, Ashing K| | UCSF Research Profile
  7. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.
    de Taeye SW, Go EP, Sliepen K, de la Peña AT, Badal K, Medina-Ramírez M, Lee WH, Desaire H, Wilson IA, Moore JP, Ward AB, Sanders RW| | PubMed
  8. Cancer incidence and mortality rates and trends in Trinidad and Tobago.
    Warner WA, Lee TY, Badal K, Williams TM, Bajracharya S, Sundaram V, Bascombe NA, Maharaj R, Lamont-Greene M, Roach A, Bondy M, Ellis MJ, Rebbeck TR, Slovacek S, Luo J, Toriola AT, Llanos AAM| | PubMed
  9. Xenin is a novel anorexigen in goldfish (Carassius auratus).
    Kerbel B, Badal K, Sundarrajan L, Blanco A, Unniappan S| | PubMed
  10. The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world.
    Warner WA, Lee TY, Fang F, Llanos AAM, Bajracharya S, Sundaram V, Badal K, Sookdeo VD, Roach V, Lamont-Greene M, Ragin C, Slovacek S, Ramsoobhag K, Brown J, Rebbeck TR, Maharaj R, Drake BF| | PubMed
  11. A situational analysis of breast cancer early detection services in Trinidad and Tobago.
    Badal K, Rampersad F, Warner WA, Toriola AT, Mohammed H, Scheffel HA, Ali R, Moosoodeen M, Konduru S, Russel A, Haraksingh R| | PubMed
  12. Perspectives in Bioethics: Precision Medicine a Threat to Health Equity
    Roach A, Badal K, Sookar N| | UCSF Research Profile
  13. Molecular Characterisation of Chikungunya Virus Infections in Trinidad and Comparison of Clinical and Laboratory Features with Dengue and Other Acute Febrile Cases.
    Sahadeo N, Mohammed H, Allicock OM, Auguste AJ, Widen SG, Badal K, Pulchan K, Foster JE, Weaver SC, Carrington CV| | PubMed
Amrita Basu small
Amrita Basu, PhD

Associate Professor of Surgery
Division of Surgical Oncology

Section:
Breast Surgery
Research Interests

Applying machine-learning computational methods leveraging genomic and clinical data to develop predictive models for early detection of cancer lesions and progression to metastatic disease

Research Type:
Basic Biomedical and Translational
Disease focus:
Predictive models of breast cancer detection and treatment response
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 22
  1. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A| | PubMed
  2. The "PRO"mise and "PRO"gress of PROs in cancer clinical trials.
    Basu A, Hershman DL| | PubMed
  3. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  4. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
    Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME| | PubMed
  5. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM| | PubMed
  6. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M| | PubMed
  7. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A| | PubMed
  8. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  9. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ| | PubMed
  10. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium| | PubMed
  11. ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress.
    Teng YC, Sundaresan A, O'Hara R, Gant VU, Li M, Martire S, Warshaw JN, Basu A, Banaszynski LA| | PubMed
  12. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A| | PubMed
  13. Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
    Matthys MB, Dempsey AM, Melisko ME, Dreher N, Che ML, Van't Veer LJ, Esserman LJ, Basu A| | PubMed
  14. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
    Basu A, Philip EJ, Dewitt B, Hanmer J, Chattopadhyay A, Yau C, Melisko ME, Esserman LJ| | PubMed
  15. Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes.
    Barnholtz-Sloan JS, Rollison DE, Basu A, Borowsky AD, Bui A, DiGiovanna J, Garcia-Closas M, Genkinger JM, Gerke T, Induni M, Lacey JV, Mirel L, Permuth JB, Saltz J, Shenkman EA, Ulrich CM, Zheng WJ, Nadaf S, Kibbe WA| | PubMed
  16. Call for Data Standardization: Lessons Learned and Recommendations in an Imaging Study.
    Basu A, Warzel D, Eftekhari A, Kirby JS, Freymann J, Knable J, Sharma A, Jacobs P| | PubMed
  17. RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines.
    Basu A, Mitra R, Liu H, Schreiber SL, Clemons PA| | PubMed
  18. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules.
    Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, Ebright RY, Stewart ML, Ito D, Wang S, Bracha AL, Liefeld T, Wawer M, Gilbert JC, Wilson AJ, Stransky N, Kryukov GV, Dancik V, Barretina J, Garraway LA, Hon CS, Munoz B, Bittker JA, Stockwell BR, Khabele D, Stern AM, Clemons PA, Shamji AF, Schreiber SL| | PubMed
  19. mChIP-KAT-MS, a method to map protein interactions and acetylation sites for lysine acetyltransferases.
    Mitchell L, Huard S, Cotrut M, Pourhanifeh-Lemeri R, Steunou AL, Hamza A, Lambert JP, Zhou H, Ning Z, Basu A, Côté J, Figeys DA, Baetz K| | PubMed
  20. Computational prediction of lysine acetylation proteome-wide.
    Basu A| | PubMed
  21. Proteome-wide prediction of acetylation substrates.
    Basu A, Rose KL, Zhang J, Beavis RC, Ueberheide B, Garcia BA, Chait B, Zhao Y, Hunt DF, Segal E, Allis CD, Hake SB| | PubMed
  22. Polycomb Group proteins: an evolutionary perspective.
    Whitcomb SJ, Basu A, Allis CD, Bernstein E| | PubMed
Michael Campbell headshot
Michael J. Campbell, PhD

Professor of Surgery
Division of Surgical Oncology

Section:
Breast Surgery
Research Interests

Biomarkers and imaging methods, and other determinants of outcomes related to breast neoplasms, cancer vaccines, and targeted immunotherapies

Research Type:
Basic Biomedical and Translational
Disease focus:
Breast cancer biomarkers
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 59
  1. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L| | PubMed
  2. Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
    McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ| | PubMed
  3. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  4. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L| | PubMed
  5. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF| | PubMed
  6. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI| | PubMed
  7. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM| | PubMed
  8. Adrenal Neoplasms: Lessons from Adrenal Multidisciplinary Tumor Boards.
    Chung R, Garratt J, Remer EM, Navin P, Blake MA, Taffel MT, Hackett CE, Sharbidre KG, Tu W, Low G, Bara M, Carney BW, Corwin MT, Campbell MJ, Lee JT, Lee CY, Dueber JC, Shehata MA, Caoili EM, Schieda N, Elsayes KM| | PubMed
  9. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  10. Limited disease progression in endocrine surgery patients with treatment delays due to COVID-19.
    Collins RA, DiGennaro C, Beninato T, Gartland RM, Chaves N, Broekhuis JM, Reddy L, Lee J, Deimiller A, Alterio MM, Campbell MJ, Lee YJ, Khilnani TK, Stewart LA, O'Brien MA, Alvarado MVY, Zheng F, McAneny D, Liou R, McManus C, Dream SY, Wang TS, Yen TW, Alhefdhi A, Finnerty BM, Fahey TJ, Graves CE, Laird AM, Nehs MA, Drake FT, Lee JA, McHenry CR, James BC, Pasieka JL, Kuo JH, Lubitz CC| | PubMed
  11. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ| | PubMed
  12. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
    Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ| | PubMed
  13. Germline genetic contribution to the immune landscape of cancer.
    Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D| | PubMed
  14. Adrenal Tumors Found During Staging and Surveillance for Colorectal Cancer: Benign Incidentalomas or Metastatic Disease?
    Yanagisawa M, Malik DG, Loehfelm TW, Fananapazir G, Corwin MT, Campbell MJ| | PubMed
  15. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C| | PubMed
  16. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L| | PubMed
  17. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ| | PubMed
  18. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ| | PubMed
  19. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ| | PubMed
  20. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ| | PubMed
  21. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ| | PubMed
  22. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
    Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ| | PubMed
  23. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ| | PubMed
  24. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID| | PubMed
  25. Breast cancer growth prevention by statins.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC| | PubMed
  26. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM| | PubMed
  27. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
    Kumar AS, Campbell M, Benz CC, Esserman LJ| | PubMed
  28. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
    Gable KL, Maddux BA, Penaranda C, Zavodovskaya M, Campbell MJ, Lobo M, Robinson L, Schow S, Kerner JA, Goldfine ID, Youngren JF| | PubMed
  29. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID| | PubMed
  30. In vitro anticancer activity of twelve Chinese medicinal herbs.
    Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ| | PubMed
  31. Immune dysfunction and micrometastases in women with breast cancer.
    Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ| | PubMed
  32. Tid1, the human homologue of a Drosophila tumor suppressor, reduces the malignant activity of ErbB-2 in carcinoma cells.
    Kim SW, Chao TH, Xiang R, Lo JF, Campbell MJ, Fearns C, Lee JD| | PubMed
  33. Reduction of MTT by aqueous herbal extracts in the absence of cells.
    Shoemaker M, Cohen I, Campbell M| | PubMed
  34. Antiproliferative activity of Chinese medicinal herbs on breast cancer cells in vitro.
    Campbell MJ, Hamilton B, Shoemaker M, Tagliaferri M, Cohen I, Tripathy D| | PubMed
  35. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ, Wollish WS, Lobo M, Esserman LJ| | PubMed
  36. Ductal growth is impeded in mammary glands of C-neu transgenic mice.
    Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G| | PubMed
  37. Biological therapies for breast carcinoma: concepts for improvement in survival.
    Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM| | PubMed
  38. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ| | PubMed
  39. Clinical trials of idiotype-specific vaccine in B-cell lymphomas.
    Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R| | PubMed
  40. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.
    Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R| | PubMed
  41. Tumor resistance induced by syngeneic bone marrow transplantation and enhanced by interleukin 2: a model for the graft versus leukemia reaction.
    Kwak LW, Campbell MJ, Levy R| | PubMed
  42. Interleukin 3 is a growth factor for human follicular B cell lymphoma.
    Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM| | PubMed
  43. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire.
    Campbell MJ, Zelenetz AD, Levy S, Levy R| | PubMed
  44. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R| | PubMed
  45. Ig VH gene expression among human follicular lymphomas.
    Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R| | PubMed
  46. Follicular lymphoma: a model of lymphoid tumor progression in man.
    Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S| | PubMed
  47. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW, Campbell M, Levy R| | PubMed
  48. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
    Kwak LW, Campbell MJ, Zelenetz AD, Levy R| | PubMed
  49. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  50. Idiotypic variation in a human B lymphoma cell line.
    Berinstein N, Campbell MJ, Lam K, Carswell C, Levy S, Levy R| | PubMed
  51. Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line.
    Levy S, Campbell MJ, Levy R| | PubMed
  52. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  53. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
    Campbell MJ, Esserman L, Levy R| | PubMed
  54. Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.
    Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC| | PubMed
  55. Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.
    Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R| | PubMed
  56. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
    Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R| | PubMed
  57. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses.
    Lowder JN, Meeker TC, Campbell M, Garcia CF, Gralow J, Miller RA, Warnke R, Levy R| | PubMed
  58. Influence of avidity and idiotope recognition on the modulation of surface immunoglobulin on malignant human B cells by rat monoclonal anti-idiotype antibodies.
    Campbell M, Bieber M, Levy R, Teng NN| | PubMed
  59. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R| | PubMed
Dr. Duh Primary
Quan-Yang Duh, MD

Professor of Surgery
Division of Surgical Oncology 
Chief, Section of Endocrine Surgery

Section:
Endocrine Surgery
Research Interests

Development of novel methods and surgical approaches for the treatment of patients with thyroid, parathyroid, adrenal, and gastrointestinal tumors

Research Type:
Basic Biomedical and Translational
Clinical Discovery and Health Services
Disease focus:
Tumors of the thyroid, parathyroid, adrenal glands
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 437
  1. Improving Intraoperative Parathyroid Hormone Specimen Handling and Processing.
    Murgatroyd J, Wagner LM, Duh QY| | PubMed
  2. Editorial: 2023 symposium on parathyroid fluorescence.
    Di Meglio I, Balasubramanian SP, Cha RJ, Duh QY, Lorenz K, Mahadevan-Jansen A, Triponez F| | PubMed
  3. Nerve monitoring in endocrine surgery: Practice patterns differ among surgeons for parathyroidectomy and thyroidectomy.
    Conroy PC, Wilhelm A, Rajwani T, Mulder M, Gosnell J, Shen WT, Duh QY, Roman S, Sosa JA| | PubMed
  4. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.
    Taïeb D, Nölting S, Perrier ND, Fassnacht M, Carrasquillo JA, Grossman AB, Clifton-Bligh R, Wanna GB, Schwam ZG, Amar L, Bourdeau I, Casey RT, Crona J, Deal CL, Del Rivero J, Duh QY, Eisenhofer G, Fojo T, Ghayee HK, Gimenez-Roqueplo AP, Gill AJ, Hicks R, Imperiale A, Jha A, Kerstens MN, de Krijger RR, Lacroix A, Lazurova I, Lin FI, Lussey-Lepoutre C, Maher ER, Mete O, Naruse M, Nilubol N, Robledo M, Sebag F, Shah NS, Tanabe A, Thompson GB, Timmers HJLM, Widimsky J, Young WJ, Meuter L, Lenders JWM, Pacak K| | PubMed
  5. Invited commentary Dr. Janice Pasieka and pheochromocytoma.
    Duh QY| | PubMed
  6. Magic Pen?-An Innovative Adjunct for Intraoperative Identification of Parathyroid Glands.
    Mulder MB, Duh QY| | PubMed
  7. Somatic and Germline Mutations in Atypical Parathyroid Tumors.
    Ullmann TM, Mulder M, Davis S, Rajwani T, Khanafshar E, Duh QY| | PubMed
  8. Challenges and controversies in adrenal surgery: A practical approach.
    Beninato T, Duh QY, Long KL, Kiernan CM, Miller BS, Patel S, Randle RW, Wachtel H, Zanocco KA, Zern NK, Drake FT| | PubMed
  9. Reflecting on Thirty Years of Experience With Active Surveillance for Papillary Thyroid Microcarcinoma.
    Mulder MB, Duh QY| | PubMed
  10. Emerging Imaging Technologies for Parathyroid Gland Identification and Vascular Assessment in Thyroid Surgery: A Review From the American Head and Neck Society Endocrine Surgery Section.
    Silver Karcioglu AL, Triponez F, Solórzano CC, Iwata AJ, Abdelhamid Ahmed AH, Almquist M, Angelos P, Benmiloud F, Berber E, Bergenfelz A, Cha J, Colaianni CA, Davies L, Duh QY, Hartl D, Kandil E, Kim WW, Kopp PA, Liddy W, Mahadevan-Jansen A, Lee KD, Mannstadt M, McMullen CP, Shonka DC, Shin JJ, Singer MC, Slough CM, Stack BC, Tearney G, Thomas G, Tolley N, Vidal-Fortuny J, Randolph GW| | PubMed
  11. Is Lobectomy as Effective as Total Thyroidectomy in Treating Patients With Intermediate-Risk Papillary Thyroid Carcinoma With Lateral Lymph Node Metastasis?
    Mulder MB, Duh QY| | PubMed
  12. Recovery After Thyroid and Parathyroid Surgery: How Do Our Patients Really Feel?
    Lee WG, Gosnell JE, Shen WT, Duh QY, Suh I, Chen Y| | PubMed
  13. A multicenter evaluation of near-infrared autofluorescence imaging of parathyroid glands in thyroid and parathyroid surgery.
    Sehnem L, Noureldine SI, Avci S, Isiktas G, Elshamy M, Saito Y, Ahmed AHA, Tierney HT, Trinh LN, Karcioglu AS, Cheung AY, Otremba M, Krishnamurthy V, Heiden K, Jin J, Shin J, Siperstein A, Zafereo M, Tufano RP, Randolph GW, Kebebew E, Milas M, Duh QY, Berber E| | PubMed
  14. Surgical Aspects of Primary Hyperparathyroidism.
    Perrier N, Lang BH, Farias LCB, Poch LL, Sywak M, Almquist M, Vriens MR, Yeh MW, Shariq O, Duh QY, Yeh R, Vu T, LiVolsi V, Sitges-Serra A| | PubMed
  15. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary.
    Yip L, Duh QY, Wachtel H, Jimenez C, Sturgeon C, Lee C, Velázquez-Fernández D, Berber E, Hammer GD, Bancos I, Lee JA, Marko J, Morris-Wiseman LF, Hughes MS, Livhits MJ, Han MA, Smith PW, Wilhelm S, Asa SL, Fahey TJ, McKenzie TJ, Strong VE, Perrier ND| | PubMed
  16. Innovations in Parathyroid Localization Imaging.
    Graves CE, Duh QY, Suh I| | PubMed
  17. Endocrine surgeons are performing more thyroid lobectomies for low-risk differentiated thyroid cancer since the 2015 ATA guidelines.
    Conroy PC, Wilhelm A, Calthorpe L, Ullmann TM, Davis S, Huang CY, Shen WT, Gosnell J, Duh QY, Roman S, Sosa JA| | PubMed
  18. Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.
    Randolph GW, Sosa JA, Hao Y, Angell TE, Shonka DC, LiVolsi VA, Ladenson PW, Blevins TC, Duh QY, Ghossein R, Harrell M, Patel KN, Shanik MH, Traweek ST, Walsh PS, Yeh MW, Abdelhamid Ahmed AH, Ho AS, Wong RJ, Klopper JP, Huang J, Kennedy GC, Kloos RT, Sadow PM| | PubMed
  19. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
    Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, Iagaru A, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S| | PubMed
  20. Isolated Lateral Neck Nodal Metastases in Patients With Papillary Thyroid Cancer: Does Cervical Compartment Matter?
    Ullmann TM, Duh QY| | PubMed
  21. Near-infrared Autofluorescence Features of Parathyroid Carcinoma.
    Merrill AL, Sims SS, Dedhia PH, Rossfeld K, Lott Limbach A, Duh QY, Phay JE| | PubMed
  22. Proceedings From the Advances in Surgery Channel Diversity, Equity, and Inclusion Series: Lessons Learned From Asian Academic Surgeons.
    Wang TS, Kim ES, Duh QY, Gosain A, Kao LS, Kothari AN, Tsai S, Tseng JF, Tsung A, Wang KS, Wexner SD| | PubMed
  23. Effects of Multi-stage Procurement on the Viability and Function of Human Donor Parathyroid Glands.
    Kelly YM, Ward C, Zhang R, Syed S, Stock PG, Duh QY, Sosa JA, Koh J| | PubMed
  24. Autofluorescence and Artificial Intelligence: The Future of Parathyroid Surgery?
    Duh QY, Davis SN| | PubMed
  25. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    Greenberg AL, Sullins VF, Donahue TR, Sundaram VM, Saldinger PF, Divino CM, Anton NE, Stefanidis D, Reilly LM, Egan RJ, Beals CKJ, Riall TS, Duh QY, Mukhtar RA, Hirose K, Lebares CC| | PubMed
  26. Procurement of Deceased Donor Parathyroid Glands With the Aid of Near-infrared Autofluorescence Imaging.
    Ward CJ, Kelly YM, Syed SM, Meier RPH, Ando T, Wisel SA, Gardner JM, Stock PG, Duh QY| | PubMed
  27. Invited Commentary: Intraoperative Percutaneous Ultrasound Examination of the Larynx: A New Adjunct to Intraoperative Recurrent Laryngeal Nerve Monitoring.
    Duh QY| | PubMed
  28. Anxiety During the COVID-19 Pandemic: A Web-Based Survey of Thyroid Cancer Survivors.
    Graves CE, Goyal N, Levin A, Nuño MA, Kim J, Campbell MJ, Shen WT, Gosnell JE, Roman SA, Sosa JA, Duh QY, Suh I| | PubMed
  29. Evaluation of Necrosis as a Diagnostic and Prognostic Indicator in Adrenocortical Carcinoma.
    Pearlstein SS, Conroy PC, Menut KC, Kim J, Graves CE, Ruiz-Cordero R, Duh QY| | PubMed
  30. Ex Vivo Intact Tissue Analysis Reveals Alternative Calcium-sensing Behaviors in Parathyroid Adenomas.
    Koh J, Zhang R, Roman S, Duh QY, Gosnell J, Shen W, Suh I, Sosa JA| | PubMed
  31. Practice Patterns and Learning Curve in Transoral Endoscopic Thyroidectomy Vestibular Approach With Neuromonitoring.
    Kuo TC, Duh QY, Wang YC, Lai CW, Chen KY, Lin MT, Wu MH| | PubMed
  32. Screening for Primary Aldosteronism is Underutilized in Patients with Obstructive Sleep Apnea.
    Conroy PC, Hernandez S, Graves CE, Menut KC, Pearlstein S, Liu C, Shen WT, Gosnell J, Sosa JA, Roman S, Duh QY, Suh I| | PubMed
  33. A cost-utility analysis of 18F-fluorocholine-positron emission tomography imaging for localizing primary hyperparathyroidism in the United States.
    Yap A, Hope TA, Graves CE, Kluijfhout W, Shen WT, Gosnell JE, Sosa JA, Roman SA, Duh QY, Suh I| | PubMed
  34. Implications of radiofrequency ablation in patients undergoing thyroid surgery for benign disease in the United States.
    Kim J, Sun Z, Cummins M, Donohue KC, Lea R, Graves CE, Shen WT, Gosnell JE, Roman SA, Sosa JA, Duh QY, Suh I| | PubMed
  35. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism.
    Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I| | PubMed
  36. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.
    Chomsky-Higgins Menut K, Pearlstein SS, Conroy PC, Roman SA, Shen WT, Gosnell J, Sosa JA, Duh QY, Suh I| | PubMed
  37. It Helps to Know Where to Look: Visual Identification of Unintentionally Resected Parathyroid Glands is Improved When Inspection is Directed by Near Infrared Autofluorescence Imaging.
    Duh QY, Graves CE| | PubMed
  38. The Public may be Right: Should We Reconsider Minimum Surgeon Volumes?
    Duh QY| | PubMed
  39. Management of endocrine surgical disorders during COVID-19 pandemic: expert opinion for non-surgical options.
    Agcaoglu O, Sezer A, Makay O, Erdogan MF, Bayram F, Guldiken S, Raffaelli M, Sonmez YA, Lee YS, Vamvakidis K, Mihai R, Duh QY, Akinci B, Alagol F, Almquist M, Barczynski M, Bayraktaroglu T, Berber E, Bukey Y, Cakmak GK, Canturk NZ, Canturk Z, Celik M, Celik O, Ceyhan BO, Cherenko S, Clerici T, Coombes DS, Demircan O, Deyneli O, Dionigi G, Emre AU, Erbil Y, Filiz AI, Gozu HI, Gurdal SO, Gurleyik G, Haciyanli M, Kebudi A, Kim S, Koutelidakis G, Kuru B, Mert M, Oruk GG, Ozbas S, Palazzo F, Pandev R, Riss P, Sabuncu T, Sahin I, Sakman G, Saygili F, Senyurek YG, Sleptsov I, Van Slycke S, Teksoz S, Terzioglu T, Tezelman S, Tunca F, Ugurlu MU, Uludag M, Villar-Del-Moral J, Vriens M, Yazici D| | PubMed
  40. Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study.
    Hope TA, Graves CE, Calais J, Ehman EC, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell JE, Shen WT, Roman SA, Sosa JA, Kluijfhout WP, Seib CD, Villaneuva-Meyer JE, Pampaloni MH, Suh I| | PubMed
  41. Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.
    Baechle JJ, Marincola Smith P, Solórzano CC, Tran TB, Postlewait LM, Maithel SK, Prescott J, Pawlik T, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Shirley LA, Fields RC, Jin L, Abbott DE, Ronnekleiv-Kelly S, Sicklick JK, Yopp A, Mansour J, Duh QY, Seiser N, Votanopoulos K, Levine EA, Poultsides G, Kiernan CM| | PubMed
  42. Choosing Wisely in the Workup of Primary Hyperaldosteronism.
    Doherty GM, Gartland RM, Duh QY| | PubMed
  43. Current state of intraoperative use of near infrared fluorescence for parathyroid identification and preservation.
    Solórzano CC, Thomas G, Berber E, Wang TS, Randolph GW, Duh QY, Triponez F| | PubMed
  44. Understanding the epidemiology of adrenal tumours.
    Duh QY| | PubMed
  45. Transoral robotic thyroidectomy versus transoral endoscopic thyroidectomy: a propensity-score-matched analysis of surgical outcomes.
    Chen YH, Kim HY, Anuwong A, Huang TS, Duh QY| | PubMed
  46. Intraoperative nerve monitoring is associated with a lower risk of recurrent laryngeal nerve injury: A national analysis of 17,610 patients.
    Kim J, Graves CE, Jin C, Duh QY, Gosnell JE, Shen WT, Suh I, Sosa JA, Roman SA| | PubMed
  47. Underdiagnosis of Primary Hyperparathyroidism-The Need for a System-Level Fix.
    Duh QY, Suh I, Stoller ML| | PubMed
  48. Anatomic Variations From 120 Mental Nerve Dissections: Lessons for Transoral Thyroidectomy.
    King SD, Arellano R, Gordon V, Olinger A, Seib CD, Duh QY, Suh I| | PubMed
  49. Commentary on the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.
    Hodak SP, Duh QY| | PubMed
  50. The Evolving Practice Patterns of Academic Endocrine Surgeons: A Cross-sectional Analysis of the Faculty Practice Solutions Center Database 2014 to 2017.
    Kuo JH, Duh QY, Chen H, Lai V, Sorensen MJ, Chabot JA, Lee JA| | PubMed
  51. A model for the institutional adoption of innovative surgical techniques.
    Jain M, Duh QY, Hirose R, Sosa JA, Suh I| | PubMed
  52. The Influence of Cosmetic Concerns on Patient Preferences for Approaches to Thyroid Lobectomy: A Discrete Choice Experiment.
    Sukpanich R, Sanglestsawai S, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I| | PubMed
  53. PTH hypersecretion triggered by a GABAB1 and Ca2+-sensing receptor heterocomplex in hyperparathyroidism.
    Chang W, Tu CL, Jean-Alphonse FG, Herberger A, Cheng Z, Hwong J, Ho H, Li A, Wang D, Liu H, White AD, Suh I, Shen W, Duh QY, Khanafshar E, Shoback DM, Xiao K, Vilardaga JP| | PubMed
  54. Variability in Opioid-Prescribing Patterns in Endocrine Surgery and Discordance With Patient Use.
    Lancaster E, Inglis-Arkell C, Hirose K, Seib CD, Wick E, Sosa JA, Duh QY| | PubMed
  55. Defining the competencies for laparoscopic transabdominal adrenalectomy: An investigation of intraoperative behaviors and decisions of experts.
    Madani A, Grover K, Kuo JH, Mitmaker EJ, Shen W, Beninato T, Livhits M, Smith PW, Miller BS, Sippel RS, Duh QY, Lee JA| | PubMed
  56. Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: Analysis from the US adrenocortical carcinoma database.
    Prendergast KM, Smith PM, Tran TB, Postlewait LM, Maithel SK, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Shirley LA, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Votanopoulos KI, Levine EA, Poultsides GA, Solórzano CC, Kiernan CM| | PubMed
  57. Challenges of training in adrenal surgery.
    Gimm O, Duh QY| | PubMed
  58. Technical Innovation in Transoral Endoscopic Endocrine Surgery: A Modified "Scarless" Technique.
    Suh I, Viscardi C, Chen Y, Nwaogu I, Sukpanich R, Gosnell JE, Shen WT, Seib CD, Duh QY| | PubMed
  59. Patient Eligibility for Transoral Endocrine Surgery Procedures in the United States.
    Grogan RH, Suh I, Chomsky-Higgins K, Alsafran S, Vasiliou E, Razavi CR, Chen LW, Tufano RP, Duh QY, Angelos P, Russell JO| | PubMed
  60. Postoperative Pain and Opioid Use After Thyroid and Parathyroid Surgery-A Pilot, Prospective SMS-Based Survey.
    Chen Y, Nwaogu I, Chomsky-Higgins K, Gosnell JE, Seib C, Shen WT, Duh QY, Suh I| | PubMed
  61. Identification of Hürthle cell cancers: solving a clinical challenge with genomic sequencing and a trio of machine learning algorithms.
    Hao Y, Duh QY, Kloos RT, Babiarz J, Harrell RM, Traweek ST, Kim SY, Fedorowicz G, Walsh PS, Sadow PM, Huang J, Kennedy GC| | PubMed
  62. Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism.
    Vorselaars WMCM, Nell S, Postma EL, Zarnegar R, Drake FT, Duh QY, Talutis SD, McAneny DB, McManus C, Lee JA, Grant SB, Grogan RH, Romero Arenas MA, Perrier ND, Peipert BJ, Mongelli MN, Castelino T, Mitmaker EJ, Parente DN, Pasternak JD, Engelsman AF, Sywak M, D'Amato G, Raffaelli M, Schuermans V, Bouvy ND, Eker HH, Bonjer HJ, Vaarzon Morel NM, Nieveen van Dijkum EJM, Vrielink OM, Kruijff S, Spiering W, Borel Rinkes IHM, Valk GD, Vriens MR, International CONNsortium study group| | PubMed
  63. Laparoscopic adrenalectomy for metastatic disease: Retrospective cohort with long-term, comprehensive follow-up.
    Drake FT, Beninato T, Xiong MX, Shah NV, Kluijfhout WP, Feeney T, Suh I, Gosnell JE, Shen WT, Duh QY| | PubMed
  64. Trends in Adrenal Surgery-The Changing Nature of Tumors and Patients.
    Chen Y, Chomsky-Higgins K, Nwaogu I, Gosnell JE, Seib C, Shen WT, Suh I, Duh QY| | PubMed
  65. Treatment of Primary Aldosteronism Reduces the Probability of Obstructive Sleep Apnea.
    Wang E, Chomsky-Higgins K, Chen Y, Nwaogu I, Seib CD, Shen WT, Duh QY, Suh I| | PubMed
  66. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.
    Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA| | PubMed
  67. Routine Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerve to Facilitate Complete Resection and Ensure Safety in Thyroid Cancer Surgery.
    Wu SY, Shen HY, Duh QY, Hsieh CB, Yu JC, Shih ML| | PubMed
  68. Risk Factors Associated With Perioperative Complications and Prolonged Length of Stay After Laparoscopic Adrenalectomy.
    Chen Y, Scholten A, Chomsky-Higgins K, Nwaogu I, Gosnell JE, Seib C, Shen WT, Suh I, Duh QY| | PubMed
  69. Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases.
    Zhang Q, Wang Z, Meng X, Duh QY, Chen G| | PubMed
  70. The prognostic significance of adrenocortical carcinomas identified incidentally.
    Rossfeld KK, Maithel SK, Prescott J, Wang TS, Fields RC, Weber SM, Sicklick JK, Yopp AC, Duh QY, Solorzano CC, Votanopoulos KI, Hatzaras I, Poultsides GA, Shirley LA, and the U.S. Adrenocortical Carcinoma Study Group| | PubMed
  71. International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data.
    Wu CW, Dionigi G, Barczynski M, Chiang FY, Dralle H, Schneider R, Al-Quaryshi Z, Angelos P, Brauckhoff K, Brooks JA, Cernea CR, Chaplin J, Chen AY, Davies L, Diercks GR, Duh QY, Fundakowski C, Goretzki PE, Hales NW, Hartl D, Kamani D, Kandil E, Kyriazidis N, Liddy W, Miyauchi A, Orloff L, Rastatter JC, Scharpf J, Serpell J, Shin JJ, Sinclair CF, Stack BC, Tolley NS, Slycke SV, Snyder SK, Urken ML, Volpi E, Witterick I, Wong RJ, Woodson G, Zafereo M, Randolph GW| | PubMed
  72. Patient Frailty Should Be Used to Individualize Treatment Decisions in Primary Hyperparathyroidism.
    Seib CD, Chomsky-Higgins K, Gosnell JE, Shen WT, Suh I, Duh QY, Finlayson E| | PubMed
  73. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
    Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW| | PubMed
  74. AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
    Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, Faquin WC, Sadow P, Baloch Z, Shindo M, Orloff L, Davies L, Randolph GW| | PubMed
  75. Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database.
    Marincola Smith P, Kiernan CM, Tran TB, Postlewait LM, Maithel SK, Prescott J, Pawlik T, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay J, Shirley LA, Fields RC, Jin L, Weber S, Salem A, Sicklick J, Gad S, Yopp A, Mansour J, Duh QY, Seiser N, Votanopoulos K, Levine EA, Poultsides G, Solórzano CC| | PubMed
  76. Hidden in Plain Sight: Transoral and Submental Thyroidectomy as a Compelling Alternative to "Scarless" Thyroidectomy.
    Chen Y, Chomsky-Higgins K, Nwaogu I, Seib CD, Gosnell JE, Shen WT, Duh QY, Suh I| | PubMed
  77. Association of Patient Frailty With Increased Morbidity After Common Ambulatory General Surgery Operations.
    Seib CD, Rochefort H, Chomsky-Higgins K, Gosnell JE, Suh I, Shen WT, Duh QY, Finlayson E| | PubMed
  78. It's Complicated: How Often are Patients with Primary Aldosteronism Cured After Adrenalectomy?
    Duh QY, Suh I| | PubMed
  79. Recombinant Parathyroid Hormone Versus Usual Care: Do the Outcomes Justify the Cost?
    Chomsky-Higgins KH, Rochefort HM, Seib CD, Gosnell JE, Shen WT, Duh QY, Suh I| | PubMed
  80. Trends of genetic screening in patients with pheochromocytoma and paraganglioma: 15-year experience in a high-volume tertiary referral center.
    Asban A, Kluijfhout WP, Drake FT, Beninato T, Wang E, Chomsky-Higgins K, Shen WT, Gosnell JE, Suh I, Duh QY| | PubMed
  81. Medullary Thyroid Carcinoma-We Should Do Better.
    Gosnell JE, Duh QY| | PubMed
  82. Safety and Outcomes of the Transoral Endoscopic Thyroidectomy Vestibular Approach.
    Anuwong A, Ketwong K, Jitpratoom P, Sasanakietkul T, Duh QY| | PubMed
  83. A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group.
    Poorman CE, Ethun CG, Postlewait LM, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solórzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK| | PubMed
  84. CLINICAL IMPLICATIONS OF POSTOPERATIVE UPSTAGING OF DIFFERENTIATED THYROID CANCER BASED UPON PATHOLOGIC EVALUATION.
    Duh QY, Shen WT| | PubMed
  85. Less is more: cost-effectiveness analysis of surveillance strategies for small, nonfunctional, radiographically benign adrenal incidentalomas.
    Chomsky-Higgins K, Seib C, Rochefort H, Gosnell J, Shen WT, Kahn JG, Duh QY, Suh I| | PubMed
  86. Squamous differentiation in papillary thyroid carcinoma: a rare feature of aggressive disease.
    Beninato T, Kluijfhout WP, Drake FT, Khanafshar E, Gosnell JE, Shen WT, Duh QY, Suh I| | PubMed
  87. Editorial: Volume-outcome relationship in adrenal surgery.
    Wang TS, Duh QY| | PubMed
  88. Improvement of TNM Staging for Medullary Thyroid Cancer.
    Duh QY, Gosnell JE| | PubMed
  89. A Systematic Review of the Methods of Diagnostic Accuracy Studies of the Afirma Gene Expression Classifier.
    Duh QY, Busaidy NL, Rahilly-Tierney C, Gharib H, Randolph G| | PubMed
  90. Striving for Clarity About the Best Approach to Thyroid Cancer Screening and Treatment: Is the Pendulum Swinging Too Far?
    Sosa JA, Duh QY, Doherty G| | PubMed
  91. Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group.
    Poorman CE, Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK| | PubMed
  92. Exclusion of Eligible Indeterminate Thyroid Nodules in Estimates of Negative Predictive Value for the Gene Expression Classifier.
    Duh QY, Rahilly-Tierney C, Gharib H| | PubMed
  93. Incidental positive lymph nodes in patients with papillary thyroid cancer is independently associated with recurrent disease.
    Kluijfhout WP, Drake FT, Pasternak JD, Beninato T, Vriens MR, Shen WT, Gosnell JE, Liu C, Suh I, Duh QY| | PubMed
  94. 18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study.
    Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I| | PubMed
  95. De novo thyroid cancer following solid organ transplantation-A 25-year experience at a high-volume institution with a review of the literature.
    Kluijfhout WP, Drake FT, Pasternak JD, Beninato T, Mitmaker EJ, Gosnell JE, Shen WT, Suh I, Freise CE, Duh QY| | PubMed
  96. Diagnostic performance of computed tomography for parathyroid adenoma localization; a systematic review and meta-analysis.
    Kluijfhout WP, Pasternak JD, Beninato T, Drake FT, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Hope TA, Suh I| | PubMed
  97. Curative Surgical Resection of Adrenocortical Carcinoma: Determining Long-term Outcome Based on Conditional Disease-free Probability.
    Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  98. Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1: Reply.
    Kluijfhout WP, Duh QY| | PubMed
  99. Unilateral Clearance for Primary Hyperparathyroidism in Selected Patients with Multiple Endocrine Neoplasia Type 1.
    Kluijfhout WP, Beninato T, Drake FT, Vriens MR, Gosnell J, Shen WT, Suh I, Liu C, Duh QY| | PubMed
  100. Resection of Pheochromocytoma Improves Diabetes Mellitus in the Majority of Patients.
    Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, Shen WT, Gosnell JE, Liu C, Suh I, Duh QY| | PubMed
  101. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
    Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Shen WT, Gosnell JE, Suh I, C L, Duh QY| | PubMed
  102. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer.
    Venkatesh S, Pasternak JD, Beninato T, Drake FT, Kluijfhout WP, Liu C, Gosnell JE, Shen WT, Clark OH, Duh QY, Suh I| | PubMed
  103. Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients.
    Lee CW, Salem AI, Schneider DF, Leverson GE, Tran TB, Poultsides GA, Postlewait LM, Maithel SK, Wang TS, Hatzaras I, Shenoy R, Phay JE, Shirley L, Fields RC, Jin LX, Pawlik TM, Prescott JD, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Weber SM| | PubMed
  104. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.
    Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh QY, Doherty GM, Herrera MF, Pasieka JL, Perrier ND, Silverberg SJ, Solórzano CC, Sturgeon C, Tublin ME, Udelsman R, Carty SE| | PubMed
  105. Actual 10-year survivors following resection of adrenocortical carcinoma.
    Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn J, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Hatzaras I, Shenoy R, Pawlik TM, Norton JA, Poultsides GA| | PubMed
  106. Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma.
    Tran TB, Maithel SK, Pawlik TM, Wang TS, Hatzaras I, Phay JE, Fields RC, Weber SM, Sicklick JK, Yopp AC, Duh QY, Solorzano CC, Votanopoulos KI, Poultsides GA| | PubMed
  107. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.
    Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT, Brandi ML, Bilezikian JP| | PubMed
  108. Lymphadenectomy for Adrenocortical Carcinoma: Is There a Therapeutic Benefit?
    Gerry JM, Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn JA, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Hatzaras I, Shenoy R, Pawlik TM, Norton JA, Poultsides GA| | PubMed
  109. Adrenal gland: New guidelines for adrenal incidentalomas.
    Duh QY| | PubMed
  110. Incidence, Risk Factors, and Clinical Outcomes of Incidental Parathyroidectomy During Thyroid Surgery.
    Applewhite MK, White MG, Xiong M, Pasternak JD, Abdulrasool L, Ogawa L, Suh I, Gosnell JE, Kaplan EL, Duh QY, Angelos P, Shen WT, Grogan RH| | PubMed
  111. Erratum to: Failed pneumoperitoneum for laparoscopic surgery following autologous Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction: a case report.
    Balkin DM, Duh QY, Kind GM, Chang DS, McGrath MH| | PubMed
  112. Performance of magnetic resonance imaging in the evaluation of first-time and reoperative primary hyperparathyroidism.
    Kluijfhout WP, Venkatesh S, Beninato T, Vriens MR, Duh QY, Wilson DM, Hope TA, Suh I| | PubMed
  113. Frequency of High-Risk Characteristics Requiring Total Thyroidectomy for 1-4 cm Well-Differentiated Thyroid Cancer.
    Kluijfhout WP, Pasternak JD, Lim J, Kwon JS, Vriens MR, Clark OH, Shen WT, Gosnell JE, Suh I, Duh QY| | PubMed
  114. Failed pneumoperitoneum for laparoscopic surgery following autologous Deep Inferior Epigastric Perforator (DIEP) flap breast reconstruction: a case report.
    Balkin DM, Duh QY, Kind GM, Chang DS, McGrath MH| | PubMed
  115. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis.
    Kluijfhout WP, Pasternak JD, Drake FT, Beninato T, Gosnell JE, Shen WT, Duh QY, Allen IE, Vriens MR, de Keizer B, Pampaloni MH, Suh I| | PubMed
  116. Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adrenocortical Carcinoma.
    Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem AI, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  117. A Novel Method of Neuromonitoring in Thyroidectomy and Parathyroidectomy Using Transcutaneous Intraoperative Vagal Stimulation.
    Suh I, Yingling C, Randolph GW, Duh QY| | PubMed
  118. Incidence of Perioperative Complications Following Resection of Adrenocortical Carcinoma and Its Association with Long-Term Survival.
    Margonis GA, Amini N, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Moses LE, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  119. Outcomes after resection of cortisol-secreting adrenocortical carcinoma.
    Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  120. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK| | PubMed
  121. Microscopic Positive Tumor Margin Does Not Increase the Risk of Recurrence in Patients with T1-T2 Well-Differentiated Thyroid Cancer.
    Kluijfhout WP, Pasternak JD, Kwon JS, Lim J, Shen WT, Gosnell JE, Khanafshar E, Duh QY, Suh I| | PubMed
  122. Defining competencies for safe thyroidectomy: An international Delphi consensus.
    Madani A, Watanabe Y, Vassiliou M, Feldman LS, Duh QY, Singer MC, Ruan DT, Tabah R, Mitmaker E| | PubMed
  123. Diagnostic utility of data from adrenal venous sampling for primary aldosteronism despite failed cannulation of the right adrenal vein.
    Pasternak JD, Epelboym I, Seiser N, Wingo M, Herman M, Cowan V, Gosnell JE, Shen WT, Kerlan RK, Lee JA, Duh QY, Suh I| | PubMed
  124. Differences Between Bilateral Adrenal Incidentalomas and Unilateral Lesions.
    Pasternak JD, Seib CD, Seiser N, Tyrell JB, Liu C, Cisco RM, Gosnell JE, Shen WT, Suh I, Duh QY| | PubMed
  125. Anaplastic Thyroid Carcinoma, Version 2.2015.
    Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M| | PubMed
  126. Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes.
    Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  127. Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma.
    Valero-Elizondo J, Kim Y, Prescott JD, Margonis GA, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  128. Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence.
    Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  129. Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma.
    Bagante F, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans DB, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM| | PubMed
  130. VEGF-D and A Preoperative Serum Levels Predict Nodal and Distant Metastases in Differentiated Thyroid Cancer Patients.
    Lai CW, Duh QY, Chen CW, Chuang FJ, Chang YJ, Lin MT, Wu MH| | PubMed
  131. The underestimated risk of cancer in patients with multinodular goiters after a benign fine needle aspiration.
    Campbell MJ, Seib CD, Candell L, Gosnell JE, Duh QY, Clark OH, Shen WT| | PubMed
  132. Thyroid carcinoma, version 2.2014.
    Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M| | PubMed
  133. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH, Shen WT, Gosnell J, Duh QY| | PubMed
  134. Unanticipated thyroid cancer in patients with substernal goiters: are we underestimating the risk?
    Campbell MJ, Candell L, Seib CD, Gosnell JE, Duh QY, Clark OH, Shen WT| | PubMed
  135. Hyalinizing trabecular tumor of thyroid: does frozen section prevent unnecessarily aggressive operation? Six new cases and a literature review.
    Sung SY, Shen HY, Hsieh CB, Duh QY, Su TF, Chan DC, Shih ML| | PubMed
  136. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.
    Udelsman R, Åkerström G, Biagini C, Duh QY, Miccoli P, Niederle B, Tonelli F| | PubMed
  137. Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer.
    Seib CD, Harari A, Conte FA, Duh QY, Clark OH, Gosnell JE| | PubMed
  138. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.
    Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF, Endocrine Society| | PubMed
  139. Adrenalectomy outcomes are superior with the participation of residents and fellows.
    Seib CD, Greenblatt DY, Campbell MJ, Shen WT, Gosnell JE, Clark OH, Duh QY| | PubMed
  140. Ultrasound-guided methylene blue dye injection for parathyroid localization in the reoperative neck.
    Candell L, Campbell MJ, Shen WT, Gosnell JE, Clark OH, Duh QY| | PubMed
  141. Variant adrenal venous anatomy in 546 laparoscopic adrenalectomies.
    Scholten A, Cisco RM, Vriens MR, Shen WT, Duh QY| | PubMed
  142. Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone.
    Park-Sigal J, Don BR, Porzig A, Recker R, Griswold V, Sebastian A, Duh QY, Portale AA, Shoback D, Schambelan M| | PubMed
  143. Virtual neck exploration for parathyroid adenomas: a first step toward minimally invasive image-guided surgery.
    D'Agostino J, Wall J, Soler L, Vix M, Duh QY, Marescaux J| | PubMed
  144. Pheochromocytoma crisis resulting in acute heart failure and cardioembolic stroke in a 37-year-old man.
    Cohen JK, Cisco RM, Scholten A, Mitmaker E, Duh QY| | PubMed
  145. Pheochromocytoma crisis is not a surgical emergency.
    Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, Tyrrell JB, Shen WT, Duh QY| | PubMed
  146. Impact of race on intraoperative parathyroid hormone kinetics: an analysis of 910 patients undergoing parathyroidectomy for primary hyperparathyroidism.
    Cisco RM, Kuo JH, Ogawa L, Scholten A, Tsinberg M, Duh QY, Clark OH, Gosnell JE, Shen WT| | PubMed
  147. Practice patterns and job satisfaction in fellowship-trained endocrine surgeons.
    Tsinberg M, Duh QY, Cisco RM, Gosnell JE, Scholten A, Clark OH, Shen WT| | PubMed
  148. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.
    Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM, American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal Surgery| | PubMed
  149. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
    Schreinemakers JM, Vriens MR, Munoz-Perez N, Guerrero MA, Suh I, Rinkes IH, Gosnell J, Shen WT, Clark OH, Duh QY| | PubMed
  150. Thyroid cancer operations for obese patients: the bad news and the good news.
    Duh QY| | PubMed
  151. No need to abandon unilateral parathyroid surgery.
    Hodin R, Angelos P, Carty S, Chen H, Clark O, Doherty G, Duh QY, Evans DB, Heller K, Inabnet W, Kebebew E, Pasieka J, Perrier N, Sturgeon C| | PubMed
  152. Successful localization of recurrent thyroid cancer in reoperative neck surgery using ultrasound-guided methylene blue dye injection.
    Harari A, Sippel RS, Goldstein R, Aziz S, Shen W, Gosnell J, Duh QY, Clark OH| | PubMed
  153. Subclinical Cushing's syndrome.
    Tsinberg M, Liu C, Duh QY| | PubMed
  154. A population-based prospective cohort study of complications after thyroidectomy in the elderly.
    Grogan RH, Mitmaker EJ, Hwang J, Gosnell JE, Duh QY, Clark OH, Shen WT| | PubMed
  155. The Bayes theorem wins: comment on "Impact of localization studies and clinical scenario in patients with hyperparathyroidism being evaluated for reoperative neck surgery".
    Duh QY| | PubMed
  156. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer.
    Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH, Kebebew E| | PubMed
  157. Parathyroid carcinoma: a 43-year outcome and survival analysis.
    Harari A, Waring A, Fernandez-Ranvier G, Hwang J, Suh I, Mitmaker E, Shen W, Gosnell J, Duh QY, Clark O| | PubMed
  158. Differences in metabolic urinary abnormalities in stone forming and nonstone forming patients with primary hyperparathyroidism.
    Sorensen MD, Duh QY, Grogan RH, Tran TC, Stoller ML| | PubMed
  159. Visual vignette. What is the diagnosis? Insulin-secreting tumor.
    Thompson M, Hiniker A, Duh QY, Corvera CU| | PubMed
  160. Laparoscopic repair of inguinal hernias.
    Carter J, Duh QY| | PubMed
  161. Robot-assisted endoscopic thyroidectomy: has the time come to abandon neck incisions?
    Duh QY| | PubMed
  162. Medullary Thyroid Cancer: It is a pain in the neck?
    Guerrero MA, Lindsay S, Suh I, Vriens MR, Khanafshar E, Shen WT, Gosnell J, Kebebew E, Duh QY, Clark OH| | PubMed
  163. Changing paradigms in the treatment of malignant pheochromocytoma.
    Grogan RH, Mitmaker EJ, Duh QY| | PubMed
  164. Higher rate of BRAF mutation in papillary thyroid cancer over time: a single-institution study.
    Mathur A, Moses W, Rahbari R, Khanafshar E, Duh QY, Clark O, Kebebew E| | PubMed
  165. Primary hyperparathyroidism patients with positive preoperative sestamibi scan and negative ultrasound are more likely to have posteriorly located upper gland adenomas (PLUGs).
    Harari A, Mitmaker E, Grogan RH, Lee J, Shen W, Gosnell J, Clark O, Duh QY| | PubMed
  166. Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
    Mitmaker EJ, Griff NJ, Grogan RH, Sarkar R, Kebebew E, Duh QY, Clark OH, Shen WT| | PubMed
  167. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy.
    Mathur A, Weng J, Moses W, Steinberg SM, Rahbari R, Rahabari R, Kitano M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E| | PubMed
  168. The management of aldosterone-producing adrenal adenomas--does adrenalectomy increase costs?
    Reimel B, Zanocco K, Russo MJ, Zarnegar R, Clark OH, Allendorf JD, Chabot JA, Duh QY, Lee JA, Sturgeon C| | PubMed
  169. The number of needle passes affects the accuracy of parathyroid hormone assay with intraoperative parathyroid aspiration.
    Guerrero MA, Suh I, Vriens MR, Shen WT, Gosnell J, Kebebew E, Clark OH, Duh QY| | PubMed
  170. Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy.
    Rahbari R, Mathur A, Kitano M, Guerrero M, Shen WT, Duh QY, Clark OH, Kebebew E| | PubMed
  171. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy.
    Moses W, Weng J, Sansano I, Peng M, Khanafshar E, Ljung BM, Duh QY, Clark OH, Kebebew E| | PubMed
  172. Thyroid carcinoma.
    Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, National Comprehensive Cancer Network| | PubMed
  173. Bilateral superficial cervical plexus block combined with general anesthesia administered in thyroid operations.
    Shih ML, Duh QY, Hsieh CB, Liu YC, Lu CH, Wong CS, Yu JC, Yeh CC| | PubMed
  174. One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy.
    Shen WT, Grogan R, Vriens M, Clark OH, Duh QY| | PubMed
  175. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
    Meyer-Rochow GY, Jackson NE, Conaglen JV, Whittle DE, Kunnimalaiyaan M, Chen H, Westin G, Sandgren J, Stålberg P, Khanafshar E, Shibru D, Duh QY, Clark OH, Kebebew E, Gill AJ, Clifton-Bligh R, Robinson BG, Benn DE, Sidhu SB| | PubMed
  176. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.
    Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, Clark OH, Kebebew E| | PubMed
  177. Adrenal incidentaloma: does an adequate workup rule out surprises?
    Grogan RH, Mitmaker E, Vriens MR, Harari A, Gosnell JE, Shen WT, Clark OH, Duh QY| | PubMed
  178. Prospective evaluation of the rate and impact of hemolysis on intraoperative parathyroid hormone (IOPTH) assay results.
    Moalem J, Ruan DT, Farkas RL, Shen WT, Miller S, Duh QY, Clark OH, Kebebew E| | PubMed
  179. Age and tumor size predicts lymph node involvement in Hürthle Cell Carcinoma.
    Guerrero MA, Suh I, Vriens MR, Shen WT, Gosnell J, Kebebew E, Duh QY, Clark OH| | PubMed
  180. Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results?
    Elaraj DM, Sippel RS, Lindsay S, Sansano I, Duh QY, Clark OH, Kebebew E| | PubMed
  181. Patterns of antibiotic prophylaxis use for thyroidectomy and parathyroidectomy: results of an international survey of endocrine surgeons.
    Moalem J, Ruan DT, Farkas RL, Shen WT, Kebebew E, Duh QY, Clark OH| | PubMed
  182. Prior head and neck radiation exposure is not a contraindication to minimally invasive parathyroidectomy.
    Rahbari R, Sansano IG, Elaraj DM, Duh QY, Clark OH, Kebebew E| | PubMed
  183. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit.
    Shen WT, Ogawa L, Ruan D, Suh I, Duh QY, Clark OH| | PubMed
  184. Medullary carcinoma.
    Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, National Comprehensive Cancer Network| | PubMed
  185. Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.
    Suh I, Weng J, Fernandez-Ranvier G, Shen WT, Duh QY, Clark OH, Kebebew E| | PubMed
  186. Central neck lymph node dissection for papillary thyroid cancer: comparison of complication and recurrence rates in 295 initial dissections and reoperations.
    Shen WT, Ogawa L, Ruan D, Suh I, Kebebew E, Duh QY, Clark OH| | PubMed
  187. Incidentaloma.
    Moalem J, Suh I, Duh QY| | PubMed
  188. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
    Suh I, Shibru D, Eisenhofer G, Pacak K, Duh QY, Clark OH, Kebebew E| | PubMed
  189. Clinical spectrum of pheochromocytoma.
    Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT, Gosnell J, Clark OH, Duh QY| | PubMed
  190. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families.
    Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark OH| | PubMed
  191. The value of intraoperative parathyroid hormone monitoring in localized primary hyperparathyroidism: a cost analysis.
    Morris LF, Zanocco K, Ituarte PH, Ro K, Duh QY, Sturgeon C, Yeh MW| | PubMed
  192. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.
    American Thyroid Association Surgery Working Group, American Association of Endocrine Surgeons,, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society, Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, Randolph GW, Stack BC, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R| | PubMed
  193. Video self-assessment augments development of videoscopic suturing skill.
    Jamshidi R, LaMasters T, Eisenberg D, Duh QY, Curet M| | PubMed
  194. Management of recurrent inguinal hernias.
    Itani KM, Fitzgibbons R, Awad SS, Duh QY, Ferzli GS| | PubMed
  195. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations.
    Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E, Kharlip J, American Association of Clinical Endocrinologists, American Association of Endocrine Surgeons| | PubMed
  196. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas.
    Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E, Kharlip J, American Association of Clinical Endocrinologists, American Association of Endocrine Surgeons| | PubMed
  197. Two hundred and two consecutive operations for secondary hyperparathyroidism: has medical management changed the profiles of patients requiring parathyroidectomy?
    Shen WT, Kebebew E, Suh I, Duh QY, Clark OH| | PubMed
  198. Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation.
    Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E| | PubMed
  199. Do patients undergoing parathyroidectomy for primary hyperparathyroidism in San Francisco, CA, and Bursa, Turkey, differ?
    Kirdak T, Duh QY, Kebebew E, Clark OH| | PubMed
  200. Patients with primary hyperparathyroidism--why do some form stones?
    Berger AD, Wu W, Eisner BH, Cooperberg MR, Duh QY, Stoller ML| | PubMed
  201. Localization of recurrent thyroid cancer using intraoperative ultrasound-guided dye injection.
    Sippel RS, Elaraj DM, Poder L, Duh QY, Kebebew E, Clark OH| | PubMed
  202. Total parathyroidectomy without autotransplantation for secondary hyperparathyroidism.
    Shih ML, Duh QY, Hsieh CB, Lin SH, Wu HS, Chu PL, Chen TY, Yu JC| | PubMed
  203. Hürthle cell carcinoma of the thyroid with contralateral malignant pleural effusion.
    Hsu KF, Hsieh CB, Duh QY, Chien CF, Li HS, Shih ML| | PubMed
  204. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH| | PubMed
  205. Hemolysis falsely decreases intraoperative parathyroid hormone levels.
    Moalem J, Ruan DT, Farkas RL, Shen WT, Gosnell JE, Miller S, Duh QY, Clark OH, Kebebew E| | PubMed
  206. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E| | PubMed
  207. Waiting for change: symptom resolution after adrenalectomy for Cushing's syndrome.
    Sippel RS, Elaraj DM, Kebebew E, Lindsay S, Tyrrell JB, Duh QY| | PubMed
  208. Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?
    Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E| | PubMed
  209. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling.
    Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH, Kebebew E| | PubMed
  210. Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers.
    Shih ML, Lee JA, Hsieh CB, Yu JC, Liu HD, Kebebew E, Clark OH, Duh QY| | PubMed
  211. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature.
    Moalem J, Suh I, Duh QY| | PubMed
  212. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13.
    Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW, Hwang J, Duh QY, Clark OH, Kebebew E| | PubMed
  213. Laparoscopic adrenalectomy after prior abdominal surgery.
    Morris L, Ituarte P, Zarnegar R, Duh QY, Ahmed L, Lee J, Inabnet W, Meyer-Rochow G, Sidhu S, Sywak M, Yeh M| | PubMed
  214. Sporadic paraganglioma.
    Lee JA, Duh QY| | PubMed
  215. Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.
    Sippel RS, Elaraj DM, Khanafshar E, Zarnegar R, Kebebew E, Duh QY, Clark OH| | PubMed
  216. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer.
    Kushchayeva Y, Duh QY, Kebebew E, D'Avanzo A, Clark OH| | PubMed
  217. Medullary thyroid carcinoma manifesting as an ovarian mass: case report and review of literature.
    Gosnell JE, Maa J, Clark OH, Duh QY| | PubMed
  218. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma.
    Zarnegar R, Young WF, Lee J, Sweet MP, Kebebew E, Farley DR, Thompson GB, Grant CS, Clark OH, Duh QY| | PubMed
  219. Laparoscopic inguinal hernia repair.
    Takata MC, Duh QY| | PubMed
  220. Is adrenal venous sampling necessary in all patients with hyperaldosteronism before adrenalectomy?
    Zarnegar R, Bloom AI, Lee J, Kerlan RK, Wilson MW, Laberge JM, Gordon RL, Kebebew E, Clark OH, Duh QY| | PubMed
  221. Laparoscopic bilateral adrenalectomy: results for 30 consecutive cases.
    Takata MC, Kebebew E, Clark OH, Duh QY| | PubMed
  222. Primary malignant fibrous histiocytoma of the thyroid: review of the literature with two new cases.
    Hsu KF, Lin YS, Hsieh CB, Yu JC, Duh QY, Sheu LF, Jen YM, Shih ML| | PubMed
  223. Laparoscopic enucleation of insulinomas.
    Sweet MP, Izumisato Y, Way LW, Clark OH, Masharani U, Duh QY| | PubMed
  224. Oral calcium supplementation associated with decreased likelihood of nephrolithiasis prior to surgery for hyperparathyroidism.
    Cooperberg MR, Duh QY, Stackhouse GB, Stoller ML| | PubMed
  225. Good blood pressure control on antihypertensives, not only response to spironolactone, predicts improved outcome after adrenalectomy for aldosteronoma.
    Zarnegar R, Lee J, Brunaud L, Lindsay S, Kebebew E, Clark OH, Duh QY| | PubMed
  226. Nonfunctioning parathyroid carcinoma: case report and review of literature.
    Fernandez-Ranvier GG, Jensen K, Khanafshar E, Quivey JM, Glastonbury C, Kebebew E, Duh QY, Clark OH| | PubMed
  227. Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid?
    Sippel RS, Elaraj DM, Khanafshar E, Kebebew E, Duh QY, Clark OH| | PubMed
  228. Laparoscopic adrenalectomy for isolated adrenal metastasis: the right thing to do and the right way to do it.
    Duh QY| | PubMed
  229. Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the "subclinical" pheochromocytoma.
    Lee JA, Zarnegar R, Shen WT, Kebebew E, Clark OH, Duh QY| | PubMed
  230. The prevalence and prognostic value of BRAF mutation in thyroid cancer.
    Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A| | PubMed
  231. Prediction of successful outcome in patients with primary aldosteronism.
    Moo TA, Zarnegar R, Duh QY| | PubMed
  232. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis?
    Fernandez-Ranvier GG, Khanafshar E, Jensen K, Zarnegar R, Lee J, Kebebew E, Duh QY, Clark OH| | PubMed
  233. Does routine consultation of thyroid fine-needle aspiration cytology change surgical management?
    Tan YY, Kebebew E, Reiff E, Caron NR, Ogilvie JB, Duh QY, Clark OH, Ljung BM, Miller T| | PubMed
  234. Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma.
    Lee J, Sogutlu G, Leard L, Zarnegar R, Bailey J, Golden J, Hays S, Kebebew E, Duh QY, Clark O| | PubMed
  235. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.
    Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH, Greenspan FS, Lindsay S, Duh QY, Morita E| | PubMed
  236. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
    Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z, Clark OH| | PubMed
  237. Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation.
    Triponez F, Kebebew E, Dosseh D, Duh QY, Hazzan M, Noel C, Chertow GM, Wambergue F, Fleury D, Lemaitre V, Proye CA, Clark OH| | PubMed
  238. Hook needle-guided excision of recurrent differentiated thyroid cancer in previously operated neck compartments: a safe technique for small, nonpalpable recurrent disease.
    Triponez F, Poder L, Zarnegar R, Goldstein R, Roayaie K, Feldstein V, Lee J, Kebebew E, Duh QY, Clark OH| | PubMed
  239. Observation or laparoscopic adrenalectomy for adrenal incidentaloma? A surgical decision analysis.
    Brunaud L, Kebebew E, Sebag F, Zarnegar R, Clark OH, Duh QY| | PubMed
  240. Predictors of single-gland vs multigland parathyroid disease in primary hyperparathyroidism: a simple and accurate scoring model.
    Kebebew E, Hwang J, Reiff E, Duh QY, Clark OH| | PubMed
  241. Selective use of steroid replacement after adrenalectomy: lessons from 331 consecutive cases.
    Shen WT, Lee J, Kebebew E, Clark OH, Duh QY| | PubMed
  242. Malignant pheochromocytoma.
    Zarnegar R, Kebebew E, Duh QY, Clark OH| | PubMed
  243. Reoperation for adrenocortical neoplasms.
    Lee JA, Duh QY| | PubMed
  244. Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.
    Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A| | PubMed
  245. Does familial non-medullary thyroid cancer adversely affect survival?
    Triponez F, Wong M, Sturgeon C, Caron N, Ginzinger DG, Segal MR, Kebebew E, Duh QY, Clark OH| | PubMed
  246. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
    Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A| | PubMed
  247. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?
    Caron NR, Tan YY, Ogilvie JB, Triponez F, Reiff ES, Kebebew E, Duh QY, Clark OH| | PubMed
  248. Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas.
    Tan YY, Ogilvie JB, Triponez F, Caron NR, Kebebew EK, Clark OH, Duh QY| | PubMed
  249. Canadian Association of General Surgeons and American College of Surgeons Evidence Based Reviews in Surgery. 16. Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism.
    Barkun J, Duh QY, Wiseman S, Evidence Based Reviews in Surgery Group| | PubMed
  250. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?
    Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E| | PubMed
  251. Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms.
    Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A| | PubMed
  252. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
    Shen WT, Wong TS, Chung WY, Wong MG, Kebebew E, Duh QY, Clark OH| | PubMed
  253. What's new in general surgery: endocrine surgery.
    Duh QY| | PubMed
  254. ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy.
    Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A| | PubMed
  255. Laparoscopic appreciation of the adrenal artery: fact or fiction?
    Joel AB, Rubenstein JN, Arredondo S, Meng MV, Duh QY, Stoller ML| | PubMed
  256. More than 500 consecutive laparoscopic donor nephrectomies without conversion or repeated surgery.
    Melcher ML, Carter JT, Posselt A, Duh QY, Stoller M, Freise CE, Kang SM| | PubMed
  257. Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy.
    Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY, Rauen KA, Kloos RT, Jhiang SM| | PubMed
  258. Should total thyroidectomy become the preferred procedure for surgical management of Graves' disease?
    Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH| | PubMed
  259. Use of the electrothermal vessel sealing system versus standard vessel ligation in thyroidectomy.
    Shen WT, Baumbusch MA, Kebebew E, Duh QY| | PubMed
  260. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors.
    Shen WT, Sturgeon C, Duh QY| | PubMed
  261. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.
    Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH| | PubMed
  262. New approaches to the minimally invasive treatment of adrenal lesions.
    Ogilvie JB, Duh QY| | PubMed
  263. GCMB gene, a master regulator of parathyroid gland development, expression, and regulation in hyperparathyroidism.
    Kebebew E, Peng M, Wong MG, Ginzinger D, Duh QY, Clark OH| | PubMed
  264. Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells.
    Kebebew E, Peng M, Treseler PA, Clark OH, Duh QY, Ginzinger D, Miner R| | PubMed
  265. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas.
    Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E| | PubMed
  266. Prognostic indications for Hürthle cell cancer.
    Kushchayeva Y, Duh QY, Kebebew E, Clark OH| | PubMed
  267. Complication of thyroidectomy in patients with radiation-induced thyroid neoplasms.
    Kikuchi S, Perrier ND, Cheah WK, Siperstein AE, Duh QY, Clark OH| | PubMed
  268. Reasons for conversion from laparoscopic to open or hand-assisted adrenalectomy: review of 261 laparoscopic adrenalectomies from 1993 to 2003.
    Shen WT, Kebebew E, Clark OH, Duh QY| | PubMed
  269. Laparoscopic surgery for melanoma metastases to the adrenal gland.
    Sturgeon C, Leong SP, Duh QY| | PubMed
  270. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy.
    Kebebew E, Duh QY, Clark OH| | PubMed
  271. Spatial ability, experience, and skill in laparoscopic surgery.
    Keehner MM, Tendick F, Meng MV, Anwar HP, Hegarty M, Stoller ML, Duh QY| | PubMed
  272. Clinical manifestation of aldosteronoma.
    Al Fehaily M, Duh QY| | PubMed
  273. Predictors of airway complications after thyroidectomy for substernal goiter.
    Shen WT, Kebebew E, Duh QY, Clark OH| | PubMed
  274. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome.
    D'Avanzo A, Ituarte P, Treseler P, Kebebew E, Wu J, Wong M, Duh QY, Siperstein AE, Clark OH| | PubMed
  275. Latency period of thyroid neoplasia after radiation exposure.
    Kikuchi S, Perrier ND, Ituarte P, Siperstein AE, Duh QY, Clark OH| | PubMed
  276. The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited?
    Eigelberger MS, Cheah WK, Ituarte PH, Streja L, Duh QY, Clark OH| | PubMed
  277. Follicular thyroid carcinoma: histology and prognosis.
    D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY, Clark OH| | PubMed
  278. Thyroid cancer in Graves disease: incidental cancer versus clinical cancer.
    Duh QY| | PubMed
  279. Intraoperative parathyroid hormone assay and parathyroid reoperations.
    Sebag F, Shen W, Brunaud L, Kebebew E, Duh QY, Clark OH| | PubMed
  280. Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines.
    Park JW, Wong MG, Lobo M, Hyun WC, Duh QY, Clark OH| | PubMed
  281. Presidential Address: Minimally invasive endocrine surgery--standard of treatment or hype?
    Duh QY| | PubMed
  282. Resecting isolated adrenal metastasis: why and how?
    Duh QY| | PubMed
  283. Accuracy of preoperative localization studies and intraoperative parathyroid hormone assay in patients with primary hyperparathyroidism and double adenoma.
    Haciyanli M, Lal G, Morita E, Duh QY, Kebebew E, Clark OH| | PubMed
  284. Incision length for standard thyroidectomy and parathyroidectomy: when is it minimally invasive?
    Brunaud L, Zarnegar R, Wada N, Ituarte P, Clark OH, Duh QY| | PubMed
  285. Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumors.
    Kanauchi H, Wada N, Ginzinger DG, Yu M, Wong MG, Clark OH, Duh QY| | PubMed
  286. Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors.
    Hung CJ, Ginzinger DG, Zarnegar R, Kanauchi H, Wong MG, Kebebew E, Clark OH, Duh QY| | PubMed
  287. Laparoscopic adrenalectomy--indications and technique.
    Lal G, Duh QY| | PubMed
  288. Parathyroidectomy for primary hyperparathyroidism in octogenarians and nonagenarians: a plea for early surgical referral.
    Kebebew E, Duh QY, Clark OH| | PubMed
  289. The helix-loop-helix protein, Id-1, is overexpressed and regulates growth in papillary thyroid cancer.
    Kebebew E, Treseler PA, Duh QY, Clark OH| | PubMed
  290. Chromosomal aberrations by comparative genomic hybridization in thyroid tumors in patients with familial nonmedullary thyroid cancer.
    Brunaud L, Zarnegar R, Wada N, Magrane G, Wong M, Duh QY, Davis O, Clark OH| | PubMed
  291. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
    Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh QY, Clark OH| | PubMed
  292. Accuracy of fine-needle aspiration cytology in patients with radiation-induced thyroid neoplasms.
    Kikuchi S, Perrier ND, Ituarte PH, Treseler PA, Siperstein AE, Duh QY, Greenspan FS, Clark OH| | PubMed
  293. Differing histologic findings after bilateral and focused parathyroidectomy.
    Genc H, Morita E, Perrier ND, Miura D, Ituarte P, Duh QY, Clark OH| | PubMed
  294. Recent advances in minimally invasive endocrine surgery.
    Duh QY| | PubMed
  295. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization.
    Miura D, Wada N, Chin K, Magrane GG, Wong M, Duh QY, Clark OH| | PubMed
  296. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection.
    Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y| | PubMed
  297. Techniques to optimize vascular control during laparoscopic donor nephrectomy.
    Meng MV, Freise CE, Kang SM, Duh QY, Stoller ML| | PubMed
  298. Accuracy of selective venous sampling for intact parathyroid hormone in difficult patients with recurrent or persistent hyperparathyroidism.
    Jones JJ, Brunaud L, Dowd CF, Duh QY, Morita E, Clark OH| | PubMed
  299. Apoptosis regulating genes, bcl-2 and bax, and human telomerase reverse transcriptase messenger RNA expression in adrenal tumors: possible diagnostic and prognostic importance.
    Kanauchi H, Wada N, Clark OH, Duh QY| | PubMed
  300. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
    Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH| | PubMed
  301. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I, Wunderlich A, Hofbauer LC, Duh QY| | PubMed
  302. Adrenal incidentalomas.
    Duh QY| | PubMed
  303. Chromosomal aberrations by comparative genomic hybridization in hürthle cell thyroid carcinomas are associated with tumor recurrence.
    Wada N, Duh QY, Miura D, Brunaud L, Wong MG, Clark OH| | PubMed
  304. Aldosteronoma.
    Brunaud L, Duh QY| | PubMed
  305. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms.
    Kebebew E, Siperstein AE, Clark OH, Duh QY| | PubMed
  306. Complications of neck dissection for thyroid cancer.
    Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh QY, Clark OH| | PubMed
  307. Laparoscopic adrenalectomy for pheochromocytoma.
    Cheah WK, Clark OH, Horn JK, Siperstein AE, Duh QY| | PubMed
  308. Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy?
    Miura D, Wada N, Arici C, Morita E, Duh QY, Clark OH| | PubMed
  309. Parathyroid gland volume increases with postmaturational aging in the rat.
    Halloran B, Udén P, Duh QY, Kikuchi S, Wieder T, Cao J, Clark O| | PubMed
  310. Parathyroid surgery: separating promise from reality.
    Perrier ND, Ituarte PH, Morita E, Hamill T, Gielow R, Duh QY, Clark OH| | PubMed
  311. Laparoscopic adrenalectomy: the optimal surgical approach.
    Kebebew E, Siperstein AE, Duh QY| | PubMed
  312. Laparoscopic nephrectomy for inflammatory renal conditions.
    Shekarriz B, Meng MV, Lu HF, Yamada H, Duh QY, Stoller ML| | PubMed
  313. Minimally invasive approaches to inguinal hernia repair.
    Safadi BY, Duh QY| | PubMed
  314. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer.
    Eigelberger MS, Wong MG, Duh QY, Clark OH| | PubMed
  315. A critical analysis of intraoperative time utilization in laparoscopic adrenalectomy.
    Berber E, Duh QY, Clark OH, Siperstein AE| | PubMed
  316. Novel method of assessing surgical margin status in laparoscopic specimens.
    Meng MV, Koppie TM, Duh QY, Stoller ML| | PubMed
  317. Radially expanding laparoscopic access for renal/adrenal surgery.
    Shekarriz B, Gholami SS, Rudnick DM, Duh QY, Stoller ML| | PubMed
  318. Laparoscopic nephrectomy and autotransplantation for severe iatrogenic ureteral injuries.
    Shekarriz B, Lu H, Duh Q, Freise CE, Stoller ML| | PubMed
  319. Transperitoneal preperitoneal laparoscopic lumbar incisional herniorrhaphy.
    Shekarriz B, Graziottin TM, Gholami S, Lu HF, Yamada H, Duh QY, Stoller ML| | PubMed
  320. False positive 99mTc sestamibi scans in patients with osteitis fibrosa cystica and brown tumours.
    D'Avanzo A, Parangi S, Morita E, Perrier ND, Wu HS, Siperstein AE, Duh QY, Treseler PA, Clark OH| | PubMed
  321. Localization and reoperation results for persistent and recurrent parathyroid carcinoma.
    Kebebew E, Arici C, Duh QY, Clark OH| | PubMed
  322. Pheochromocytoma.
    Eigelberger MS, Duh QY| | PubMed
  323. The laparoscopic cigarette sponge.
    Gholami SS, Shekarriz B, Rudnick D, Duh QY, Stoller ML| | PubMed
  324. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival.
    Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH| | PubMed
  325. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
    Tatar FA, Morita E, Ituarte PH, Cavalieri RR, Duh QY, Price DC, Siperstein AE, Clark OH| | PubMed
  326. Can localization studies be used to direct focused parathyroid operations?
    Arici C, Cheah WK, Ituarte PH, Morita E, Lynch TC, Siperstein AE, Duh QY, Clark OH| | PubMed
  327. Evolving surgical management for patients with pheochromocytoma.
    Duh QY| | PubMed
  328. Follicular thyroid cancer cells: a model of metastatic tumor in vitro (review).
    Hoelting T, Goretzki PE, Duh QY| | PubMed
  329. Laparoscopic live donor nephrectomy at the University of California San Francisco.
    Meng MV, Kang SM, Duh QY, Stoller ML, Freise C| | PubMed
  330. Death from thyroid cancer of follicular cell origin.
    Wu HS, Young MT, Ituarte PH, D'Avanzo A, Duh QY, Greenspan FS, Loh KC, Clark OH| | PubMed
  331. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series.
    Alsanea O, Wada N, Ain K, Wong M, Taylor K, Ituarte PH, Treseler PA, Weier HU, Freimer N, Siperstein AE, Duh QY, Takami H, Clark OH| | PubMed
  332. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY| | PubMed
  333. The helix-loop-helix transcription factor, Id-1, is overexpressed in medullary thyroid cancer.
    Kebebew E, Treseler PA, Duh QY, Clark OH| | PubMed
  334. Intraoperative parathyroid aspiration and parathyroid hormone assay as an alternative to frozen section for tissue identification.
    Perrier ND, Ituarte P, Kikuchi S, Siperstein AE, Duh QY, Clark OH, Gielow R, Hamill T| | PubMed
  335. Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model.
    Kebebew E, Duh QY, Clark OH| | PubMed
  336. Recurrent or persistent thyroid cancer of follicular cell origin.
    Duren M, Duh QY, Siperstein AE, Clark OH| | PubMed
  337. Laparoscopic posterior adrenalectomy: technical considerations.
    Siperstein AE, Berber E, Engle KL, Duh QY, Clark OH| | PubMed
  338. Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer.
    Kebebew E, Kikuchi S, Duh QY, Clark OH| | PubMed
  339. How should you choose a thyroid surgeon?
    Sherman S, Udelsman R, Duh QY| | PubMed
  340. Hyperparathyroidism after thyroid surgery and autotransplantation of histologically normal parathyroid glands.
    D'Avanzo A, Parangi S, Morita E, Duh QY, Siperstein AE, Clark OH| | PubMed
  341. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH| | PubMed
  342. Classification and treatment of follicular thyroid neoplasms are discordant between and within medical specialties.
    Perrier ND, Ituarte PH, Treseler P, D'Avanzo A, Siperstein A, Duh QY, Clark OH| | PubMed
  343. Invasion of human follicular thyroid carcinoma cells in an in vivo invasion model.
    Gerling MC, Jossart G, Duh QY, Weier HU, Clark OH, Young DM| | PubMed
  344. Reliability of fine-needle aspiration in patients with familial nonmedullary thyroid cancer.
    Vriens MR, Sabanci U, Epstein HD, Ngai S, Duh QY, Siperstein AE, Clark OH| | PubMed
  345. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function.
    Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH| | PubMed
  346. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients.
    Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH| | PubMed
  347. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism.
    Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY| | PubMed
  348. Development of reverse transcription-competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter.
    Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY, Clark OH, Mazzaferri EL, Jhiang SM| | PubMed
  349. Thyroidectomy for the treatment of Graves' disease.
    Duh QY| | PubMed
  350. Laparoscopic gastrostomy and jejunostomy: safety and cost with local vs general anesthesia.
    Duh QY, Senokozlieff-Englehart AL, Choe YS, Siperstein AE, Rowland K, Way LW| | PubMed
  351. Normal thyroid pathology in patients undergoing thyroidectomy for finding a RETgene germline mutation: a report of three cases and review of the literature.
    Kebebew E, Tresler PA, Siperstein AE, Duh QY, Clark OH| | PubMed
  352. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion.
    Zielke A, Hoffmann S, Plaul U, Duh QY, Clark OH, Rothmund M| | PubMed
  353. Advanced laparoscopy: "the next generation". The adrenal, kidney, spleen, pancreas, and liver.
    Payne JH, Tashima W, Lapschies B, Washecka R, Hariharan A, Duh QY| | PubMed
  354. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-Up.
    Kebebew E, Duh QY| | PubMed
  355. Insulinoma--experience from 1950 to 1995.
    Boukhman MP, Karam JH, Shaver J, Siperstein AE, Duh QY, Clark OH| | PubMed
  356. Desensitization in normal and neoplastic human thyroid cell lines.
    al-Sobhi SS, Soh EY, Wong MG, Siperstein AE, Duh QY, Clark OH| | PubMed
  357. Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin.
    Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, Duh QY, Clark OH| | PubMed
  358. Heterologous desensitization in neoplastic thyroid cells: influence of the phospholipase C signal transduction system on the thyrotropin-adenylate cyclase signal transduction system.
    Tezelman S, Hoelting T, Jossart GH, Wong MG, Siperstein AE, Duh QY, Clark OH| | PubMed
  359. A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants.
    Zielke A, Bresalier RS, Siperstein AE, Clark OH, Rothmund M, Duh QY| | PubMed
  360. Clinical profile of primary hyperparathyroidism in adolescents and young adults.
    Loh KC, Duh QY, Shoback D, Gee L, Siperstein A, Clark OH| | PubMed
  361. [Transfection of follicular thyroid gland carcinoma cells with human TSH receptor changes growth, invasion and adhesion].
    Hoelting T, Duh QY, Clark OH, Herfarth C| | PubMed
  362. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
    Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH| | PubMed
  363. Invasion of metastatic human follicular thyroid cancer is inhibited via antagonism of protein kinase C.
    Hoelting T, Duh QY, Clark OH, Herfarth C| | PubMed
  364. Antiproliferative effect of suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells.
    Zielke A, Wong MG, Siperstein AE, Clark OH, Rothmund M, Duh QY| | PubMed
  365. Sestamibi scanning is inadequate for directing unilateral neck exploration for first-time parathyroidectomy.
    Shen W, Sabanci U, Morita ET, Siperstein AE, Duh QY, Clark OH| | PubMed
  366. The role of growth factors in proliferation and invasion of thyroid cancer.
    Hoelting T, Duh Q, Clark O, Herfarth C| | PubMed
  367. Primary hyperparathyroidism: functioning hemorrhagic parathyroid cyst.
    Gooding GA, Duh QY| | PubMed
  368. Familial hyperparathyroidism without multiple endocrine neoplasia.
    Huang SM, Duh QY, Shaver J, Siperstein AE, Kraimps JL, Clark OH| | PubMed
  369. Desensitization of cyclic adenosine 3,5'-monophosphate response to thyrotropin in normal and primary or metastatic papillary thyroid cancer cells in vitro.
    Tezelman S, Siperstein AE, Duh QY, Wong MG, Clark OH| | PubMed
  370. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines.
    Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, Duh QY| | PubMed
  371. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines.
    Jossart GH, Epstein HD, Shaver JK, Weier HU, Greulich KM, Tezelman S, Grossman RF, Siperstein AE, Duh QY, Clark OH| | PubMed
  372. Laparoscopic adrenalectomy. Comparison of the lateral and posterior approaches.
    Duh QY, Siperstein AE, Clark OH, Schecter WP, Horn JK, Harrison MR, Hunt TK, Way LW| | PubMed
  373. Reoperation for persistent or recurrent primary hyperparathyroidism.
    Shen W, Düren M, Morita E, Higgins C, Duh QY, Siperstein AE, Clark OH| | PubMed
  374. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo.
    Hoelting T, Duh QY, Clark OH, Herfarth C| | PubMed
  375. Tamoxifen antagonizes proliferation and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C.
    Hoelting T, Duh QY, Clark OH, Herfarth C| | PubMed
  376. A novel multicolor hybridization scheme applied to localization of a transcribed sequence (D10S170/H4) and deletion mapping in the thyroid cancer cell line TPC-1.
    Jossart GH, O'Brien B, Cheng JF, Tong Q, Jhiang SM, Duh Q, Clark OH, Weier HU| | PubMed
  377. The regulation of proliferation and invasion in differentiated thyroid cancer by growth factors.
    Hoelting T, Duh QY, Clark OH, Herfarth C| | PubMed
  378. Molecular and cytogenetic characterization of a t(1;10;21) translocation in the human papillary thyroid cancer cell line TPC-1 expressing the ret/H4 chimeric transcript.
    Jossart GH, Greulich KM, Siperstein AE, Duh Q, Clark OH, Weier HU| | PubMed
  379. Persistent or recurrent hyperparathyroidism in patients with double adenomas.
    Tezelman S, Shen W, Siperstein AE, Duh QY, Clark OH| | PubMed
  380. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study.
    Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH| | PubMed
  381. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment.
    Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH| | PubMed
  382. The laminin alpha 1 chain Ile-Lys-Val-Ala-Val (IKVAV)-containing peptide promotes liver colonization by human colon cancer cells.
    Bresalier RS, Schwartz B, Kim YS, Duh QY, Kleinman HK, Sullam PM| | PubMed
  383. Thyroid growth factors, signal transduction pathways, and oncogenes.
    Duh QY, Grossman RF| | PubMed
  384. Immunoprecipitation isolates multiple TSH receptor forms from human thyroid tissue.
    Grossman RF, Ban T, Duh QY, Tezelman S, Jossart G, Soh EY, Clark OH, Siperstein AE| | PubMed
  385. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro.
    Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH| | PubMed
  386. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro.
    Hölting T, Siperstein AE, Clark OH, Duh QY| | PubMed
  387. Prospective evaluation of the safety and efficacy of laparoscopic jejunostomy.
    Duh QY, Senokozlieff-Englehart AL, Siperstein AE, Pearl J, Grant JP, Twomey PL, Gadacz TR, Prinz RA, Wolfe BM, Soper NJ| | PubMed
  388. Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy.
    Tezelman S, Rodriguez JM, Shen W, Siperstein AE, Duh QY, Clark OH| | PubMed
  389. Tamoxifen inhibits growth, migration, and invasion of human follicular and papillary thyroid cancer cells in vitro and in vivo.
    Hoelting T, Siperstein AE, Duh QY, Clark OH| | PubMed
  390. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines.
    Hölting T, Zielke A, Siperstein AE, Clark OH, Duh QY| | PubMed
  391. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.
    Hoelting T, Siperstein AE, Clark OH, Duh QY| | PubMed
  392. Localization procedures in patients with persistent or recurrent hyperparathyroidism.
    Rodriquez JM, Tezelman S, Siperstein AE, Duh QY, Higgins C, Morita E, Dowd CF, Clark OH| | PubMed
  393. Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.
    Hoelting T, Zielke A, Siperstein AE, Clark OH, Duh QY| | PubMed
  394. Desensitization of adenylate cyclase in Chinese hamster ovary cells transfected with human thyroid-stimulating hormone receptor.
    Tezelman S, Shaver JK, Grossman RF, Liang W, Siperstein AE, Duh QY, Clark OH| | PubMed
  395. Primary parathyroid hyperplasia associated with thyroid hemiagenesis and agenesis of the isthmus.
    Duh QY, Ciulla TA, Clark OH| | PubMed
  396. Diagnosis, treatment, and outcome of follicular thyroid carcinoma.
    Emerick GT, Duh QY, Siperstein AE, Burrow GN, Clark OH| | PubMed
  397. Laparoscopic procedures for small bowel disease.
    Duh QY| | PubMed
  398. Thyroid-stimulating hormone activates phospholipase C in normal and neoplastic thyroid tissue.
    Shaver JK, Tezelman S, Siperstein AE, Duh QY, Clark OH| | PubMed
  399. Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC- rather than PKA-activation.
    Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH| | PubMed
  400. Double parathyroid adenomas. Clinical and biochemical characteristics before and after parathyroidectomy.
    Tezelman S, Shen W, Shaver JK, Siperstein AE, Duh QY, Klein H, Clark OH| | PubMed
  401. Tumoral calcinosis. Controversies in the etiology and alternatives in the treatment.
    Tezelman S, Siperstein AE, Duh QY, Clark OH| | PubMed
  402. Diagnostic laparoscopy and laparoscopic cecostomy for colonic pseudo-obstruction.
    Duh QY, Way LW| | PubMed
  403. Increased phospholipase C activity in neoplastic thyroid membrane.
    Kobayashi K, Shaver JK, Liang W, Siperstein AE, Duh QY, Clark OH| | PubMed
  404. Laparoscopic gastrostomy using T-fasteners as retractors and anchors.
    Duh QY, Way LW| | PubMed
  405. Laparoscopic jejunostomy using T-fasteners as retractors and anchors.
    Duh QY, Way LW| | PubMed
  406. Hyperparathyroidism in multiple endocrine neoplasia syndrome.
    Kraimps JL, Duh QY, Demeure M, Clark OH| | PubMed
  407. Set-point for parathyroid hormone release increases with postmaturational aging in the rat.
    Udén P, Halloran B, Daly R, Duh QY, Clark O| | PubMed
  408. Normocalcemic hyperparathyroidism. Biochemical and symptom profiles before and after surgery.
    Siperstein AE, Shen W, Chan AK, Duh QY, Clark OH| | PubMed
  409. Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery.
    Udén P, Chan A, Duh QY, Siperstein A, Clark OH| | PubMed
  410. Unilateral neck exploration for primary hyperparathyroidism: analysis of a controversy using a mathematical model.
    Duh QY, Udén P, Clark OH| | PubMed
  411. Reoperative thyroid surgery.
    Levin KE, Clark AH, Duh QY, Demeure M, Siperstein AE, Clark OH| | PubMed
  412. The efficacy and limitations of percutaneous endoscopic gastrostomy.
    Jarnagin WR, Duh QY, Mulvihill SJ, Ridge JA, Schrock TR, Way LW| | PubMed
  413. Thyroid growth factors and oncogenes.
    Clark OH, Duh QY| | PubMed
  414. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach.
    Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH| | PubMed
  415. Calciphylaxis in secondary hyperparathyroidism. Diagnosis and parathyroidectomy.
    Duh QY, Lim RC, Clark OH| | PubMed
  416. Diagnosis and management of asymptomatic hyperparathyroidism: safety, efficacy, and deficiencies in our knowledge.
    Clark OH, Wilkes W, Siperstein AE, Duh QY| | PubMed
  417. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis.
    Bresalier RS, Niv Y, Byrd JC, Duh QY, Toribara NW, Rockwell RW, Dahiya R, Kim YS| | PubMed
  418. Thyroid cancer.
    Clark OH, Duh QY| | PubMed
  419. Actin architecture of cultured human thyroid cancer cells: predictor of differentiation?
    Demeure MJ, Hughes-Fulford M, Goretzki PE, Duh QY, Clark OH| | PubMed
  420. Results of surgical treatment for hyperparathyroidism associated with renal disease.
    Demeure MJ, McGee DC, Wilkes W, Duh QY, Clark OH| | PubMed
  421. Two G protein oncogenes in human endocrine tumors.
    Lyons J, Landis CA, Harsh G, Vallar L, Grünewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR| | PubMed
  422. Epidermal growth factor receptors and adenylate cyclase activity in human thyroid tissues.
    Duh QY, Siperstein AE, Miller RA, Sancho JJ, Demeure MJ, Clark OH| | PubMed
  423. Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis.
    Bresalier RS, Rockwell RW, Dahiya R, Duh QY, Kim YS| | PubMed
  424. A new experimental model for secondary hyperparathyroidism.
    Sancho JJ, Duh QY, Oms L, Sitges-Serra A, Hammond ME, Arnaud CD, Clark OH| | PubMed
  425. TSH binding correlates with TSH-stimulated thyroid adenylate cyclase activity in human thyroid tissues.
    Duh QY, Siperstein AE, Miller RA, Smeds S, Clark OH| | PubMed
  426. Medullary thyroid carcinoma. The need for early diagnosis and total thyroidectomy.
    Duh QY, Sancho JJ, Greenspan FS, Hunt TK, Galante M, deLorimier AA, Conte FA, Clark OH| | PubMed
  427. Primary hyperparathyroidism. A surgical perspective.
    Clark OH, Duh QY| | PubMed
  428. Localizing studies in patients with persistent or recurrent hyperparathyroidism.
    Levin KE, Gooding GA, Okerlund M, Higgins CB, Norman D, Newton TH, Duh QY, Arnaud CD, Siperstein AE, Zeng QH| | PubMed
  429. Carcinoids associated with multiple endocrine neoplasia syndromes.
    Duh QY, Hybarger CP, Geist R, Gamsu G, Goodman PC, Gooding GA, Clark OH| | PubMed
  430. Factors influencing the growth of normal and neoplastic thyroid tissue.
    Duh QY, Clark OH| | PubMed
  431. Parathyroid localization. Clinical review.
    Duh QY, Sancho JJ, Clark OH| | PubMed
  432. Parathyroid hormone: before and after parathyroidectomy.
    Duh QY, Arnaud CD, Levin KE, Clark OH| | PubMed
  433. Decrease in serum uric acid level following parathyroidectomy in patients with primary hyperparathyroidism.
    Duh QY, Morris RC, Arnaud CD, Clark OH| | PubMed
  434. Epidermal growth factor receptors in parathyroid tumors.
    Duh QY, Gum ET, Sancho JJ, Levin KE, Raper SE, Clark OH| | PubMed
  435. Epidermal growth factor receptors in normal and neoplastic thyroid tissue.
    Duh QY, Gum ET, Gerend PL, Raper SE, Clark OH| | PubMed
  436. Localization studies in patients with persistent or recurrent hyperparathyroidism.
    Clark OH, Okerlund MD, Moss AA, Stark D, Norman D, Newton TH, Duh QY, Arnaud CD, Harris S, Gooding GA| | PubMed
  437. Value of high resolution real-time ultrasonography in secondary hyperparathyroidism.
    Clark OH, Stark DA, Duh QY, Arnaud CD, Gooding GA| | PubMed
laura_esserman new
Laura J. Esserman, MD, MBA

Professor of Surgery and Radiology
Chief, Section of Breast Care Surgery
Division of Surgical Oncology
Alfred A. de Lorimier Endowed Chair in General Surgery
Director, UCSF Breast Care Center

Section:
Breast Surgery
Research Interests

Translational and basic science approaches combining bioinformatics, medical and clinical informatics, patient advocacy, and systems integration to improve breast cancer clinical care

Research Type:
Basic Biomedical and Translational
Clinical Discovery and Health Services
Disease focus:
Multi-disciplinary clinical trials to improve breast cancer care
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 467
  1. Impact of IVF Restriction on Patients With Cancer and Surgeons.
    Glencer AC, Esserman LJ| | PubMed
  2. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
    Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ| | PubMed
  3. National yearly cost of breast cancer screening in the USA and projected cost of advocated guidelines: a simulation study with life table modelling.
    Badal K, Staib J, Tice JA, Kim MO, Eklund M, Wilson L, Dacosta Byfield S, Catlett K, Maffey L, Soonavala R, Shieh Y, Esserman LJ| | PubMed
  4. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
    Mukhtar RA, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, Boughey JC, Goetz MP, Hoskin T, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Provenzano E, Sammut SJ, Thomas JS, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, J van 't Veer L, Cameron D, Esserman LJ, Fraser Symmans W| | PubMed
  5. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
    Boughey JC, Yu H, Switalla K, Velle L, Lopes A, Wallace AM, Lancaster RB, Reyna CR, Tuttle TM, Jaskowiak N, Tchou J, Rao R, Lee MC, Naik AM, Golshan M, Arciero CA, Sauder CAM, Matsen CB, Yau C, Esserman L, Mukhtar RA, I-SPY2 Locoregional Working Group| | PubMed
  6. Implantation of engineered adipocytes suppresses tumor progression in cancer models.
    Nguyen HP, An K, Ito Y, Kharbikar BN, Sheng R, Paredes B, Murray E, Pham K, Bruck M, Zhou X, Biellak C, Ushiki A, Nobuhara M, Fong SL, Bernards DA, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Klein JA, Valdiviez L, Fiehn O, Esserman L, Desai TA, Yee SW, Rosenbluth JM, Ahituv N| | PubMed
  7. Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk.
    O'Keefe TJ, Alvarado MD, Esserman LJ| | PubMed
  8. Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
    Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L| | PubMed
  9. Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
    Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M, Valdez J, Morgan T, Garber J, Esserman L| | PubMed
  10. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, Melisko M, Castillo P, Brown T, Heditsian D, Brain S, Simmons C, Hieken T, Ruddy KJ, Mainor C, Afghahi A, Tevis S, Blaes A, Kang I, Asare A, Esserman L, Hershman DL, Basu A| | PubMed
  11. Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.
    Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Tobin NP, Yau C, Benz CC, Esserman LJ, van 't Veer LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS| | PubMed
  12. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ| | PubMed
  13. Relationship Between Perceived COVID-19 Risk and Change in Perceived Breast Cancer Risk: Prospective Observational Study.
    Baxter-King R, Naeim A, Huang TQ, Sepucha K, Stanton A, Rudkin A, Ryu R, Sabacan L, Vavreck L, Esserman L, Stover Fiscalini A, Wenger NS| | PubMed
  14. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
    Li W, Le NN, Nadkarni R, Onishi N, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Mukhtar RA, Gennatas ED, Kornak J, Magbanua MJM, Van't Veer LJ, LeStage B, Esserman LJ, Hylton NM| | PubMed
  15. A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.
    Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M, Valdez J, Morgan T, Garber J, Esserman L| | PubMed
  16. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    Falade I, Switalla K, Quirarte A, Baxter M, Soroudi D, Rothschild H, Abe SE, Goodwin K, Piper M, Alvarado M, Julian BQ, Ewing C, Wong J, Rose J, Esserman L, Foster R, Mukhtar RA| | PubMed
  17. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L| | PubMed
  18. Screening Mammography for 40-Year-Old Women-Whose Decision?
    Kerlikowske K, Esserman L, Tice JA| | PubMed
  19. Gut and oral microbial compositional differences in women with breast cancer, women with ductal carcinoma in situ, and healthy women.
    McCune E, Sharma A, Johnson B, O'Meara T, Theiner S, Campos M, Heditsian D, Brain S, Gilbert JA, Esserman L, Campbell MJ| | PubMed
  20. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
    Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS| | PubMed
  21. Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
    Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ| | PubMed
  22. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ| | PubMed
  23. Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.
    Fabian CJ, Mudaranthakam DP, Gajewski B, Young K, Winblad O, Khan SA, Garber JE, Esserman LJ, Yee LD, Nye L, Powers KR, Ranallo L, Kreutzjans AL, Pittman K, Altman C, Metheny T, Zelenchuk A, Komm BS, Kimler BF| | PubMed
  24. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ| | PubMed
  25. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ| | PubMed
  26. Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence.
    Franklin JB, Marra C, Abebe KZ, Butte AJ, Cook DJ, Esserman L, Fleisher LA, Grossman CI, Kass NE, Krumholz HM, Rowan K, Abernethy AP, JAMA Summit on Clinical Trials Participants| | PubMed
  27. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  28. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA| | PubMed
  29. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, , ISPY2 Locoregional Working Group| | PubMed
  30. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  31. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L| | PubMed
  32. Reproductive rights in the United States: acquiescence is not a strategy.
    Esserman LJ, Yee D| | PubMed
  33. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME, Wulfkuhle J, Gallagher RI, Gomez H, Isaacs C, Bharti V, Wilson JT, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Hirst GL, Brown Swigart L, van 't Veer LJ, Esserman LJ, Petricoin EF, Pietenpol JA, Balko JM| | PubMed
  34. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
    Ríos-Hoyo A, Cobain E, Huppert LA, Beitsch PD, Buchholz TA, Esserman L, van 't Veer LJ, Rugo HS, Pusztai L| | PubMed
  35. RE: Supplemental magnetic resonance imaging plus mammography compared with magnetic resonance imaging or mammography by extent of breast density.
    Omoleye OJ, Esserman LJ, Olopade OI| | PubMed
  36. Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).
    Lindgren ES, Yan R, Cil O, Verkman AS, Chan MF, Seitzman GD, Farooq AV, Huppert LA, Rugo HS, Pohlmann PR, Lu J, Esserman LJ, Pasricha ND| | PubMed
  37. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Yu S, Hirst G, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H| | PubMed
  38. 18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
    Diwanji D, Onishi N, Hathi DK, Lawhn-Heath C, Kornak J, Li W, Guo R, Molina-Vega J, Seo Y, Flavell RR, Heditsian D, Brain S, Esserman LJ, Joe BN, Hylton NM, Jones EF, Ray KM| | PubMed
  39. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    Alkhafaji S, Wolf DM, Magbanua MJM, J van 't Veer L, Park JW, Esserman L, Mukhtar RA| | PubMed
  40. Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.
    Alipanah-Lechner N, Hurst-Hopf J, Delucchi K, Swigart L, Willmore A, LaCombe B, Dewar R, Lane HC, Lallemand P, Liu KD, Esserman L, Matthay MA, Calfee CS, I-SPY COVID Consortium| | PubMed
  41. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
    Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ| | PubMed
  42. Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.
    O'Keefe T, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, McGuire J, Griffin A, Wallace A, Esserman L, Harismendy O, Hirst G| | PubMed
  43. Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.
    Umashankar S, Li M, Blevins K, Kim MO, Majure M, Park J, Huppert LA, Melisko M, Rugo HS, Esserman L, Chien AJ| | PubMed
  44. Precision Oncology in Breast Cancer Surgery.
    Abbasi AB, Wu V, Lang JE, Esserman LJ| | PubMed
  45. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF| | PubMed
  46. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI| | PubMed
  47. Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients.
    Umashankar S, Basu A, Esserman L, Van't Veer L, Melisko ME| | PubMed
  48. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA| | PubMed
  49. Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
    Ho KKY, Kaiser UB, Chanson P, Gadelha M, Wass J, Nieman L, Little A, Aghi MK, Raetzman L, Post K, Raverot G, Borowsky AD, Erickson D, Castaño JP, Laws ER, Zatelli MC, Sisco J, Esserman L, Yuen KCJ, Reincke M, Melmed S| | PubMed
  50. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    Kaur M, Patterson A, Molina-Vega J, Rothschild H, Clelland E, Ewing CA, Mujir F, Esserman LJ, Olopade OI, Mukhtar RA| | PubMed
  51. Early Ascertainment of Breast Cancer Diagnoses Comparing Self-Reported Questionnaires and Electronic Health Record Data Warehouse: The WISDOM Study.
    Leggat-Barr K, Ryu R, Hogarth M, Stover-Fiscalini A, Veer LV', Park HL, Lewis T, Thompson C, Borowsky A, Hiatt RA, LaCroix A, Parker B, Madlensky L, Naeim A, Esserman L| | PubMed
  52. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    Rothschild HT, Clelland EN, Abel MK, Chien AJ, Shui AM, Esserman L, Khan SA, Mukhtar RA| | PubMed
  53. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    Rothschild HT, Clelland EN, Mujir F, Record H, Wong J, Esserman LJ, Alvarado M, Ewing C, Mukhtar RA| | PubMed
  54. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network| | PubMed
  55. A Truly Pro-Life Position Requires Access to Reproductive Health Care.
    Hull SC, Chou JC, Yee LM, Yee D, Esserman L| | PubMed
  56. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA| | PubMed
  57. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group| | PubMed
  58. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M| | PubMed
  59. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study.
    Arasu VA, Habel LA, Achacoso NS, Buist DSM, Cord JB, Esserman LJ, Hylton NM, Glymour MM, Kornak J, Kushi LH, Lewis DA, Liu VX, Lydon CM, Miglioretti DL, Navarro DA, Pu A, Shen L, Sieh W, Yoon HC, Lee C| | PubMed
  60. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    Mukhtar RA, Yau C, Esserman LJ| | PubMed
  61. Development and testing of a polygenic risk score for breast cancer aggressiveness.
    Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer LV, Esserman LJ, Ziv E| | PubMed
  62. Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.
    Wang T, Che M, Huilgol YS, Keane H, Goodman D, Soonavala R, Ozanne E, Shieh Y, Belkora JK, Fiscalini AS, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ| | PubMed
  63. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  64. Time to Surgery in Breast Cancer-Is Faster Always Better?
    Mukhtar RA, Esserman LJ| | PubMed
  65. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ| | PubMed
  66. Guiding principles for the responsible development of artificial intelligence tools for healthcare.
    Badal K, Lee CM, Esserman LJ| | PubMed
  67. Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy.
    Chitalia R, Miliotis M, Jahani N, Tastsoglou S, McDonald ES, Belenky V, Cohen EA, Newitt D, Van't Veer LJ, Esserman L, Hylton N, DeMichele A, Hatzigeorgiou A, Kontos D| | PubMed
  68. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression.
    Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N| | PubMed
  69. When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
    Esserman LJ, Ali H, McKenzie T| | PubMed
  70. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    Barnes LL, Foster R, Mukhtar RA, Esserman LJ, Ewing C, Alvarado M, Wong J, Piper M| | PubMed
  71. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A| | PubMed
  72. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  73. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  74. Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A| | PubMed
  75. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA| | PubMed
  76. Informed consent process in the ISPY COVID trial is ethically acceptable.
    Files DC, Esserman L, Liu KD, Calfee CS| | PubMed
  77. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment.
    Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE| | PubMed
  78. Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy.
    Li W, Le NN, Onishi N, Newitt DC, Wilmes LJ, Gibbs JE, Carmona-Bozo J, Liang J, Partridge SC, Price ER, Joe BN, Kornak J, Magbanua MJM, Nanda R, LeStage B, Esserman LJ, Van't Veer LJ, Hylton NM| | PubMed
  79. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS| | PubMed
  80. Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.
    Noordhoek I, Bastiaannet E, de Glas NA, Scheepens J, Esserman LJ, Wesseling J, Scholten AN, Schröder CP, Elias SG, Kroep JR, Portielje JEA, Kleijn M, Liefers GJ| | PubMed
  81. Why It Is Time to Challenge Entrenched Beliefs About Breast Cancer Screening.
    Esserman LJ, Parker BA, LaCroix AZ| | PubMed
  82. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A| | PubMed
  83. Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting.
    Chien AJ, Kyalwazi B, Esserman LJ| | PubMed
  84. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.
    Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeehan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD, ISPY COVID Adaptive Platform Trial Network, undefined| | PubMed
  85. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ| | PubMed
  86. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium| | PubMed
  87. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer.
    Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM| | PubMed
  88. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    Mukhtar R, Symmans WF, Esserman LJ| | PubMed
  89. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
    Johansson A, Yu NY, Iftimi A, Tobin NP, van 't Veer L, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, Esserman LJ, Yau C, Lindström LS| | PubMed
  90. Survivorship after neoadjuvant chemotherapy - Authors' reply.
    Yau C, Osdoit M, Esserman LJ, Symmans WF| | PubMed
  91. Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship-Associated Distress: Survey Study.
    Umashankar S, Mamounas ME, Matthys M, Hadeler EK, Wong EC, Hicks G, Hwang J, Chien AJ, Rugo HS, Hamolsky D, Esserman L, Melisko M| | PubMed
  92. Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.
    Lopes Cardozo JMN, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, van 't Veer LJ| | PubMed
  93. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O| | PubMed
  94. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    Abel MK, Shui AM, Melisko M, Chien AJ, Yoshida EJ, Lancaster EM, Van 't Veer L, Esserman LJ, Mukhtar RA| | PubMed
  95. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF| | PubMed
  96. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer.
    Dreher N, Matthys M, Hadeler E, Shieh Y, Acerbi I, McAuley FM, Melisko M, Eklund M, Tice JA, Esserman LJ, Veer LJV| | PubMed
  97. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
    Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM| | PubMed
  98. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A| | PubMed
  99. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ| | PubMed
  100. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    Abel MK, Melisko ME, Rugo HS, Chien AJ, Diaz I, Levine JK, Griffin A, McGuire J, Esserman LJ, Borno HT, Mukhtar RA| | PubMed
  101. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ| | PubMed
  102. Pre-Appointment Nurse Navigation: Patient-Centered Findings From a Survey of Patients With Breast Cancer.
    Wang T, Huilgol YS, Black J, D'Andrea C, James J, Northrop A, Belkora J, Esserman LJ| | PubMed
  103. Health screening needs independent regular re-evaluation.
    Ropers FG, Barratt A, Wilt TJ, Nicholls SG, Taylor-Phillips S, Kramer BS, Esserman LJ, Norris SL, Gibson LM, Harris RP, Carter SM, Jacklyn G, Jørgensen KJ| | PubMed
  104. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    Khoury AL, Keane H, Varghese F, Hosseini A, Mukhtar R, Eder SE, Weinstein PR, Esserman LJ| | PubMed
  105. The WISDOM study: a new approach to screening can and should be tested.
    Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M| | PubMed
  106. The use of neoadjuvant therapy to further personalize breast cancer treatment.
    Esserman LJ| | PubMed
  107. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM| | PubMed
  108. Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.
    Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ| | PubMed
  109. Authors' Reply: To the Letter to the Editor by Groheux et al.
    Heath CL, Esserman LJ, Flavell RR, Melisko ME| | PubMed
  110. Advancing precision medicine for acute respiratory distress syndrome.
    Beitler JR, Thompson BT, Baron RM, Bastarache JA, Denlinger LC, Esserman L, Gong MN, LaVange LM, Lewis RJ, Marshall JC, Martin TR, McAuley DF, Meyer NJ, Moss M, Reineck LA, Rubin E, Schmidt EP, Standiford TJ, Ware LB, Wong HR, Aggarwal NR, Calfee CS| | PubMed
  111. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.
    Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ| | PubMed
  112. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
    Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  113. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA| | PubMed
  114. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A| | PubMed
  115. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS| | PubMed
  116. Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
    Glencer AC, Wong JM, Hylton NM, Krings G, McCune E, Rothschild HT, Loveday TA, Alvarado MD, Esserman LJ, Campbell MJ| | PubMed
  117. Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.
    Matthys MB, Dempsey AM, Melisko ME, Dreher N, Che ML, Van't Veer LJ, Esserman LJ, Basu A| | PubMed
  118. Mask-Guided Convolutional Neural Network for Breast Tumor Prognostic Outcome Prediction on 3D DCE-MR Images.
    Liu G, Mitra D, Jones EF, Franc BL, Behr SC, Nguyen A, Bolouri MS, Wisner DJ, Joe BN, Esserman LJ, Hylton NM, Seo Y| | PubMed
  119. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
    Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L| | PubMed
  120. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    Abel MK, Greenwood H, Kelil T, Guo R, Brabham C, Hylton N, Wong J, Alvarado M, Ewing C, Esserman LJ, Boughey JC, Mukhtar RA| | PubMed
  121. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF| | PubMed
  122. Characterizing the Tumor Immune Microenvironment with Tyramide-Based Multiplex Immunofluorescence.
    Mori H, Bolen J, Schuetter L, Massion P, Hoyt CC, VandenBerg S, Esserman L, Borowsky AD, Campbell MJ| | PubMed
  123. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    Scheepens JCC, Veer LV', Esserman L, Belkora J, Mukhtar RA| | PubMed
  124. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    Hansen KS, Ghersin H, Piper M, Tavakol M, Lee B, Esserman LJ, Roberts JP, Freise C, Ascher NL, Mukhtar RA| | PubMed
  125. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer.
    Steenbruggen TG, Schaapveld M, Horlings HM, Sanders J, Hogewoning SJ, Lips EH, Vrancken Peeters MT, Kok NF, Wiersma T, Esserman L, van 't Veer LJ, Linn SC, Siesling S, Sonke GS| | PubMed
  126. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    Mukhtar RA, Brabham CE, Guo R, Abel MK, Wong J, Ewing C, Esserman LJ, Alvarado M| | PubMed
  127. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
    Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ| | PubMed
  128. Prime Time for Consultation Audio Recordings: Supporting Shared Decision Making During and After the COVID-19 Era.
    Kwon DH, Aggarwal RR, Esserman LJ, Belkora JK| | PubMed
  129. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET.
    Hathi DK, Li W, Seo Y, Flavell RR, Kornak J, Franc BL, Joe BN, Esserman LJ, Hylton NM, Jones EF| | PubMed
  130. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
    Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM| | PubMed
  131. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ| | PubMed
  132. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O| | PubMed
  133. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
    Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME| | PubMed
  134. Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M| | PubMed
  135. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
    Basu A, Philip EJ, Dewitt B, Hanmer J, Chattopadhyay A, Yau C, Melisko ME, Esserman LJ| | PubMed
  136. The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment.
    Hewitt K, Son J, Glencer A, Borowsky AD, Cooperberg MR, Esserman LJ| | PubMed
  137. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA| | PubMed
  138. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L| | PubMed
  139. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA| | PubMed
  140. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective.
    Sharib J, Esserman L, Koay EJ, Maitra A, Shen Y, Kirkwood KS, Ozanne EM| | PubMed
  141. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
    Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators| | PubMed
  142. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    Abel MK, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Park C, Mukhtar RA| | PubMed
  143. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    Abel MK, Brabham CE, Guo R, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Mukhtar RA| | PubMed
  144. Personalized early detection and prevention of breast cancer: ENVISION consensus statement.
    Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, De Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M| | PubMed
  145. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM| | PubMed
  146. Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy.
    Nguyen AA, Arasu VA, Strand F, Li W, Onishi N, Gibbs J, Jones EF, Joe BN, Esserman LJ, Newitt DC, Hylton NM| | PubMed
  147. Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial.
    Onishi N, Li W, Gibbs J, Wilmes LJ, Nguyen A, Jones EF, Arasu V, Kornak J, Joe BN, Esserman LJ, Newitt DC, Hylton NM| | PubMed
  148. Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Li W, Newitt DC, Yun B, Jones EF, Arasu V, Wilmes LJ, Gibbs J, Nguyen AA, Onishi N, Kornak J, Joe BN, Esserman LJ, Hylton NM| | PubMed
  149. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ| | PubMed
  150. Personalization of Treatment is the Way Forward in Care and Trials.
    Esserman LJ| | PubMed
  151. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Mukhtar RA, Krings G, Chen YY, Mamounas ME, Fahrner-Scott K, Wong J, Alvarado M, Ewing C, Esserman LJ, Rugo H| | PubMed
  152. Response to Carter et al.
    Eklund M, Broglio K, Yau C, Connor JT, Fiscalini AS, Esserman LJ| | PubMed
  153. Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
    Hwang ES, Hyslop T, Hendrix LH, Duong S, Bedrosian I, Price E, Caudle A, Hieken T, Guenther J, Hudis CA, Winer E, Lyss AP, Dickson-Witmer D, Hoefer R, Ollila DW, Hardman T, Marks J, Chen YY, Krings G, Esserman L, Hylton N| | PubMed
  154. We need more evidence to answer questions about screening.
    Esserman L| | PubMed
  155. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS| | PubMed
  156. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    Piper ML, Wong J, Fahrner-Scott K, Ewing C, Alvarado M, Esserman LJ, Mukhtar RA| | PubMed
  157. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
    Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS| | PubMed
  158. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel.
    Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ| | PubMed
  159. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW| | PubMed
  160. Fitbit Usage in Patients With Breast Cancer Undergoing Chemotherapy.
    Dreher N, Hadeler EK, Hartman SJ, Wong EC, Acerbi I, Rugo HS, Majure MC, Chien AJ, Esserman LJ, Melisko ME| | PubMed
  161. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
    Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J, I-SPY 2 Consortium, Esserman LJ, Hylton NM| | PubMed
  162. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM| | PubMed
  163. A response to "Personalised medicine and population health: breast and ovarian cancer".
    Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E| | PubMed
  164. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium| | PubMed
  165. Should we rename low risk cancers?
    Esserman LJ, Varma M| | PubMed
  166. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
    Ozanne EM, Howe R, Mallinson D, Esserman L, Van't Veer LJ, Kaplan CP| | PubMed
  167. The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
    Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscalini A, Esserman LJ| | PubMed
  168. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators| | PubMed
  169. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E| | PubMed
  170. Precision risk-based screening might maximize benefit and minimize harm.
    Esserman LJ, LaCroix AZ| | PubMed
  171. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
    Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM, ACRIN Trial Team and I-SPY 2 TRIAL Investigators| | PubMed
  172. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.
    Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW| | PubMed
  173. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
    Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM, ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators| | PubMed
  174. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators| | PubMed
  175. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
    Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF| | PubMed
  176. Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.
    Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y| | PubMed
  177. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L| | PubMed
  178. The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.
    Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS| | PubMed
  179. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, STO Trialists Group| | PubMed
  180. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K| | PubMed
  181. Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers.
    Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR, Beswick A, Greenwood R, Ingram JC, Saunders C, Vaidya JS, Esserman L, Jatoi I, Brunt AM| | PubMed
  182. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
    Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network| | PubMed
  183. Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy.
    Chiu C, Aleshi P, Esserman LJ, Inglis-Arkell C, Yap E, Whitlock EL, Harbell MW| | PubMed
  184. Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization.
    Price ER, Khoury AL, Esserman LJ, Joe BN, Alvarado MD| | PubMed
  185. Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction.
    Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B| | PubMed
  186. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
    Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC| | PubMed
  187. Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
    Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM| | PubMed
  188. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.
    DeMichele A, Yee D, Esserman L| | PubMed
  189. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS| | PubMed
  190. The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H| | PubMed
  191. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME| | PubMed
  192. The WISDOM Study: breaking the deadlock in the breast cancer screening debate.
    Esserman LJ, WISDOM Study and Athena Investigators| | PubMed
  193. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L| | PubMed
  194. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L| | PubMed
  195. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS| | PubMed
  196. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP| | PubMed
  197. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A| | PubMed
  198. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY| | PubMed
  199. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N, Yau C, Li J, Esserman LJ, Rugo HS| | PubMed
  200. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
    Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP| | PubMed
  201. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS| | PubMed
  202. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.
    Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T| | PubMed
  203. Precision surgery and avoiding over-treatment.
    Hosseini A, Khoury AL, Esserman LJ| | PubMed
  204. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA, Athena Breast Health Network Investigators| | PubMed
  205. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K| | PubMed
  206. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM| | PubMed
  207. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
    Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM, ACRIN Trial team ISPY-1 Investigators| | PubMed
  208. Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction?
    Wang F, Chin R, Piper M, Esserman L, Sbitany H| | PubMed
  209. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.
    Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM, ACRIN 6657 Trial Team and I-SPY Investigators Network| | PubMed
  210. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C| | PubMed
  211. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L| | PubMed
  212. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Berry D, Esserman L| | PubMed
  213. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.
    Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ| | PubMed
  214. The I-SPY approach to drug development.
    Esserman L| | PubMed
  215. Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences.
    Esserman LJ, Thompson IM| | PubMed
  216. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ| | PubMed
  217. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators| | PubMed
  218. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators| | PubMed
  219. When Less Is Better, but Physicians Are Afraid Not to Intervene.
    Esserman L| | PubMed
  220. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
    Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS| | PubMed
  221. Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review.
    Piper ML, Esserman LJ, Sbitany H, Peled AW| | PubMed
  222. Population-based screening for cancer: hope and hype.
    Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ| | PubMed
  223. When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature.
    Borowsky A, Esserman L| | PubMed
  224. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
    Esserman L, Yau C| | PubMed
  225. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
    Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM| | PubMed
  226. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN| | PubMed
  227. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)?
    Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM, MIAMI (Multiple Ipsilateral breast conserving surgery versus mastectomy) Trial Management Group| | PubMed
  228. Detection of ductal carcinoma in situ and subsequent interval cancers.
    Shieh Y, Eklund M, Esserman L| | PubMed
  229. CLINICAL DECISIONS. Ductal Carcinoma In Situ.
    Merrill AL, Esserman L, Morrow M| | PubMed
  230. Less Is More: The Evolving Surgical Approach to Breast Cancer.
    Esserman L, Gallant E, Alvarado M| | PubMed
  231. Neoadjuvant as Future for Drug Development in Breast Cancer--Response.
    DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ, I-SPY2 Investigators| | PubMed
  232. The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction.
    Wang F, Peled AW, Chin R, Fowble B, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H| | PubMed
  233. Tissue Expander Reconstruction After Total Skin-Sparing Mastectomy: Defining the Effects of Coverage Technique on Nipple/Areola Preservation.
    Sbitany H, Wang F, Peled AW, Alvarado M, Ewing CA, Esserman LJ, Foster RD| | PubMed
  234. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome.
    Johnson J, Esserman L, Ewing C, Alvarado M, Park C, Fowble B| | PubMed
  235. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.
    Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators| | PubMed
  236. Rethinking the Standard for Ductal Carcinoma In Situ Treatment.
    Esserman L, Yau C| | PubMed
  237. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer.
    Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ| | PubMed
  238. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.
    Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP| | PubMed
  239. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
    Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF, Residual Disease Characterization Working Group of the Breast International Group-North American Bre| | PubMed
  240. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ| | PubMed
  241. Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease?
    Peled AW, Wang F, Foster RD, Alvarado M, Ewing CA, Sbitany H, Esserman LJ| | PubMed
  242. In Regard to Hepel and Wazer.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M| | PubMed
  243. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    Mukhtar RA, Wong JM, Esserman LJ| | PubMed
  244. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
    Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ| | PubMed
  245. Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management.
    Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman LJ| | PubMed
  246. Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program.
    Belkora J, Volz S, Loth M, Teng A, Zarin-Pass M, Moore D, Esserman L| | PubMed
  247. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
    Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D, Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration| | PubMed
  248. Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction.
    Piper M, Peled AW, Sbitany H, Foster RD, Esserman LJ, Price ER| | PubMed
  249. Approaches to microvascular breast reconstruction after total skin-sparing mastectomy: a comparison of techniques.
    Raghavan S, Peled AW, Hansen SL, Esserman LJ, Sbitany H| | PubMed
  250. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy.
    Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A| | PubMed
  251. Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer.
    Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M, TARGIT trialists' group| | PubMed
  252. The impact of breast mass on outcomes of total skin-sparing mastectomy and immediate tissue expander-based breast reconstruction.
    Wang F, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H| | PubMed
  253. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
    DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ| | PubMed
  254. Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization.
    Warner JL, Maddux SE, Hughes KS, Krauss JC, Yu PP, Shulman LN, Mayer DK, Hogarth M, Shafarman M, Stover Fiscalini A, Esserman L, Alschuler L, Koromia GA, Gonzaga Z, Ambinder EP| | PubMed
  255. Preoperative Breast Pain Predicts Persistent Breast Pain and Disability After Breast Cancer Surgery.
    Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, Hamolsky D, Mastick J, Paul SM, Cooper B, Kober K, Dodd M, Dunn L, Aouizerat B, Miaskowski C| | PubMed
  256. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease.
    Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS| | PubMed
  257. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer.
    Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME| | PubMed
  258. Expression profiling of circulating tumor cells in metastatic breast cancer.
    Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW| | PubMed
  259. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes.
    Sbitany H, Wang F, Peled AW, Lentz R, Alvarado M, Ewing CA, Esserman LJ, Fowble B, Foster RD| | PubMed
  260. Aggregate cost of mammography screening in the United States.
    Eklund M, O'Donoghue C, Esserman LJ| | PubMed
  261. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction.
    Degnim AC, Hoskin TL, Brahmbhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, Ballman K, Baddour LM, Esserman LJ| | PubMed
  262. Haste makes waste, but lack of urgency is opportunity lost.
    Esserman L, Hayes M, Alvarado M| | PubMed
  263. Impact of total skin-sparing mastectomy incision type on reconstructive complications following radiation therapy.
    Peled AW, Foster RD, Ligh C, Esserman LJ, Fowble B, Sbitany H| | PubMed
  264. Moving beyond the breast cancer screening debate.
    Esserman L, O'Kane ME| | PubMed
  265. Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes.
    Wang F, Peled AW, Garwood E, Fiscalini AS, Sbitany H, Foster RD, Alvarado M, Ewing C, Hwang ES, Esserman LJ| | PubMed
  266. Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile.
    Sbitany H, Wang F, Saeed L, Alvarado M, Ewing CA, Esserman LJ, Foster RD| | PubMed
  267. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.
    Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM| | PubMed
  268. Addressing overdiagnosis and overtreatment in cancer: a prescription for change.
    Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S| | PubMed
  269. Fifty years of age-based screening: time for a new risk-based screening approach.
    Kerlikowske K, O'Kane ME, Esserman LJ| | PubMed
  270. Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
    Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ| | PubMed
  271. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy.
    Peled AW, Sbitany H, Foster RD, Esserman LJ| | PubMed
  272. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction.
    Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, Sbitany H| | PubMed
  273. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change?
    Esserman LJ, DeMichele A| | PubMed
  274. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).
    Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A, I-SPY1 Investigators| | PubMed
  275. Setting a research agenda for ductal carcinoma in situ that meets the current need for change.
    Esserman L, Alvarado M| | PubMed
  276. Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time?
    Esserman LJ, Alvarado MD, Howe RJ, Mohan AJ, Harrison B, Park C, O'Donoghue C, Ozanne EM| | PubMed
  277. Abstract 124: outcomes of total skin-sparing mastectomy and reconstruction in 924 breasts over 11 years.
    Wang F, Peled A, Foster R, Wang E, Ewing C, Alvarado M, Esserman L, Sbitany H| | PubMed
  278. Making better doctors: a survey of premedical interns working as health coaches.
    Zarin-Pass M, Belkora J, Volz S, Esserman L| | PubMed
  279. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.
    Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG, Northwestern Cancer Genetics Group| | PubMed
  280. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines.
    O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ| | PubMed
  281. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.
    Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM| | PubMed
  282. Mammographic screening detects low-risk tumor biology breast cancers.
    Drukker CA, Schmidt MK, Rutgers EJ, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, Van't Veer LJ| | PubMed
  283. Development of a personalized decision aid for breast cancer risk reduction and management.
    Ozanne EM, Howe R, Omer Z, Esserman LJ| | PubMed
  284. Changing the terminology of cancer--reply.
    Esserman LJ, Thompson IM, Reid BJ| | PubMed
  285. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.
    Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM| | PubMed
  286. Evolving paradigm for imaging, diagnosis, and management of DCIS.
    Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ| | PubMed
  287. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery.
    Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM| | PubMed
  288. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M, TARGIT trialists' group| | PubMed
  289. Screening: biology dictates the fate of young women with breast cancer.
    Eklund M, Esserman LJ| | PubMed
  290. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ| | PubMed
  291. Impact of ductal carcinoma in situ terminology on patient treatment preferences.
    Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM| | PubMed
  292. Overdiagnosis and overtreatment in cancer: an opportunity for improvement.
    Esserman LJ, Thompson IM, Reid B| | PubMed
  293. Total skin-sparing mastectomy in BRCA mutation carriers.
    Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ| | PubMed
  294. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care.
    Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman LJ, Athena Breast Health Network| | PubMed
  295. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
    Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM| | PubMed
  296. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ| | PubMed
  297. Feasibility of Performing Total Skin-Sparing Mastectomy in Patients With Prior Circumareolar Mastopexy or Reduction Mammoplasty Incisions.
    Vaughn CJ, Peled AW, Esserman LJ, Foster RD| | PubMed
  298. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.
    Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman LJ| | PubMed
  299. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.
    O'Donoghue C, Esserman L| | PubMed
  300. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications.
    Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ| | PubMed
  301. Developing safety criteria for introducing new agents into neoadjuvant trials.
    DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L| | PubMed
  302. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy.
    Peled AW, Esserman LJ| | PubMed
  303. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC| | PubMed
  304. Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions.
    Pass M, Volz S, Teng A, Esserman L, Belkora J| | PubMed
  305. Will early detection for breast cancer ever work?
    Esserman L, Ozanne E, van't Veer L| | PubMed
  306. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.
    Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L| | PubMed
  307. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
    Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American Society of Clinical Oncology| | PubMed
  308. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.
    Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L, I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF| | PubMed
  309. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators| | PubMed
  310. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.
    Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, Van't Veer L, Esserman LJ| | PubMed
  311. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure.
    Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B| | PubMed
  312. Breast cancer screening: the questions answered.
    Autier P, Esserman LJ, Flowers CI, Houssami N| | PubMed
  313. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors.
    Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M| | PubMed
  314. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer.
    Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L| | PubMed
  315. Biology of breast cancer in Nigerian women: a pilot study.
    Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ| | PubMed
  316. Whole-genome analysis informs breast cancer response to aromatase inhibition.
    Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER| | PubMed
  317. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.
    Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M, BIG-NABCG collaboration| | PubMed
  318. Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy.
    Chang EI, Peled AW, Foster RD, Lin C, Zeidler KR, Ewing CA, Alvarado M, Hwang ES, Esserman LJ| | PubMed
  319. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD, ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators| | PubMed
  320. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study.
    Peled AW, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, Hwang ES, Esserman LJ| | PubMed
  321. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N| | PubMed
  322. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ| | PubMed
  323. Breast cancer recurrence is dictated by high-risk biology, not choice of surgery.
    Esserman LJ| | PubMed
  324. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts.
    Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, Hwang ES, Esserman LJ| | PubMed
  325. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
    Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A| | PubMed
  326. Overdiagnosis and overtreatment of breast cancer.
    Alvarado M, Ozanne E, Esserman L| | PubMed
  327. Targeting Molecular Aberrations in Breast Cancer: Is It about Time?
    Esserman L, Benz C, Demichele A| | PubMed
  328. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators| | PubMed
  329. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J| | PubMed
  330. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types.
    Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR| | PubMed
  331. Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
    Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ| | PubMed
  332. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.
    Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES| | PubMed
  333. Leukocyte composition of human breast cancer.
    Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM| | PubMed
  334. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators| | PubMed
  335. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ| | PubMed
  336. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC| | PubMed
  337. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
    Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF| | PubMed
  338. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA| | PubMed
  339. Characterizing the impact of 25 years of DCIS treatment.
    Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ| | PubMed
  340. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.
    Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES| | PubMed
  341. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ| | PubMed
  342. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC| | PubMed
  343. The Communication and Care Plan: a novel approach to patient-centered clinical information systems.
    Hogarth M, Hajopoulos K, Young M, Cowles N, Churin J, Hornthal B, Esserman L| | PubMed
  344. Long-term prognostic role of functional limitations among women with breast cancer.
    Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ| | PubMed
  345. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.
    Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ| | PubMed
  346. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience.
    Liu LC, Lang JE, Lu Y, Roe D, Hwang SE, Ewing CA, Esserman LJ, Morita E, Treseler P, Leong SP| | PubMed
  347. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
    Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES| | PubMed
  348. Lessons learned from genetic testing.
    Esserman L, Kaklamani V| | PubMed
  349. Expanding the reach of decision and communication aids in a breast care center: a quality improvement study.
    Belkora JK, Teng A, Volz S, Loth MK, Esserman LJ| | PubMed
  350. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
    Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M| | PubMed
  351. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
    Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B| | PubMed
  352. Solving the overdiagnosis dilemma.
    Esserman L, Thompson I| | PubMed
  353. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.
    Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ| | PubMed
  354. Application of screening principles to the reconstructed breast.
    Zakhireh J, Fowble B, Esserman LJ| | PubMed
  355. Rethinking screening for breast cancer and prostate cancer.
    Esserman L, Shieh Y, Thompson I| | PubMed
  356. Bacteriologic features of surgical site infections following breast surgery.
    Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES| | PubMed
  357. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
    Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES| | PubMed
  358. A comparison of RNA amplification techniques at sub-nanogram input concentration.
    Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM| | PubMed
  359. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ| | PubMed
  360. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
    Olson JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ| | PubMed
  361. Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer.
    Lang JE, Liu LC, Lu Y, Jenkins T, Hwang SE, Esserman LJ, Ewing CA, Alvarado M, Morita E, Treseler P, Leong SP| | PubMed
  362. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis.
    Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ| | PubMed
  363. The UCSC Cancer Genomics Browser.
    Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T| | PubMed
  364. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.
    Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L| | PubMed
  365. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients.
    Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M, Foster RD, Esserman LJ| | PubMed
  366. When informed, all women do not prefer breast conservation.
    Throckmorton AD, Esserman LJ| | PubMed
  367. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.
    Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J| | PubMed
  368. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
    Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F| | PubMed
  369. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer.
    Zakhireh J, Gomez R, Esserman L| | PubMed
  370. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer?
    Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, Sokol S, Alvarado M, Esserman LJ, Morita E, Treseler P, Leong SP| | PubMed
  371. Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center.
    Belkora JK, Loth MK, Chen DF, Chen JY, Volz S, Esserman LJ| | PubMed
  372. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
    Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM| | PubMed
  373. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates.
    Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L| | PubMed
  374. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
    Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ| | PubMed
  375. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference.
    Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP| | PubMed
  376. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
    Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF| | PubMed
  377. Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow-up interviews about barriers and facilitators to the implementation of consultation planning.
    Belkora J, Edlow B, Aviv C, Sepucha K, Esserman L| | PubMed
  378. Optimizing the total skin-sparing mastectomy.
    Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ| | PubMed
  379. A role for biomarkers in the screening and diagnosis of breast cancer in younger women.
    Esserman LJ, Shieh Y, Park JW, Ozanne EM| | PubMed
  380. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R| | PubMed
  381. Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer.
    Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman LJ| | PubMed
  382. Pilot trial of a computerized decision aid for breast cancer prevention.
    Ozanne EM, Annis C, Adduci K, Showstack J, Esserman L| | PubMed
  383. Ductal carcinoma in situ in BRCA mutation carriers.
    Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL| | PubMed
  384. Analysis of molecular inversion probe performance for allele copy number determination.
    Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M| | PubMed
  385. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
    Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW| | PubMed
  386. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES| | PubMed
  387. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ.
    Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ| | PubMed
  388. Magnetic resonance imaging captures the biology of ductal carcinoma in situ.
    Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM| | PubMed
  389. Breast cancer growth prevention by statins.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC| | PubMed
  390. Evaluation of a visit preparation intervention implemented in two rural, underserved counties of Northern California.
    Belkora J, Katapodi M, Moore D, Franklin L, Hopper K, Esserman L| | PubMed
  391. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM| | PubMed
  392. Clinical trials are required to prove the chemopreventive worth of statins.
    Kumar AS, Benz CC, Esserman LJ| | PubMed
  393. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes.
    Kumar AS, Campbell M, Benz CC, Esserman LJ| | PubMed
  394. Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography.
    Esserman L, Sexton R, Yu QQ, Cabello-Inchausti B| | PubMed
  395. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations.
    Ozanne EM, Klemp JR, Esserman LJ| | PubMed
  396. Genetic/familial high-risk assessment: breast and ovarian.
    Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN, National Comprehensive Cancer Network| | PubMed
  397. Statins: health-promoting agents show promise for breast cancer prevention.
    Kumar AS, Esserman LJ| | PubMed
  398. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis.
    Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM| | PubMed
  399. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI| | PubMed
  400. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer.
    Tan YY, Wu CT, Fan YG, Hwang S, Ewing C, Lane K, Esserman L, Lu Y, Treseler P, Morita E, Leong SP| | PubMed
  401. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
    Fan YG, Tan YY, Wu CT, Treseler P, Lu Y, Chan CW, Hwang S, Ewing C, Esserman L, Morita E, Leong SP| | PubMed
  402. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients.
    Tan YY, Fan YG, Lu Y, Hwang S, Ewing C, Esserman L, Morita E, Treseler P, Leong SP| | PubMed
  403. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.
    Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM| | PubMed
  404. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
    Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA| | PubMed
  405. Immune dysfunction and micrometastases in women with breast cancer.
    Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ| | PubMed
  406. Integration of imaging in the management of breast cancer.
    Esserman L| | PubMed
  407. Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans.
    Misell LM, Hwang ES, Au A, Esserman L, Hellerstein MK| | PubMed
  408. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease.
    Foster RD, Hansen SL, Esserman LJ, Hwang ES, Ewing C, Lane K, Anthony JP| | PubMed
  409. Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment.
    Park C, Seid P, Morita E, Iwanaga K, Weinberg V, Quivey J, Hwang ES, Esserman LJ, Leong SP| | PubMed
  410. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital.
    Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, Esserman L, Shaw L, McLennan J, Strachowski L, Luce J, Ziegler J| | PubMed
  411. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation.
    Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES| | PubMed
  412. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis.
    Ozanne EM, Esserman LJ| | PubMed
  413. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma.
    Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM| | PubMed
  414. Applying the neoadjuvant paradigm to ductal carcinoma in situ.
    Esserman L, Sepucha K, Ozanne E, Hwang ES| | PubMed
  415. Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.
    Esserman L| | PubMed
  416. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
    Hwang ES, Esserman L| | PubMed
  417. An XML message broker framework for exchange and integration of microarray data.
    Tjandra D, Wong S, Shen W, Pulliam B, Yu E, Esserman L| | PubMed
  418. Racial differences in mammographic breast density.
    del Carmen MG, Hughes KS, Halpern E, Rafferty E, Kopans D, Parisky YR, Sardi A, Esserman L, Rust S, Michaelson J| | PubMed
  419. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
    Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ| | PubMed
  420. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.
    Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM| | PubMed
  421. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?
    Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM| | PubMed
  422. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients.
    Wu CT, Morita ET, Treseler PA, Esserman LJ, Hwang ES, Kuerer HM, Santos CL, Leong SP| | PubMed
  423. Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions.
    Parisky YR, Sardi A, Hamm R, Hughes K, Esserman L, Rust S, Callahan K| | PubMed
  424. Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template.
    Sepucha KR, Belkora JK, Aviv C, Mutchnik S, Esserman LJ| | PubMed
  425. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
    Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM| | PubMed
  426. Axillary metastasis from a malignant mullerian mixed tumor.
    Cura MA, Blanco M, Esserman L| | PubMed
  427. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers.
    Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM| | PubMed
  428. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G| | PubMed
  429. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians.
    Sepucha KR, Belkora JK, Mutchnick S, Esserman LJ| | PubMed
  430. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
    Campbell MJ, Wollish WS, Lobo M, Esserman LJ| | PubMed
  431. Magnetic resonance imaging for primary breast cancer management: current role and new applications.
    Esserman L, Wolverton D, Hylton N| | PubMed
  432. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma.
    Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H| | PubMed
  433. New approaches to the imaging, diagnosis, and biopsy of breast lesions.
    Esserman LJ| | PubMed
  434. Improving the accuracy of mammography: volume and outcome relationships.
    Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A| | PubMed
  435. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer.
    Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB| | PubMed
  436. Does timely assessment affect the anxiety associated with an abnormal mammogram result?
    Haas J, Kaplan C, McMillan A, Esserman LJ| | PubMed
  437. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.
    Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N| | PubMed
  438. The impact of alternative practices on the cost and quality of mammographic screening in the United States.
    Burnside E, Belkora J, Esserman L| | PubMed
  439. Ductal growth is impeded in mammary glands of C-neu transgenic mice.
    Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G| | PubMed
  440. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging.
    Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM| | PubMed
  441. Integration of breast imaging into cancer management.
    Esserman LJ, Wolverton D, Hylton N| | PubMed
  442. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.
    Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM| | PubMed
  443. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
    Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ| | PubMed
  444. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer.
    Sepucha KR, Belkora JK, Tripathy D, Esserman LJ| | PubMed
  445. Management of ductal carcinoma in situ.
    Hwang ES, Esserman LJ| | PubMed
  446. Biological therapies for breast carcinoma: concepts for improvement in survival.
    Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM| | PubMed
  447. Prophylactic mastectomy in women with a high risk of breast cancer.
    Kuerer HM, Hwang ES, Esserman LJ| | PubMed
  448. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ| | PubMed
  449. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.
    Esserman L, Hylton N, George T, Weidner N| | PubMed
  450. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging.
    Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E| | PubMed
  451. A multicenter randomized trial of DIAC for cyclical mastopathy.
    Ballagh SA, Stover TL, Maragos TG, Reynolds MD, Wolfley GD, Esserman LJ, Herbst JR, Kirkegaard LW, Teichman SL| | PubMed
  452. Is routine frozen section assessment feasible in the practice environment of the 1990s?
    Esserman L, Weidner N| | PubMed
  453. Hormone replacement therapy and breast cancer risk.
    Burke CC, Gullatte MM, Vigliani M, Ruggiero RJ, Esserman L, Crawford B| | PubMed
  454. Ultrasound tissue characterization of breast biopsy specimens: expanded study.
    Mortensen CL, Edmonds PD, Gorfu Y, Hill JR, Jensen JF, Schattner P, Shifrin LA, Valdes AD, Jeffrey SS, Esserman LJ| | PubMed
  455. Barriers to care and treatment: the challenge of daily radiation therapy.
    Igoe S, Collins C, Hamolsky D, Esserman LJ| | PubMed
  456. Should we recommend screening mammography for women aged 40 to 49?
    Esserman L, Kerlikowske K| | PubMed
  457. Breast.
    Weidner N, Esserman LJ| | PubMed
  458. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast.
    Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD| | PubMed
  459. Potentially ineffective care. A new outcome to assess the limits of critical care.
    Esserman L, Belkora J, Lenert L| | PubMed
  460. Cost per anomaly: what does a diaphragmatic hernia cost?
    Metkus AP, Esserman L, Sola A, Harrison MR, Adzick NS| | PubMed
  461. An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site.
    Takahashi S, Esserman L, Levy R| | PubMed
  462. Follicular lymphoma: a model of lymphoid tumor progression in man.
    Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S| | PubMed
  463. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  464. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
    Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R| | PubMed
  465. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide.
    Campbell MJ, Esserman L, Levy R| | PubMed
  466. Myocardial performance and extracellular ionized calcium in a severely failing human heart.
    Ginsburg R, Esserman LJ, Bristow MR| | PubMed
  467. A novel method for emergency immobilization of the wrist during cross-country skiing.
    Goldman MP, Esserman LJ, Bausback KN, Camargo CA, Nagel DA| | PubMed
View Clinical Trials
  1. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (NCT03053193)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  2. DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (NCT06075953)
    Related Conditions: Ductal Carcinoma in Situ, Breast Cancer, Carcinoma| Start Date: | End Date:
  3. I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (NCT04488081)
    Related Conditions: COVID-19| Start Date: | End Date:
  4. Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens (NCT04821141)
    Related Conditions: Breast Cancer, Menopause| Start Date: | End Date:
  5. Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (NCT02620852)
    Related Conditions: Breast Cancer, Cancer, General| Start Date: | End Date:
  6. Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) (NCT02872025)
    Related Conditions: Carcinoma, Intraductal, Noninfiltrating, Immunotherapy, Carcinoma| Start Date: | End Date:
  7. Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast (NCT00788112)
    Related Conditions: Breast Cancer, Carcinoma| Start Date: | End Date:
  8. Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery (NCT00033397)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  9. Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer (NCT00416403)
    Related Conditions: Breast Cancer, Carcinoma| Start Date: | End Date:
  10. Postoperative Pain Control With Fentanyl Patch in Patients Undergoing Mastectomy and TRAM or DIEP Flap Reconstruction (NCT01258296)
    Related Conditions: Postoperative Pain| Start Date: | End Date:
  11. Study of Ductal Lavage in Women at High Risk for Breast Cancer (NCT00429988)
    Related Conditions: Breast Cancer| Start Date: | End Date:
  12. Statins and Breast Cancer Biomarkers (NCT00914017)
    Related Conditions: Breast Cancer| Start Date:
Gillian Hirst
Gillian L Hirst, PhD

Associate Professor of Surgery
Division of Surgical Oncology
UCSF Carol Franc Buck Breast Care Center
Administrative Director
T32 Training Grant in Surgical Oncology

Section:
Breast Surgery
Research Interests

Surgical oncology education, and molecular biomarkers to optimize breast cancer treatment and outcomes

Research Type:
Basic Biomedical and Translational
Disease focus:
Biomarker development and education in breast cancer
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 62
  1. Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
    Ramalingam K, Woody R, Glencer A, Schwartz CJ, Mori H, Wong J, Hirst G, Rosenbluth J, Onishi N, Gibbs J, Hylton N, Borowsky AD, Campbell M, Esserman LJ| | PubMed
  2. Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
    Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L| | PubMed
  3. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
    Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, I-SPY2 Investigators, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L| | PubMed
  4. Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
    Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS| | PubMed
  5. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    Jacob S, Christofferson A, Fisch S, Norwood P, Castillo P, Yu H, Hirst G, Soliman H, Nanda R, Mukhtar RA, Ewing C, Majure M, Melisko M, Rugo HS, Esserman L, Price E, Chien AJ| | PubMed
  6. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ| | PubMed
  7. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ| | PubMed
  8. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  9. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  10. Tumor microenvironmental determinants of high-risk DCIS progression.
    Borowsky A, Glencer A, Ramalingam K, Schindler N, Mori H, Ghule P, Lee K, Nachmanson D, Officer A, Harismendy O, Stein J, Stein G, Evans M, Weaver D, Yau C, Hirst G, Campbell M, Esserman L| | PubMed
  11. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC, Sun X, Gonzalez-Ericsson P, Hanna A, Taylor BC, Sanchez V, Bronzini J, Opalenik SR, Sanders ME, Wulfkuhle J, Gallagher RI, Gomez H, Isaacs C, Bharti V, Wilson JT, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Hirst GL, Brown Swigart L, van 't Veer LJ, Esserman LJ, Petricoin EF, Pietenpol JA, Balko JM| | PubMed
  12. Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer.
    Kulkarni AA, Jain A, Jewett PI, Desai N, Van 't Veer L, Hirst G, Yee D, Blaes AH, ISPY2 consortium| | PubMed
  13. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Yu S, Hirst G, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H| | PubMed
  14. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
    Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ| | PubMed
  15. Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers
    Thomas O’Keefe
    Christina Yau
    Emma Iaconetti,
    Eliza Jeong
    Case Brabham,
    Paul Kim
    Joseph McGuire
    Ann Griffin
    Anne Wallace
    Laura Esserman
    Olivier Harismendy
    Gillian Hirst    | | UCSF Research Profile
  16. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF| | PubMed
  17. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI| | PubMed
  18. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
    Steenbruggen TG, Wolf DM, Campbell MJ, Sanders J, Cornelissen S, Thijssen B, Salgado RA, Yau C, O-Grady N, Basu A, Bhaskaran R, Mittempergher L, Hirst GL, Coppe JP, Kok M, Sonke GS, van 't Veer LJ, Horlings HM| | PubMed
  19. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M| | PubMed
  20. Development and testing of a polygenic risk score for breast cancer aggressiveness.
    Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer LV, Esserman LJ, Ziv E| | PubMed
  21. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  22. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ| | PubMed
  23. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    Glencer AC, Miller PN, Greenwood H, Maldonado Rodas CK, Freimanis R, Basu A, Mukhtar RA, Brabham C, Kim P, Hwang ES, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky AD, Esserman LJ| | PubMed
  24. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  25. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ| | PubMed
  26. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O| | PubMed
  27. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF| | PubMed
  28. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
    Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM| | PubMed
  29. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ| | PubMed
  30. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer.
    Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM, I-SPY2 Trial Team| | PubMed
  31. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
    Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  32. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A| | PubMed
  33. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
    Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L| | PubMed
  34. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF| | PubMed
  35. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ| | PubMed
  36. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O| | PubMed
  37. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
    Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME| | PubMed
  38. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L| | PubMed
  39. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA| | PubMed
  40. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
    Arasu VA, Kim P, Li W, Strand F, McHargue C, Harnish R, Newitt DC, Jones EF, Glymour MM, Kornak J, Esserman LJ, Hylton NM, ISPY2 investigators| | PubMed
  41. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ| | PubMed
  42. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
    Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH, Human Tumor Atlas Network| | PubMed
  43. Mutational signatures in tumours induced by high and low energy radiation in Trp53 deficient mice.
    Rose Li Y, Halliwill KD, Adams CJ, Iyer V, Riva L, Mamunur R, Jen KY, Del Rosario R, Fredlund E, Hirst G, Alexandrov LB, Adams D, Balmain A| | PubMed
  44. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium| | PubMed
  45. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators| | PubMed
  46. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
    Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF| | PubMed
  47. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L| | PubMed
  48. Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer.
    Quigley DA, Kandyba E, Huang P, Halliwill KD, Sjölund J, Pelorosso F, Wong CE, Hirst GL, Wu D, Delrosario R, Kumar A, Balmain A| | PubMed
  49. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators| | PubMed
  50. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators| | PubMed
  51. Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers.
    McCreery MQ, Halliwill KD, Chin D, Delrosario R, Hirst G, Vuong P, Jen KY, Hewinson J, Adams DJ, Balmain A| | PubMed
  52. Forty years of cancer modelling in the mouse.
    Hirst GL, Balmain A| | PubMed
  53. Automated fluorescent detection of microsatellite instability.
    Hirst GL, Illand M| | PubMed
  54. Detection of the Replication Error Phenotype in Ovarian Cancer-PCR Analysis of Microsatellite Instability.
    Hirst GL, Brown R| | PubMed
  55. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes.
    Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, Borts RH, Brown R| | PubMed
  56. PCR analysis of microsatellite instability.
    Hirst GL| | PubMed
  57. Estrogen regulation of transforming growth factor-alpha in ovarian cancer.
    Simpson BJ, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JM, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF, Miller WR| | PubMed
  58. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA| | PubMed
  59. Expression of the heat shock protein HSP27 in human ovarian cancer.
    Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, Miller WR| | PubMed
  60. Growth-control of human ovarian-carcinoma cells by insulin-like growth-factors.
    Bartlett JM, Rabiasz GJ, Scott WN, Langdon SP, Hirst GL, Lee A, Smyth JF, Miller WR| | PubMed
  61. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines.
    Langdon SP, Hirst GL, Miller EP, Hawkins RA, Tesdale AL, Smyth JF, Miller WR| | PubMed
  62. Identification of M cells and their distribution in rabbit intestinal Peyer's patches and appendix.
    Jepson MA, Simmons NL, Hirst GL, Hirst BH| | PubMed

Links

ksk portrait
Kimberly Kirkwood, MD

Professor of Surgery
Division of Surgical Oncology

Section:
HPB-GISS
Research Interests

Minimally invasive methods to treat abdominal tumors, and development of biomarkers and cellular indicators of pancreatic cancer

Research Type:
Basic Biomedical and Translational
Disease focus:
Abdominal and Pancreatic Cancers
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 70
  1. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  2. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    Yin H, Romero-Hernandez F, Ganjouei AA, Wang JJ, Brown A, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Wilhelm A, Peng JS, Alseidi A, Adam MA| | PubMed
  3. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    Hoffman D, Ganjouei AA, Hernandez FR, Ifuku K, Miller P, Glencer A, Corvera C, Kirkwood K, Alseidi A, Adam M, Maker A, Hirose K, Hirose R, Nakakura EK| | PubMed
  4. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  5. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  6. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  7. National practice patterns in the use of endoscopic ultrasound biopsy for resectable Pancreatic Neuroendocrine Tumors: Insights into the role of DOTATATE PET/CT in diagnosis.
    Casey M, Brown A, Romero-Hernandez F, Wang JJ, Ganjouei AA, Tozzi F, Rashidian N, Kirkwood K, Corvera C, Nakakura E, Alseidi A, Adam M| | PubMed
  8. A Novel Machine Learning Approach to Predict Textbook Outcome in Colectomy.
    Ashraf Ganjouei A, Romero-Hernandez F, Conroy PC, Miller PN, Calthorpe L, Wang JJ, Lin JJ, Feng J, Kirkwood KS, Alseidi A, Sarin A, Adam MA| | PubMed
  9. Addressing the unmet clinical need for low-volume assays in early diagnosis of pancreatic cancer.
    Sheik DA, Byers K, Thomas M, Rajesh UC, Ifuku K, Kirkwood K, Al-Haddad M, Craik CS, Davisson VJ| | PubMed
  10. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
    Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, Casey M, Frye W, Hoffman D, Hirose K, Nakakura E, Corvera C, Maker AV, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  11. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  12. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  13. Robotic-assisted approach for complex cholecystectomies.
    Zhu G, Ifuku KA, Kirkwood KS| | PubMed
  14. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
    Lin JJ, Conroy PC, Romero-Hernandez F, Yilma M, Feng J, Hirose K, Nakakura E, Maker AV, Corvera C, Kirkwood K, Alseidi A, Adam MA| | PubMed
  15. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
    Calthorpe L, Romero-Hernandez F, Miller P, Conroy PC, Hirose K, Kim A, Kirkwood K, Nakakura E, Corvera C, Maker AV, Alseidi A, Adam MA| | PubMed
  16. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
    Conroy PC, Mohamedaly S, Karimzada M, Brian R, Im C, Hernandez S, Roman S, Hirose K, Mukhtar R, Kirkwood K, O'Sullivan P, Alseidi A| | PubMed
  17. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
    Miller PN, Romero-Hernandez F, Conroy P, Calthorpe L, Yilma M, Mohamedaly S, Kelly YM, Feng J, Hirose K, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  18. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
    Romero-Hernandez F, Mohamedaly S, Miller P, Rodriguez N, Calthorpe L, Conroy PC, Ganjouei AA, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  19. Accurate Identification of Mucinous Pancreatic Cystic Lesions Using Small-Volume Analytes.
    Caiazza F, Conroy PC, Ivry SL, York T, Lin J, Hernandez S, Hoffmann TJ, Francis SS, Park WG, Yip-Schneider MT, Schmidt CM, Brand R, Craik CS, Kirkwood K| | PubMed
  20. Translation of a Protease Turnover Assay for Clinical Discrimination of Mucinous Pancreatic Cysts.
    Suresh V, Byers K, Rajesh UC, Caiazza F, Zhu G, Craik CS, Kirkwood K, Davisson VJ, Sheik DA| | PubMed
  21. Assessing the role of robotic proctectomy in obese patients: a contemporary NSQIP analysis.
    Glencer AC, Lin JA, Trang K, Greenberg A, Kirkwood KS, Adam MA, Sarin A| | PubMed
  22. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    Conroy PC, Calthorpe L, Lin JA, Mohamedaly S, Kim A, Hirose K, Nakakura E, Corvera C, Sosa JA, Sarin A, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  23. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    Conroy PC, Calthorpe L, Lin JA, Mohamedaly S, Kim A, Hirose K, Nakakura E, Corvera C, Sosa JA, Sarin A, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  24. The surgical resident experience in serious illness communication: A qualitative needs assessment with proposed solutions.
    Lin JA, Im CJ, O'Sullivan P, Kirkwood KS, Cook AC| | PubMed
  25. Burden of Ionizing Radiation in the Diagnosis and Management of Necrotizing Pancreatitis.
    Thiruvengadam NR, Miranda J, Kim C, Behr S, Corvera C, Dai SC, Kirkwood K, Harris HW, Hirose K, Nakakura E, Ostroff JW, Kochman ML, Arain MA| | PubMed
  26. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
    Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S| | PubMed
  27. Cost-effectiveness of consensus guideline based management of pancreatic cysts: The sensitivity and specificity required for guidelines to be cost-effective.
    Sharib J, Esserman L, Koay EJ, Maitra A, Shen Y, Kirkwood KS, Ozanne EM| | PubMed
  28. Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.
    Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ| | PubMed
  29. Ampullary stenosis and choledocholithiasis post Roux-En-Y gastric bypass: challenges of biliary access and intervention.
    Wisneski AD, Carter J, Nakakura EK, Posselt A, Rogers SJ, Cello JP, Arain M, Kirkwood KS, Hirose K, Stewart L, Corvera CU| | PubMed
  30. The lysosomal aminopeptidase tripeptidyl peptidase 1 displays increased activity in malignant pancreatic cysts.
    Ivry SL, Knudsen GM, Caiazza F, Sharib JM, Jaradeh K, Ravalin M, O'Donoghue AJ, Kirkwood KS, Craik CS| | PubMed
  31. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    Cao CX, Sharib JM, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS| | PubMed
  32. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE| | PubMed
  33. Managing Refractory Postoperative Fistulas as Chronic Wounds Using Video-Assisted Hydrodebridement (VAHD).
    Changala M, Laberge J, Kerlan R, Taylor A, Arain M, Kirkwood K| | PubMed
  34. Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making?
    Sharib JM, Fonseca AL, Swords DS, Jaradeh K, Bracci PM, Firpo MA, Hatcher S, Scaife CL, Wang H, Kim GE, Mulvihill SJ, Maitra A, Koay EJ, Kirkwood KS| | PubMed
  35. Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.
    Fonseca AL, Kirkwood K, Kim MP, Maitra A, Koay EJ| | PubMed
  36. Gangrenous cholecystitis: innovative laparoscopic techniques to facilitate subtotal fenestrating cholecystectomy when a critical view of safety cannot be achieved.
    Kirkwood R, Damon L, Wang J, Hong E, Kirkwood K| | PubMed
  37. Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts.
    Ivry SL, Sharib JM, Dominguez DA, Roy N, Hatcher SE, Yip-Schneider MT, Schmidt CM, Brand RE, Park WG, Hebrok M, Kim GE, O'Donoghue AJ, Kirkwood KS, Craik CS| | PubMed
  38. Early and accurate diagnosis of pancreatic cancer?
    Sharib J, Kirkwood K| | PubMed
  39. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH| | PubMed
  40. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions.
    Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, Bondada S, Kirkwood K, Sen S| | PubMed
  41. Serine proteases and protease-activated receptor 2 mediate the proinflammatory and algesic actions of diverse stimulants.
    Cattaruzza F, Amadesi S, Carlsson JF, Murphy JE, Lyo V, Kirkwood K, Cottrell GS, Bogyo M, Knecht W, Bunnett NW| | PubMed
  42. Transient receptor potential ankyrin 1 mediates chronic pancreatitis pain in mice.
    Cattaruzza F, Johnson C, Leggit A, Grady E, Schenk AK, Cevikbas F, Cedron W, Bondada S, Kirkwood R, Malone B, Steinhoff M, Bunnett N, Kirkwood KS| | PubMed
  43. Informed consent for innovative surgery: a survey of patients and surgeons.
    Lee Char SJ, Hills NK, Lo B, Kirkwood KS| | PubMed
  44. Active cathepsins B, L, and S in murine and human pancreatitis.
    Lyo V, Cattaruzza F, Kim TN, Walker AW, Paulick M, Cox D, Cloyd J, Buxbaum J, Ostroff J, Bogyo M, Grady EF, Bunnett NW, Kirkwood KS| | PubMed
  45. Ethical management of conflict of interest: proposed standards for academic surgical societies.
    Minter RM, Angelos P, Coimbra R, Dale P, de Vera ME, Hardacre J, Hawkins W, Kirkwood K, Matthews JB, McLoughlin J, Peralta E, Schmidt M, Zhou W, Schwarze ML| | PubMed
  46. Serine proteases mediate inflammatory pain in acute pancreatitis.
    Ceppa EP, Lyo V, Grady EF, Knecht W, Grahn S, Peterson A, Bunnett NW, Kirkwood KS, Cattaruzza F| | PubMed
  47. Transient receptor potential ion channels V4 and A1 contribute to pancreatitis pain in mice.
    Ceppa E, Cattaruzza F, Lyo V, Amadesi S, Pelayo JC, Poole DP, Vaksman N, Liedtke W, Cohen DM, Grady EF, Bunnett NW, Kirkwood KS| | PubMed
  48. Technique for placement of lumboperitoneal catheters using a combined laparoscopic procedure with the Seldinger micropuncture technique.
    Maa J, Carter JT, Kirkwood KS, Gosnell JE, Wang V, McDermott MW| | PubMed
  49. MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder.
    Finzi L, Barbu V, Burgel PR, Mergey M, Kirkwood KS, Wick EC, Scoazec JY, Peschaud F, Paye F, Nadel JA, Housset C| | PubMed
  50. Trends in laparoscopic splenectomy for massive splenomegaly.
    Grahn SW, Alvarez J, Kirkwood K| | PubMed
  51. Calcitonin gene-related peptide partially mediates nociception in acute experimental pancreatitis.
    Wick EC, Pikios S, Grady EF, Kirkwood KS| | PubMed
  52. Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance P mediate nociception in acute pancreatitis.
    Wick EC, Hoge SG, Grahn SW, Kim E, Divino LA, Grady EF, Bunnett NW, Kirkwood KS| | PubMed
  53. Neutral endopeptidase determines the severity of pancreatitis-associated lung injury.
    Day AL, Wick E, Jordan TH, Jaffray CE, Bunnett NW, Grady EF, Kirkwood KS| | PubMed
  54. Transient receptor potential vanilloid (TRPV-1) promotes neurogenic inflammation in the pancreas via activation of the neurokinin-1 receptor (NK-1R).
    Hutter MM, Wick EC, Day AL, Maa J, Zerega EC, Richmond AC, Jordan TH, Grady EF, Mulvihill SJ, Bunnett NW, Kirkwood KS| | PubMed
  55. Medical versus surgical management of biliary tract disease in pregnancy.
    Lu EJ, Curet MJ, El-Sayed YY, Kirkwood KS| | PubMed
  56. Pancreatic resection in the elderly.
    Lightner AM, Glasgow RE, Jordan TH, Krassner AD, Way LW, Mulvihill SJ, Kirkwood KS| | PubMed
  57. Activation of nociceptive neurons in T9 and T10 in cerulein pancreatitis.
    Kim EH, Hoge SG, Lightner AM, Grady EF, Coelho AM, Kirkwood KS| | PubMed
  58. SIR 2003 film panel case 5: massive hemorrhage from portal vein disruption.
    Kerlan RK, LaBerge JM, Wilson MW, Gordon RL, Kirkwood K, Sawhney R| | PubMed
  59. Lovastatin alters biliary lipid composition and dissolves gallstones: a long-term study in prairie dogs.
    Abedin MZ, Narins SC, Park EH, Smith PR, Kirkwood KS| | PubMed
  60. Recombinant human neutral endopeptidase ameliorates pancreatic elastase-induced lung injury.
    Lightner AM, Jordan TH, Bunnett NW, Grady EF, Kirkwood KS| | PubMed
  61. Pathophysiology of gallstone pancreatitis.
    Lightner AM, Kirkwood KS| | PubMed
  62. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A.
    Kirkwood KS, Bunnett NW, Maa J, Castagliolo I, Liu B, Gerard N, Zacks J, Pothoulakis C, Grady EF| | PubMed
  63. NK-1 receptor desensitization and neutral endopeptidase terminate SP-induced pancreatic plasma extravasation.
    Maa J, Grady EF, Kim EH, Yoshimi SK, Hutter MM, Bunnett NW, Kirkwood KS| | PubMed
  64. Substance P is a determinant of lethality in diet-induced hemorrhagic pancreatitis in mice.
    Maa J, Grady EF, Yoshimi SK, Drasin TE, Kim EH, Hutter MM, Bunnett NW, Kirkwood KS| | PubMed
  65. Substance P mediates inflammatory oedema in acute pancreatitis via activation of the neurokinin-1 receptor in rats and mice.
    Grady EF, Yoshimi SK, Maa J, Valeroso D, Vartanian RK, Rahim S, Kim EH, Gerard C, Gerard N, Bunnett NW, Kirkwood KS| | PubMed
  66. Substance P inhibits pancreatic exocrine secretion via a neural mechanism.
    Kirkwood KS, Kim EH, He XD, Calaustro EQ, Domush C, Yoshimi SK, Grady EF, Maa J, Bunnett NW, Debas HT| | PubMed
  67. Recent advances. General surgery.
    Corvera CU, Kirkwood KS| | PubMed
  68. Prognostic indicators for cancer. Gastric cancer.
    Kirkwood KS, Khitin LM, Barwick KW| | PubMed
  69. Substance P and bradykinin stimulate plasma extravasation in the mouse gastrointestinal tract and pancreas.
    Figini M, Emanueli C, Grady EF, Kirkwood K, Payan DG, Ansel J, Gerard C, Geppetti P, Bunnett N| | PubMed
  70. Neuroendocrine tumors: common presentations of uncommon diseases.
    Kirkwood KS, Debas HT| | PubMed
View Clinical Trials
  1. UCSF PANC Cyst Registry (NCT04291651)
    Related Conditions: Pancreatic Cyst, Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Diseases, Intraductal Papillary Mucinous Neoplasm, Pancreatic Ductal Adenocarcinoma, Neoplasms| Start Date: | End Date:
jk_ucsf_profile_picture
James Koh, PhD

Professor of Surgery
Division of Surgical Oncology
Director, Endocrine Neoplasia Research Lab

Section:
Endocrine Surgery
Research Interests

Molecular, murine modeling, live-cell imaging, and ex vivo organ culture interrogative methods to examine the underlying mechanisms of disrupted biochemical signaling in human endocrine tumors

Research Type:
Basic Biomedical and Translational
Disease focus:
Tumors of the thyroid, parathyroid, adrenal glands
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 15
  1. Digital spatial profiling of human parathyroid tumors reveals cellular and molecular alterations linked to vitamin D deficiency.
    Tu CL, Chang W, Sosa JA, Koh J| | PubMed
  2. Effects of Multi-stage Procurement on the Viability and Function of Human Donor Parathyroid Glands.
    Kelly YM, Ward C, Zhang R, Syed S, Stock PG, Duh QY, Sosa JA, Koh J| | PubMed
  3. Ex Vivo Intact Tissue Analysis Reveals Alternative Calcium-sensing Behaviors in Parathyroid Adenomas.
    Koh J, Zhang R, Roman S, Duh QY, Gosnell J, Shen W, Suh I, Sosa JA| | PubMed
  4. Parathyroid-Targeted Overexpression of Regulator of G-Protein Signaling 5 (RGS5) Causes Hyperparathyroidism in Transgenic Mice.
    Balenga N, Koh J, Azimzadeh P, Hogue J, Gabr M, Stains JP, Olson JA| | PubMed
  5. Transcriptional profiling reveals distinct classes of parathyroid tumors in PHPT.
    Koh J, Hogue JA, Roman SA, Scheri RP, Fradin H, Corcoran DL, Sosa JA| | PubMed
  6. Polyclonal origin of parathyroid tumors is common and is associated with multiple gland disease in primary hyperparathyroidism.
    Shi Y, Azimzadeh P, Jamingal S, Wentworth S, Ferlitch J, Koh J, Balenga N, Olson JA| | PubMed
  7. Live-Cell Visualization of Calcium Flux in Vibratome-Cut Thick Sections of Viable Tumor Tissue.
    Koh J, Hogue JA, Sosa JA| | PubMed
  8. Impaired calcium sensing distinguishes primary hyperparathyroidism (PHPT) patients with low bone mineral density.
    Weber TJ, Koh J, Thomas SM, Hogue JA, Scheri RP, Roman SA, Sosa JA| | PubMed
  9. Orphan Adhesion GPCR GPR64/ADGRG2 Is Overexpressed in Parathyroid Tumors and Attenuates Calcium-Sensing Receptor-Mediated Signaling.
    Balenga N, Azimzadeh P, Hogue JA, Staats PN, Shi Y, Koh J, Dressman H, Olson JA| | PubMed
  10. A Novel Ex Vivo Method for Visualizing Live-Cell Calcium Response Behavior in Intact Human Tumors.
    Koh J, Hogue JA, Sosa JA| | PubMed
  11. Single-cell approaches for molecular classification of endocrine tumors.
    Koh J, Allbritton NL, Sosa JA| | PubMed
  12. Single-cell functional analysis of parathyroid adenomas reveals distinct classes of calcium sensing behaviour in primary hyperparathyroidism.
    Koh J, Hogue JA, Wang Y, DiSalvo M, Allbritton NL, Shi Y, Olson JA, Sosa JA| | PubMed
  13. Functional and genetic studies of isolated cells from parathyroid tumors reveal the complex pathogenesis of parathyroid neoplasia.
    Shi Y, Hogue J, Dixit D, Koh J, Olson JA| | PubMed
  14. Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor.
    Koh J, Dar M, Untch BR, Dixit D, Shi Y, Yang Z, Adam MA, Dressman H, Wang X, Gesty-Palmer D, Marks JR, Spurney R, Druey KM, Olson JA| | PubMed
  15. Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.
    Adam MA, Untch BR, Danko ME, Stinnett S, Dixit D, Koh J, Marks JR, Olson JA| | PubMed
View Lab Site
ajay maker md
Ajay V. Maker, MD, FACS, FSSO

Professor of Surgery
Chief, Division of Surgical Oncology
Maurice Galante Distinguished Professor in Surgical Oncology

Section:
HPB-GISS
Research Interests

Improving early detection of pancreatic cancer and development of novel immunotherapies for treating metastatic disease
 

Research Type:
Basic Biomedical and Translational
Clinical Discovery and Health Services
Disease focus:
Pancreatic Cancer
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 131
  1. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  2. ASO Visual Abstract: Essential Elements in Synoptic Operative Reports for Hepato-Pancreato-Biliary Cancer Surgery-An HPB/CGSO Training Program Survey.
    Kone LB, Seok D, Kimble MM, Maker AV, Patil S, Mittal V, Jacobs M| | PubMed
  3. Essential Elements in Synoptic Operative Reports for Hepato-Pancreato-Biliary Cancer Surgery: An HPB/CGSO Training Program Survey.
    Kone LB, Seok D, Kimble MM, Maker AV, Patil S, Mittal V, Jacobs M| | PubMed
  4. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    Yin H, Romero-Hernandez F, Ganjouei AA, Wang JJ, Brown A, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Wilhelm A, Peng JS, Alseidi A, Adam MA| | PubMed
  5. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    Hoffman D, Ganjouei AA, Hernandez FR, Ifuku K, Miller P, Glencer A, Corvera C, Kirkwood K, Alseidi A, Adam M, Maker A, Hirose K, Hirose R, Nakakura EK| | PubMed
  6. ASO Author Reflections: Is Adjuvant Therapy Necessary for All Patients with Invasive Mucinous Cystic Neoplasms of the Pancreas? Let's De-escalate.
    Wong P, Pollini T, Maker AV| | PubMed
  7. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  8. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  9. Multi-omic profiling of intraductal papillary neoplasms of the pancreas reveals distinct expression patterns and potential markers of progression.
    Wang Y, Lih TM, Lee JW, Ohtsuka T, Hozaka Y, Mino-Kenudson M, Adsay NV, Luchini C, Scarpa A, Maker AV, Kim GE, Paulino J, Chen L, Jiao L, Sun Z, Goodman D, Pflüger MJ, Roberts NJ, Matthaei H, Wood LD, Furukawa T, Zhang H, Hruban RH| | PubMed
  10. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.
    Oviedo P, Burns S, Chen WP, Mandl HK, Rosso C, Radgoudarzi N, Crosetti A, Zamora S, Perry LM, Bold RJ, Labora AN, Donahue TR, Maker A, Valerin JB, Zell JA, White RR| | PubMed
  11. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  12. Insights on liver-directed surgical innovations, targeted therapies, and immunotherapy for biliary tract cancer: navigating the new European Society for Medical Oncology (ESMO) Clinical Practice Guidelines.
    Maker AV| | PubMed
  13. Pancreas Cyst Diagnosis and Advances in Cyst Fluid Analysis.
    Pollini T, Todeschini L, Maker AV| | PubMed
  14. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
    Wong P, Wisneski AD, Tsai KK, Chang TT, Hirose K, Nakakura EK, Daud AI, Maker AV, Corvera CU| | PubMed
  15. Intraoperative hepatic artery infusion pump perfusion testing with indocyanine green near-infrared imaging offers multiple potential advantages.
    Wong P, Hoffman D, Pollini T, Zampese M, Corvera CU, Maker AV| | PubMed
  16. "Mickey Mouse sign" to identify and remove cystic duct stones in postcholecystectomy syndrome.
    O'Rear J, Wong P, Pollini T, Maker VK, Maker AV| | PubMed
  17. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    Pollini T, Tran T, Wong P, Adam MA, Alseidi A, Corvera C, Hirose K, Nakakura E, Warren R, Maker VK, Maker AV| | PubMed
  18. Educating Cancer-Associated Fibroblasts (CAFs): Are They the Student or the Teacher?
    Maker AV, Karakousis G| | PubMed
  19. Surgical Cancer Care in Safety-Net Hospitals: a Systematic Review.
    Wong P, Victorino GP, Sadjadi J, Knopf K, Maker AV, Thornblade LW| | PubMed
  20. Impact of safety-net hospital burden on achievement of textbook oncologic outcomes following resection in for stage I-IV colorectal cancer.
    Wong P, Victorino GP, Miraflor E, Alseidi A, Maker AV, Thornblade LW| | PubMed
  21. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
    Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, Casey M, Frye W, Hoffman D, Hirose K, Nakakura E, Corvera C, Maker AV, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  22. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  23. Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.
    Wiley MB, Bauer J, Mehrotra K, Zessner-Spitzenberg J, Kolics Z, Cheng W, Castellanos K, Nash MG, Gui X, Kone L, Maker AV, Qiao G, Reddi D, Church DN, Kerr RS, Kerr DJ, Grippo PJ, Jung B| | PubMed
  24. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  25. It is not necessary to resect all mucinous cystic neoplasms of the pancreas: current guidelines do not reflect the actual risk of malignancy.
    Pollini T, Marchegiani G, Facciorusso A, Balduzzi A, Biancotto M, Bassi C, Maker AV, Salvia R| | PubMed
  26. Drain Placement After Pancreatic Resection: Friend or Foe For Surgical Site Infections?
    Pollini T, Wong P, Kone LB, Khoury RE, Kabir C, Maker VK, Banulescu M, Maker AV| | PubMed
  27. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
    Lin JJ, Conroy PC, Romero-Hernandez F, Yilma M, Feng J, Hirose K, Nakakura E, Maker AV, Corvera C, Kirkwood K, Alseidi A, Adam MA| | PubMed
  28. The Landmark Series: Intraductal Papillary Mucinous Neoplasms of the Pancreas-From Prevalence to Early Cancer Detection.
    Pollini T, Wong P, Maker AV| | PubMed
  29. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
    Calthorpe L, Romero-Hernandez F, Miller P, Conroy PC, Hirose K, Kim A, Kirkwood K, Nakakura E, Corvera C, Maker AV, Alseidi A, Adam MA| | PubMed
  30. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
    Miller PN, Romero-Hernandez F, Conroy P, Calthorpe L, Yilma M, Mohamedaly S, Kelly YM, Feng J, Hirose K, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  31. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
    Romero-Hernandez F, Mohamedaly S, Miller P, Rodriguez N, Calthorpe L, Conroy PC, Ganjouei AA, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  32. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms.
    Pollini T, Adsay V, Capurso G, Dal Molin M, Esposito I, Hruban R, Luchini C, Maggino L, Matthaei H, Marchegiani G, Scarpa A, Wood LD, Bassi C, Salvia R, Mino-Kenudson M, Maker AV| | PubMed
  33. Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: An US safety net collaborative analysis.
    Leder Macek AJ, Wang A, Turgeon MK, Lee RM, Russell MC, Porembka MR, Alterio R, Ju M, Kronenfeld J, Goel N, Datta J, Maker AV, Fernandez M, Richter H, Berman RS, Correa-Gallego C, Lee AY| | PubMed
  34. Physical exam reveals etiology of liver and pancreatic tumors.
    Kone LB, Maker AV| | PubMed
  35. Langer's arch: An anatomic variant complicating axillary node dissection.
    Baskin AS, Wang K, Maker AV| | PubMed
  36. Robotic Surgery for Biliary Tract Cancer.
    Kone LB, Bystrom PV, Maker AV| | PubMed
  37. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
    Qiao G, Kone LB, Phillips EH, Lee SS, Brown GE, Khetani SR, Thakur A, Lum LG, Prabhakar BS, Maker AV| | PubMed
  38. Clinical Presentation Patterns and Survival Outcomes of Hispanic Patients With Gastric Cancer.
    Vitiello GA, Hani L, Wang A, Porembka MR, Alterio R, Ju M, Turgeon MK, Lee RM, Russell MC, Kronenfeld J, Goel N, Datta J, Maker AV, Fernandez M, Richter H, Correa-Gallego C, Berman RS, Lee AY| | PubMed
  39. Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety-Net Collaborative analysis.
    Kronenfeld JP, Collier AL, Turgeon MK, Ju M, Alterio R, Wang A, Fernandez M, Porembka MR, Richter H, Lee AY, Russell MC, Merchant NB, Maker AV, Datta J| | PubMed
  40. The Evolution of Cancer Immunotherapy.
    Khan M, Maker AV, Jain S| | PubMed
  41. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?
    Turgeon MK, Lee RM, Keilson JM, Ju MR, Porembka MR, Alterio RE, Kronenfeld J, Datta J, Goel N, Wang A, Lee AY, Fernandez M, Richter H, Maker AV, Maithel SK, Russell MC| | PubMed
  42. Race and Gender Differences in Awareness of Colorectal Cancer Screening Tests and Guidelines Among Recently Diagnosed Colon Cancer Patients in an Urban Setting.
    Carnahan LR, Jones L, Brewer KC, Watts EA, Peterson CE, Ferrans CE, Cipriano-Steffens T, Polite B, Maker AV, Chowdhery R, Molina Y, Rauscher GH| | PubMed
  43. Combining On-Table Embolization with Immediate Resection to Safely Excise Giant Hepatic Hemangiomas.
    Maker AV, Al Rameni D, Prabhakar N| | PubMed
  44. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
    Fernandez MF, Qiao G, Tulla K, Prabhakar BS, Maker AV| | PubMed
  45. ASO Author Reflections: How Can We Improve the Postoperative Experience for Our Pancreatic Cancer Patients? A Practical Technique to Optimize Pain Control After Major Abdominal Surgery.
    Maker AV| | PubMed
  46. Surgeon-Placed Continuous Wound Infusion Pain Catheters Markedly Decrease Narcotic Use and Improve Outcomes After Pancreatic Tumor Resection.
    Kone LB, Kunda NM, Tran TB, Maker AV| | PubMed
  47. Epidural Analgesia Is Associated with Prolonged Length of Stay After Open HPB Surgery in Over 27,000 Patients.
    Kone LB, Maker VK, Banulescu M, Maker AV| | PubMed
  48. Perioperative Broad-spectrum Antibiotics are Associated With Decreased Surgical Site Infections Compared to 1st-3rd Generation Cephalosporins After Open Pancreaticoduodenectomy in Patients With Jaundice or a Biliary Stent.
    Kone LB, Torres C, Banulescu M, Maker VK, Maker AV| | PubMed
  49. Should Drains Suck? A Propensity Score Analysis of Closed-Suction Versus Closed-Gravity Drainage After Pancreatectomy.
    Kone LB, Maker VK, Banulescu M, Maker AV| | PubMed
  50. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.
    Dai S, Lv Y, Xu W, Yang Y, Liu C, Dong X, Zhang H, Prabhakar BS, Maker AV, Seth P, Wang H| | PubMed
  51. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations.
    Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G, Levine E, Maker A, Mamounas E, McGuire K, Merchant N, Shibata D, Sohn V, Solorzano C, Turaga K, White R, Yang A, Yoon S, Society of Surgical Oncology| | PubMed
  52. A propensity score analysis of over 12,000 pancreaticojejunal anastomoses after pancreaticoduodenectomy: does technique impact the clinically relevant fistula rate?
    Kone LB, Maker VK, Banulescu M, Maker AV| | PubMed
  53. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S, Sripada L, Tulla K, Qiao G, Kunda N, Maker AV, Prabhakar BS| | PubMed
  54. Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential.
    Maker AV, Hu V, Kadkol SS, Hong L, Brugge W, Winter J, Yeo CJ, Hackert T, Büchler M, Lawlor RT, Salvia R, Scarpa A, Bassi C, Green S| | PubMed
  55. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
    Saini S, Sripada L, Tulla K, Kumar P, Yue F, Kunda N, Maker AV, Prabhakar BS| | PubMed
  56. Impact of Immunotherapy after Resection of Pancreatic Cancer.
    Tran TB, Maker VK, Maker AV| | PubMed
  57. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer.
    Saini S, Maker AV, Burman KD, Prabhakar BS| | PubMed
  58. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.
    Mansour JC, Chavin K, Morris-Stiff G, Warner SG, Cardona K, Fong ZV, Maker A, Libutti SK, Warren R, St Hill C, Celinski S, Newell P, Ly QP, Howe J, Coburn N| | PubMed
  59. Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors.
    Maker AV, Tran TB, Coburn N, Fong ZV, Cardona K, Newell P, Morris-Stiff G, Chavin K, Mansour J, members of the AHPBA Research Committee Consensus Conference| | PubMed
  60. Therapeutic advances in anaplastic thyroid cancer: a current perspective.
    Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS| | PubMed
  61. ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers.
    Maker AV| | PubMed
  62. Identification of a Novel OX40L+ Dendritic Cell Subset That Selectively Expands Regulatory T cells.
    Marinelarena A, Bhattacharya P, Kumar P, Maker AV, Prabhakar BS| | PubMed
  63. KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs.
    Principe DR, Overgaard NH, Park AJ, Diaz AM, Torres C, McKinney R, Dorman MJ, Castellanos K, Schwind R, Dawson DW, Rana A, Maker A, Munshi HG, Rund LA, Grippo PJ, Schook LB| | PubMed
  64. Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.
    Qin J, Kunda NM, Qiao G, Tulla K, Prabhakar BS, Maker AV| | PubMed
  65. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.
    Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS| | PubMed
  66. What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year.
    Khoury RE, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV| | PubMed
  67. Do Drains Contribute to Pancreatic Fistulae? Analysis of over 5000 Pancreatectomy Patients.
    El Khoury R, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV| | PubMed
  68. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.
    Tulla KA, Maker AV| | PubMed
  69. Port-Site Resection in the Surgical Management of Incidental Gallbladder Cancer: A Still Inconclusive Question: A Reply.
    Maker AV, Jarnagin WR| | PubMed
  70. Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study.
    Jones LA, Ferrans CE, Polite BN, Brewer KC, Maker AV, Pauls HA, Rauscher GH| | PubMed
  71. The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform.
    Schachtschneider KM, Schwind RM, Newson J, Kinachtchouk N, Rizko M, Mendoza-Elias N, Grippo P, Principe DR, Park A, Overgaard NH, Jungersen G, Garcia KD, Maker AV, Rund LA, Ozer H, Gaba RC, Schook LB| | PubMed
  72. PKC-ѳ is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells.
    Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Bhattacharya P, Sun Z, Epstein AL, Maker AV, Prabhakar BS| | PubMed
  73. Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.
    Maker AV, Sheikh R, Bhagia V, Diabetes Control and Complications Trial (DCCT) Research Group| | PubMed
  74. A Technique to Define Extrahepatic Biliary Anatomy Using Robotic Near-Infrared Fluorescent Cholangiography.
    Maker AV, Kunda N| | PubMed
  75. Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect.
    Grippo P, Maker AV| | PubMed
  76. Mitochondrial protein 18 (MTP18) plays a pro-apoptotic role in chemotherapy-induced gastric cancer cell apoptosis.
    Aung LHH, Li R, Prabhakar BS, Maker AV, Li P| | PubMed
  77. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    Ejaz A, Casadaban L, Maker AV| | PubMed
  78. LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases.
    Qiao G, Qin J, Kunda N, Calata JF, Mahmud DL, Gann P, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV| | PubMed
  79. Isolated Pancreatic Uncinate Duct IPMN.
    Maker AV, Maker VK| | PubMed
  80. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.
    Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV| | PubMed
  81. Can Colon Cancer Recurrence and Metastases Be Determined After Surgical Resection Using a Gene Expression Signature?
    Casadaban L, Maker AV| | PubMed
  82. Gene-expression profiling to predict responsiveness to immunotherapy.
    Jamieson NB, Maker AV| | PubMed
  83. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.
    Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV| | PubMed
  84. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.
    Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV| | PubMed
  85. Techniques to perform robotic left adrenalectomy in the obese patient.
    Maker AV, Maker VK| | PubMed
  86. Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis.
    Maker AV, August C, Maker VK, Weisenberg E| | PubMed
  87. A Minimally Invasive Technique to Obtain Optimal Tumor Margins in Anatomically Confined Locations Using a Contoured Stapler.
    Maker AV, Valbuena V, Maker VK| | PubMed
  88. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT.
    Maker AV| | PubMed
  89. The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses.
    Maker AV, Prabhakar B, Pardiwala K| | PubMed
  90. Techniques to perform a laparoscopic right adrenalectomy for metastases abutting the liver, renal vein, and posterior vena cava.
    Maker AV, Carr R| | PubMed
  91. Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy.
    Bhagwandin SB, Weisenberg ES, Ozer H, Maker AV| | PubMed
  92. Tailoring GIST therapy—biology is still king.
    Maker AV| | PubMed
  93. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.
    Kopanja D, Pandey A, Kiefer M, Wang Z, Chandan N, Carr JR, Franks R, Yu DY, Guzman G, Maker A, Raychaudhuri P| | PubMed
  94. Simultaneous Occurrence of Glandular and Neuroendocrine Components in Lymph Node Metastasis of Gastric MANEC.
    August C, Maker AV, Weisenberg E| | PubMed
  95. Closure of Melanoma Defects on the Sole of the Foot Using Glaborous Skin: The End of the Flap?
    Maker AV, Iteld L| | PubMed
  96. Operative management of portal annular pancreas during pancreaticoduodenectomy.
    Pardiwala KH, Maker AV| | PubMed
  97. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases.
    Maker AV, Ito H, Mo Q, Weisenberg E, Qin LX, Turcotte S, Maithel S, Shia J, Blumgart L, Fong Y, Jarnagin WR, DeMatteo RP, D'Angelica MI| | PubMed
  98. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms.
    Maker AV, Carrara S, Jamieson NB, Pelaez-Luna M, Lennon AM, Dal Molin M, Scarpa A, Frulloni L, Brugge WR| | PubMed
  99. Appendicitis secondary to metastatic melanoma: review of the National Institutes of Health experience.
    Kitano M, Maker AV, Lanier BJ, Danforth DN, Kammula US| | PubMed
  100. Calcifying fibrous tumor of the small intestine associated with Castleman-like lymphadenopathy.
    Valladolid G, Weisenberg E, Sundaresan R, Maker AV| | PubMed
  101. Dedifferentiated gastrointestinal stromal tumor arising de novo from the small intestine.
    Choi JJ, Sinada-Bottros L, Maker AV, Weisenberg E| | PubMed
  102. IG20/MADD plays a critical role in glucose-induced insulin secretion.
    Li LC, Wang Y, Carr R, Haddad CS, Li Z, Qian L, Oberholzer J, Maker AV, Wang Q, Prabhakar BS| | PubMed
  103. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer.
    Ito H, Mo Q, Qin LX, Viale A, Maithel SK, Maker AV, Shia J, Kingham P, Allen P, DeMatteo RP, Fong Y, Jarnagin WR, D'Angelica M| | PubMed
  104. Benign adrenal hemangiomas may mimic metastases on PET.
    Calata JF, Sukerkar AN, August CZ, Maker AV| | PubMed
  105. Management of patients with abdominal malignancy after remote jejunoileal bypass: surgical considerations decades later.
    Kaminski JP, Maker VK, Maker AV| | PubMed
  106. A technique for laparoendoscopic resection of posterior fundic gastric GISTs without need for a gastrotomy.
    Maker AV| | PubMed
  107. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes.
    Avraham JB, Villines D, Maker VK, August C, Maker AV| | PubMed
  108. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases.
    Qin JZ, Upadhyay V, Prabhakar B, Maker AV| | PubMed
  109. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
    Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS| | PubMed
  110. Primary hepatic lymphoma presenting as an isolated solitary hepatic cyst.
    Valladolid G, Adams LL, Weisenberg E, Maker VK, Maker AV| | PubMed
  111. Can we predict which residents are going to pass/fail the oral boards?
    Maker VK, Zahedi MM, Villines D, Maker AV| | PubMed
  112. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases.
    Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, DeMatteo RP| | PubMed
  113. Malignant masquerade of xanthogranulomatous cholecystitis on intraoperative ultrasound of the liver.
    Maker AV, Maker VK| | PubMed
  114. Video: totally laparoscopic left lateral segmentectomy for hepatic malignancies: a modified technique.
    Maker AV, Jamal W, Gayet B| | PubMed
  115. Is port site resection necessary in the surgical management of gallbladder cancer?
    Maker AV, Butte JM, Oxenberg J, Kuk D, Gonen M, Fong Y, Dematteo RP, D'Angelica MI, Allen PJ, Jarnagin WR| | PubMed
  116. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
    Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J, Maker AV, Prabhakar BS| | PubMed
  117. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.
    Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, Jarnagin WR, Allen PJ| | PubMed
  118. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
    Maker AV, Katabi N, Gonen M, DeMatteo RP, D'Angelica MI, Fong Y, Jarnagin WR, Brennan MF, Allen PJ| | PubMed
  119. Randomized clinical trials in pancreatic adenocarcinoma.
    Rudloff U, Maker AV, Brennan MF, Allen PJ| | PubMed
  120. Novel presentation of a familial pancreatic cancer syndrome.
    Maker AV, Warth JA, Zinner MJ| | PubMed
  121. Cytology from pancreatic cysts has marginal utility in surgical decision-making.
    Maker AV, Lee LS, Raut CP, Clancy TE, Swanson RS| | PubMed
  122. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
    Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA| | PubMed
  123. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.
    Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA| | PubMed
  124. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
    Maker AV, Attia P, Rosenberg SA| | PubMed
  125. Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope.
    Maker AV, Nguyen DM| | PubMed
  126. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
    Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA| | PubMed
  127. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA| | PubMed
  128. Loss of S100 antigenicity in metastatic melanoma.
    Aisner DL, Maker A, Rosenberg SA, Berman DM| | PubMed
  129. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
    Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA| | PubMed
  130. Rapid acute amiodarone-induced hepatotoxicity in a burn patient.
    Maker AV, Orgill DP| | PubMed
  131. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane.
    Eisenberg ML, Maker AV, Slezak LA, Nathan JD, Sritharan KC, Jena BP, Geibel JP, Andersen DK| | PubMed
View Lab Site
nakakura eric 21261
Eric Nakakura, MD, PhD

Professor of Surgery   
Division of Surgical Oncology

Section:
HPB-GISS
Research Interests

Investigating the etiology of neuroendocrine tumors of the small intestine and pancreas

Research Type:
Basic Biomedical and Translational
Clinical Discovery and Health Services
Disease focus:
Neuroendocrine tumors
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 109
  1. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK| | PubMed
  2. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer.
    Ejie J, Ashraf Ganjouei A, Hernandez S, Wang JJ, Romero-Hernandez F, Foroutani L, Hirose K, Nakakura E, Corvera CU, Alseidi A, Adam MA| | PubMed
  3. ASO Visual Abstract: Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  4. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    Yin H, Romero-Hernandez F, Ganjouei AA, Wang JJ, Brown A, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Wilhelm A, Peng JS, Alseidi A, Adam MA| | PubMed
  5. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    Hoffman D, Ganjouei AA, Hernandez FR, Ifuku K, Miller P, Glencer A, Corvera C, Kirkwood K, Alseidi A, Adam M, Maker A, Hirose K, Hirose R, Nakakura EK| | PubMed
  6. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  7. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    Wong P, Pollini T, Adam MA, Alseidi A, Corvera CU, Hirose K, Kirkwood KS, Nakakura EK, Thornblade L, Maker AV| | PubMed
  8. Enucleation of Neuroendocrine Liver Metastases.
    Yogo A, Kasai Y, Nakakura EK| | PubMed
  9. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    Parikh AR, Chee BH, Tsai J, Rich TA, Price KS, Patel SA, Zhang L, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Corcoran RB, Van Loon K, Atreya CE| | PubMed
  10. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
    Miller PN, Nakakura EK| | PubMed
  11. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    Miller PN, Romero-Hernandez F, Calthorpe L, Wang JJ, Kim SS, Corvera CU, Hirose K, Kirkwood KS, Hirose R, Maker AV, Alseidi AA, Adam MA, Kim GE, Tempero MA, Ko AH, Nakakura EK| | PubMed
  12. ASO Author Reflections: Minimally Invasive Surgery for Prototypical Small Intestinal Neuroendocrine Tumors.
    Yogo A, Nakakura EK| | PubMed
  13. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  14. National practice patterns in the use of endoscopic ultrasound biopsy for resectable Pancreatic Neuroendocrine Tumors: Insights into the role of DOTATATE PET/CT in diagnosis.
    Casey M, Brown A, Romero-Hernandez F, Wang JJ, Ganjouei AA, Tozzi F, Rashidian N, Kirkwood K, Corvera C, Nakakura E, Alseidi A, Adam M| | PubMed
  15. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
    Wong P, Wisneski AD, Tsai KK, Chang TT, Hirose K, Nakakura EK, Daud AI, Maker AV, Corvera CU| | PubMed
  16. Robotic-assisted endoluminal gastric leiomyoma resection: a novel surgical technique for benign gastroesophageal junction tumors.
    Yin H, Ganjouei AA, Wang JJ, Romero-Hernandez F, Nakakura E, Alseidi A, Adam MA| | PubMed
  17. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    Pollini T, Tran T, Wong P, Adam MA, Alseidi A, Corvera C, Hirose K, Nakakura E, Warren R, Maker VK, Maker AV| | PubMed
  18. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
    Ashraf Ganjouei A, Romero-Hernandez F, Wang JJ, Casey M, Frye W, Hoffman D, Hirose K, Nakakura E, Corvera C, Maker AV, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  19. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  20. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA| | PubMed
  21. Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis.
    Kasai Y, Nakakura EK, Yogo A, Nagai K, Masui T, Hatano E| | PubMed
  22. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
    Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD| | PubMed
  23. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    Calthorpe L, Romero-Hernandez F, Casey M, Nunez M, Conroy PC, Hirose K, Kim A, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  24. Laparoscopic Gastrectomy for Gastric Cancer.
    Hoffman DB, Nakakura EK| | PubMed
  25. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E| | PubMed
  26. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK| | PubMed
  27. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
    Lin JJ, Conroy PC, Romero-Hernandez F, Yilma M, Feng J, Hirose K, Nakakura E, Maker AV, Corvera C, Kirkwood K, Alseidi A, Adam MA| | PubMed
  28. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
    Calthorpe L, Romero-Hernandez F, Miller P, Conroy PC, Hirose K, Kim A, Kirkwood K, Nakakura E, Corvera C, Maker AV, Alseidi A, Adam MA| | PubMed
  29. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
    Miller PN, Romero-Hernandez F, Conroy P, Calthorpe L, Yilma M, Mohamedaly S, Kelly YM, Feng J, Hirose K, Kirkwood K, Maker AV, Corvera C, Nakakura E, Alseidi A, Adam MA| | PubMed
  30. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
    Romero-Hernandez F, Mohamedaly S, Miller P, Rodriguez N, Calthorpe L, Conroy PC, Ganjouei AA, Hirose K, Maker AV, Nakakura E, Corvera C, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  31. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.
    Mäkinen N, Zhou M, Zhang Z, Kasai Y, Perez E, Kim GE, Thirlwell C, Nakakura E, Meyerson M| | PubMed
  32. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    Conroy PC, Calthorpe L, Lin JA, Mohamedaly S, Kim A, Hirose K, Nakakura E, Corvera C, Sosa JA, Sarin A, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  33. Optimal Staging for Gastric Cancer Starts With High-Resolution Computed Tomography.
    Brown AE, Nakakura EK| | PubMed
  34. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    Conroy PC, Calthorpe L, Lin JA, Mohamedaly S, Kim A, Hirose K, Nakakura E, Corvera C, Sosa JA, Sarin A, Kirkwood KS, Alseidi A, Adam MA| | PubMed
  35. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S| | PubMed
  36. Evidence-Based Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasm Management: Still a Lot of Room to Grow.
    Conroy PC, Nakakura E| | PubMed
  37. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M| | PubMed
  38. Burden of Ionizing Radiation in the Diagnosis and Management of Necrotizing Pancreatitis.
    Thiruvengadam NR, Miranda J, Kim C, Behr S, Corvera C, Dai SC, Kirkwood K, Harris HW, Hirose K, Nakakura E, Ostroff JW, Kochman ML, Arain MA| | PubMed
  39. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV| | PubMed
  40. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K| | PubMed
  41. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK| | PubMed
  42. Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center.
    Gomez A, Wisneski AD, Luu HY, Hirose K, Roberts JP, Hirose R, Freise CE, Nakakura EK, Corvera CU| | PubMed
  43. Hybrid Low-Grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma of the Pancreas.
    Kramer SP, Bowman CJ, Wang ZJ, Sheahon KM, Nakakura EK, Cho SJ, Umetsu SE, Behr SC| | PubMed
  44. Randomized Clinical Trial of Nasogastric Tube Placement After Pancreaticoduodenectomy.
    Sharib JM, Nakakura EK| | PubMed
  45. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    Wisneski AD, Jin C, Huang CY, Warren R, Hirose K, Nakakura EK, Corvera CU| | PubMed
  46. Awareness of a mesenteric mass as a common manifestation of ileal neuroendocrine tumor.
    Kasai Y, Nakakura EK| | PubMed
  47. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors.
    Zhang Z, Mäkinen N, Kasai Y, Kim GE, Diosdado B, Nakakura E, Meyerson M| | PubMed
  48. Ampullary stenosis and choledocholithiasis post Roux-En-Y gastric bypass: challenges of biliary access and intervention.
    Wisneski AD, Carter J, Nakakura EK, Posselt A, Rogers SJ, Cello JP, Arain M, Kirkwood KS, Hirose K, Stewart L, Corvera CU| | PubMed
  49. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  50. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  51. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  52. Adjuvant Therapy for Ampullary Cancer.
    Ko AH, Nakakura EK| | PubMed
  53. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  54. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K| | PubMed
  55. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE| | PubMed
  56. Pancreatic Adenocarcinoma, Version 1.2019.
    Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G| | PubMed
  57. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  58. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  59. Outcomes of arterial bypass preceding resection of retroperitoneal masses involving major vessels.
    Luu HY, Wang ED, Syed SM, Xu X, Hansen SL, Eichler CM, Nakakura EK| | PubMed
  60. Progress in the March to Precision Cancer Medicine: Left, Right, Left.
    Nakakura EK| | PubMed
  61. Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix.
    Nakakura EK| | PubMed
  62. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S| | PubMed
  63. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade.
    Greene C, Nakakura EK, Ko AH| | PubMed
  64. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF| | PubMed
  65. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK| | PubMed
  66. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH| | PubMed
  67. Finding the Common Thread in Rare Diseases.
    Nakakura EK| | PubMed
  68. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK| | PubMed
  69. Solid pseudopapillary neoplasm of the pancreas head in a pregnant woman: safe pancreaticoduodenectomy postpartum.
    Yee AM, Kelly BG, Gonzalez-Velez JM, Nakakura EK| | PubMed
  70. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E| | PubMed
  71. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.
    Walker EJ, Simko JP, Nakakura EK, Ko AH| | PubMed
  72. Bone metastases and skeletal-related events from neuroendocrine tumors.
    Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK| | PubMed
  73. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    Bergsland EK, Nakakura EK| | PubMed
  74. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
    Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA| | PubMed
  75. Time to put another surgical dogma to sleep?
    Nakakura EK| | PubMed
  76. Home, sweet home, after surgery.
    Nakakura EK| | PubMed
  77. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS| | PubMed
  78. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
    Wang SC, Fidelman N, Nakakura EK| | PubMed
  79. Reply to P.H. Sugarbaker.
    Nakakura EK| | PubMed
  80. Can CT features differentiate between inferior vena cava leiomyosarcomas and primary retroperitoneal masses?
    Webb EM, Wang ZJ, Westphalen AC, Nakakura EK, Coakley FV, Yeh BM| | PubMed
  81. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK| | PubMed
  82. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks| | PubMed
  83. Pseudomyxoma peritonei: more questions than answers.
    Nakakura EK| | PubMed
  84. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    Tseng WW, Wang SC, Eichler CM, Warren RS, Nakakura EK| | PubMed
  85. Unique patterns of metastases in common and rare types of malignancy.
    Leong SP, Nakakura EK, Pollock R, Choti MA, Morton DL, Henner WD, Lal A, Pillai R, Clark OH, Cady B| | PubMed
  86. Pancreatic adenocarcinoma.
    Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma| | PubMed
  87. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  88. Arterial embolization for the management of gastrointestinal hemorrhage from metastatic renal cell carcinoma.
    Fidelman N, Freed RC, Nakakura EK, Rosenberg J, Bloom AI| | PubMed
  89. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | PubMed
  90. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  91. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
    Olson P, Lu J, Zhang H, Shai A, Chun MG, Wang Y, Libutti SK, Nakakura EK, Golub TR, Hanahan D| | PubMed
  92. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E| | PubMed
  93. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  94. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    Guo L, Clark JP, Warren RS, Nakakura EK| | PubMed
  95. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas.
    Horvai AE, Schaefer JT, Nakakura EK, O'Donnell RJ| | PubMed
  96. Introduction.
    Warren RS, Nakakura EK| | PubMed
  97. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
    Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C| | PubMed
  98. Palliative care for patients with advanced pancreatic and biliary cancers.
    Nakakura EK, Warren RS| | PubMed
  99. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    Nakakura EK, Venook AP, Bergsland EK| | PubMed
  100. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    Nakakura EK, Bergsland EK| | PubMed
  101. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
    Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD| | PubMed
  102. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling.
    Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW| | PubMed
  103. Notch signaling induces rapid degradation of achaete-scute homolog 1.
    Sriuranpong V, Borges MW, Strock CL, Nakakura EK, Watkins DN, Blaumueller CM, Nelkin BD, Ball DW| | PubMed
  104. Mammalian Scratch participates in neuronal differentiation in P19 embryonal carcinoma cells.
    Nakakura EK, Watkins DN, Sriuranpong V, Borges MW, Nelkin BD, Ball DW| | PubMed
  105. Mammalian Scratch: a neural-specific Snail family transcriptional repressor.
    Nakakura EK, Watkins DN, Schuebel KE, Sriuranpong V, Borges MW, Nelkin BD, Ball DW| | PubMed
  106. Management of hepatocellular carcinoma.
    Nakakura EK, Choti MA| | PubMed
  107. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy.
    Nakakura EK, Shorthouse RA, Zheng B, McCabe SM, Jardieu PM, Morris RE| | PubMed
  108. A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts.
    Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, Morris RE| | PubMed
  109. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion.
    Nakakura EK, McCabe SM, Zheng B, Shorthouse RA, Scheiner TM, Blank G, Jardieu PM, Morris RE| | PubMed
Qiao_Guilin
Guilin Qiao, PhD

Associate Professor of Surgery
Division of Surgical Oncology

Section:
Colorectal Surgery
Research Interests

Combination immunotherapies for the treament of immunotherapy-resistant colorectal cancer

Research Type:
Basic Biomedical and Translational
Disease focus:
Colorectal Cancer
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 8
  1. Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.
    Wiley MB, Bauer J, Mehrotra K, Zessner-Spitzenberg J, Kolics Z, Cheng W, Castellanos K, Nash MG, Gui X, Kone L, Maker AV, Qiao G, Reddi D, Church DN, Kerr RS, Kerr DJ, Grippo PJ, Jung B| | PubMed
  2. LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
    Qiao G, Kone LB, Phillips EH, Lee SS, Brown GE, Khetani SR, Thakur A, Lum LG, Prabhakar BS, Maker AV| | PubMed
  3. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
    Fernandez MF, Qiao G, Tulla K, Prabhakar BS, Maker AV| | PubMed
  4. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S, Sripada L, Tulla K, Qiao G, Kunda N, Maker AV, Prabhakar BS| | PubMed
  5. Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.
    Qin J, Kunda NM, Qiao G, Tulla K, Prabhakar BS, Maker AV| | PubMed
  6. LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases.
    Qiao G, Qin J, Kunda N, Calata JF, Mahmud DL, Gann P, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV| | PubMed
  7. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death.
    Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV| | PubMed
  8. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.
    Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV| | PubMed
Robert Warren headshot
Robert S. Warren, MD

Professor of Surgery
Division of Surgical Oncology
Warren Lab in Surgical Oncology

Section:
Colorectal Surgery
Research Interests

Autocrine growth factors and angiogenesis in colorectal cancer; molecular predictors of clinical outcome in primary and metastatic colorectal cancer

Research Type:
Basic Biomedical and Translational
Disease focus:
Primary and metastatic colon cancer
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 70
  1. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E| | PubMed
  2. STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20.
    Antonia RJ, Karelehto E, Toriguchi K, Matli M, Warren RS, Pfeffer LM, Donner DB| | PubMed
  3. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    Wisneski AD, Jin C, Huang CY, Warren R, Hirose K, Nakakura EK, Corvera CU| | PubMed
  4. RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon.
    Yu J, Navickas A, Asgharian H, Culbertson B, Fish L, Garcia K, Olegario JP, Dermit M, Dodel M, Hänisch B, Luo Y, Weinberg EM, Dienstmann R, Warren RS, Mardakheh FK, Goodarzi H| | PubMed
  5. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  6. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  7. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  8. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J| | PubMed
  9. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  10. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P| | PubMed
  11. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  12. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  13. Sampling strategies to capture single-cell heterogeneity.
    Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ| | PubMed
  14. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA| | PubMed
  15. Reply to L. Casadaban et al.
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  16. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM| | PubMed
  17. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  18. Unexpected insights for anti-EGFR cancer therapy.
    Depeille P, Warren RS, Roose JP| | PubMed
  19. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP| | PubMed
  20. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology| | PubMed
  21. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR| | PubMed
  22. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.
    Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R| | PubMed
  23. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM| | PubMed
  24. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
    Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS| | PubMed
  25. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS| | PubMed
  26. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM| | PubMed
  27. Imaging a functional tumorigenic biomarker in the transformed epithelium.
    LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS| | PubMed
  28. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK| | PubMed
  29. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM| | PubMed
  30. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
    Venook AP, Bendell JC, Warren RS| | PubMed
  31. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    Tseng WW, Wang SC, Eichler CM, Warren RS, Nakakura EK| | PubMed
  32. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
    Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA| | PubMed
  33. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
    Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS| | PubMed
  34. Pancreatic adenocarcinoma.
    Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma| | PubMed
  35. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  36. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | PubMed
  37. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  38. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
    Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M| | PubMed
  39. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M| | PubMed
  40. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E| | PubMed
  41. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  42. Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
    Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS| | PubMed
  43. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    Guo L, Clark JP, Warren RS, Nakakura EK| | PubMed
  44. Prognostic importance of superior diaphragmatic adenopathy at computed tomography in patients with resectable hepatic metastases from colorectal carcinoma.
    Aslam R, Coakley FV, Williams G, Yeh BM, Joe BN, Zuraek MB, Warren RS| | PubMed
  45. Introduction.
    Warren RS, Nakakura EK| | PubMed
  46. Palliative care for patients with advanced pancreatic and biliary cancers.
    Nakakura EK, Warren RS| | PubMed
  47. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.
    LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD| | PubMed
  48. Pancreatoblastoma in an adult: case report and review of the literature.
    Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK| | PubMed
  49. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ| | PubMed
  50. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
    Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA, National Comprehensive Cancer Network| | PubMed
  51. [Liver metastases from colorectal cancer. Is the practice of surgery based on the best clinical evidence possible?].
    Durán Giménez-Rico H, García-Aguilar J, Warren RS, Iborra P, Guerrero V| | PubMed
  52. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro.
    Arvold ND, Guha N, Wang D, Matli M, Deen DF, Warren RS, Haas-Kogan DA| | PubMed
  53. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM| | PubMed
  54. Liver-directed therapies in colorectal cancer.
    Ruan DT, Warren RS| | PubMed
  55. Palliative techniques for hepatic cancer.
    Ruan DT, Warren RS| | PubMed
  56. Characterization of triacsin C inhibition of short-, medium-, and long-chain fatty acid: CoA ligases of human liver.
    Vessey DA, Kelley M, Warren RS| | PubMed
  57. Aggressive surgery for metastatic liver neuroendocrine tumors.
    Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT| | PubMed
  58. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
    Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V, Randazzo F, Gundel R, Warren RS, Escobedo J, Aukerman SL, Taylor RN, Fantl WJ| | PubMed
  59. Distinguishing features of self-limiting adult small-bowel intussusception identified at CT.
    Lvoff N, Breiman RS, Coakley FV, Lu Y, Warren RS| | PubMed
  60. Isolation, sequencing, and expression of a cDNA for the HXM-A form of xenobiotic/medium-chain fatty acid:CoA ligase from human liver mitochondria.
    Vessey DA, Lau E, Kelley M, Warren RS| | PubMed
  61. Thorotrast-induced liver neoplasia: a collective review.
    Lipshutz GS, Brennan TV, Warren RS| | PubMed
  62. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF| | PubMed
  63. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.
    Warren RS, Kirn DH| | PubMed
  64. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.
    Wang D, Lehman RE, Donner DB, Matli MR, Warren RS, Welton ML| | PubMed
  65. Quantitative fractionation of alkaline phosphatase isoenzymes according to their thermostability.
    PetitClerc C| | PubMed
  66. Activity and longevity of insect growth regulators against mosquitoes.
    Mulla MS, Darwazeh HA| | PubMed
  67. A double-blind controlled therapeutic trial of lorazepam vs medazepam in psychosomatic conditions in general practice.
    Sim M, Bindman E, Morrison I, Sandilands D| | PubMed
  68. Analyses of rumen fluid from "sudden death", lactic acidotic and healthy cattle fed high concentrate ration.
    Wilson JR, Bartley EE, Anthony HD, Brent BE, Sapienza DA, Chapman TE, Dayton AD, Milleret RJ, Frey RA, Meyer RM| | PubMed
  69. Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin.
    Järvisalo J, Saris NE| | PubMed
  70. Digitoxin metabolism by rat liver microsomes.
    Schmoldt A, Benthe HF, Haberland G| | PubMed
View Lab Site
rnf9301 weaver valerie 013118 resized final copy
Valerie M. Weaver, PhD

Professor of Surgery
Division of Surgical Oncology
Director, Center for Bioengineering & Tissue Regeneration

Section:
Breast Surgery
Research Interests

Investigating how mechanical and topological properties of the extracellular matrix influence (1) mammary tissue development and tumor progression, and (2) embryonic and adult stem cell fate

Research Type:
Basic Biomedical and Translational
Disease focus:
Stromal-epithelial interactions in the extracellular matrix
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 192
  1. Live imaging of the extracellular matrix with a glycan-binding fluorophore.
    Fiore A, Yu G, Northey JJ, Patel R, Ravenscroft TA, Ikegami R, Kolkman W, Kumar P, Dilan TL, Ruetten VMS, Ahrens MB, Shroff H, Wang S, Weaver VM, Pedram K| | PubMed
  2. Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling.
    Nakagawa R, Beardsley A, Durney S, Hayward MK, Subramanyam V, Meyer NP, Wismer H, Goodarzi H, Weaver VM, Van de Mark D, Goga A| | PubMed
  3. Tension-induced organelle stress: an emerging target in fibrosis.
    Kai F, Leidal AM, Weaver VM| | PubMed
  4. Forcing the code: tension modulates signaling to drive morphogenesis and malignancy.
    Narain R, Muncie-Vasic JM, Weaver VM| | PubMed
  5. Differential stiffness between brain vasculature and parenchyma promotes metastatic infiltration through vessel co-option.
    Uroz M, Stoddard AE, Sutherland BP, Courbot O, Oria R, Li L, Ravasio CR, Ngo MT, Yang J, Tefft JB, Eyckmans J, Han X, Elosegui-Artola A, Weaver VM, Chen CS| | PubMed
  6. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer.
    Hendley AM, Ashe S, Urano A, Ng M, Phu TA, Peng XL, Luan C, Finger AM, Jang GH, Kerper NR, Berrios DI, Jin D, Lee J, Riahi IR, Gbenedio OM, Chung C, Roose JP, Yeh JJ, Gallinger S, Biankin AV, O'Kane GM, Ntranos V, Chang DK, Dawson DW, Kim GE, Weaver VM, Raffai RL, Hebrok M| | PubMed
  7. Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment.
    Tharp KM, Kersten K, Maller O, Timblin GA, Stashko C, Canale FP, Menjivar RE, Hayward MK, Berestjuk I, Ten Hoeve J, Samad B, Ironside AJ, di Magliano MP, Muir A, Geiger R, Combes AJ, Weaver VM| | PubMed
  8. Patterning and folding of intestinal villi by active mesenchymal dewetting.
    Huycke TR, Häkkinen TJ, Miyazaki H, Srivastava V, Barruet E, McGinnis CS, Kalantari A, Cornwall-Scoones J, Vaka D, Zhu Q, Jo H, Oria R, Weaver VM, DeGrado WF, Thomson M, Garikipati K, Boffelli D, Klein OD, Gartner ZJ| | PubMed
  9. Imaging the extracellular matrix in live tissues and organisms with a glycan-binding fluorophore.
    Fiore A, Yu G, Northey JJ, Patel R, Ravenscroft TA, Ikegami R, Kolkman W, Kumar P, Grimm JB, Dilan TL, Ruetten VMS, Ahrens MB, Shroff H, Lavis LD, Wang S, Weaver VM, Pedram K| | PubMed
  10. Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
    Goyette MA, Stevens LE, DePinho CR, Seehawer M, Nishida J, Li Z, Wilde CM, Li R, Qiu X, Pyke AL, Zhao S, Lim K, Tender GS, Northey JJ, Riley NM, Long HW, Bertozzi CR, Weaver VM, Polyak K| | PubMed
  11. Asymmetric crowders and membrane morphology at the nexus of intracellular trafficking and oncology.
    Parihar K, Ko SB, Bradley RP, Taylor P, Ramakrishnan N, Baumgart T, Guo W, Weaver VM, Janmey PA, Radhakrishnan R| | PubMed
  12. Free energy calculations for membrane morphological transformations and insights to physical biology and oncology.
    Parihar K, Ko SH, Bradley R, Taylor P, Ramakrishnan N, Baumgart T, Guo W, Weaver VM, Janmey PA, Radhakrishnan R| | PubMed
  13. Assessing Heterogeneity in the N-Telopeptides of Type I Collagen by Mass Spectrometry.
    Darula Z, McCabe MC, Barrett A, Schmitt LR, Maslanka MD, Saviola AJ, Orgel J, Burlingame A, Staab-Weijnitz CA, Stenmark K, Weaver V, Chalkley RJ, Hansen KC| | PubMed
  14. Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth.
    Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, Munro J, Schröder E, Zhou J, Brunton VG, Barker N, Clevers H, Sansom OJ, Anderson KI, Weaver VM, Olson MF| | PubMed
  15. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
    Northey JJ, Hayward MK, Yui Y, Stashko C, Kai F, Mouw JK, Thakar D, Lakins JN, Ironside AJ, Samson S, Mukhtar RA, Hwang ES, Weaver VM| | PubMed
  16. The microenvironment dictates glycocalyx construction and immune surveillance.
    Tharp KM, Park S, Timblin GA, Richards AL, Berg JA, Twells NM, Riley NM, Peltan EL, Shon DJ, Stevenson E, Tsui K, Palomba F, Lefebvre AEYT, Soens RW, Ayad NME, Hoeve-Scott JT, Healy K, Digman M, Dillin A, Bertozzi CR, Swaney DL, Mahal LK, Cantor JR, Paszek MJ, Weaver VM| | PubMed
  17. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins.
    Pedram K, Shon DJ, Tender GS, Mantuano NR, Northey JJ, Metcalf KJ, Wisnovsky SP, Riley NM, Forcina GC, Malaker SA, Kuo A, George BM, Miller CL, Casey KM, Vilches-Moure JG, Ferracane MJ, Weaver VM, Läubli H, Bertozzi CR| | PubMed
  18. Tissue tension permits β-catenin phosphorylation to drive mesoderm specification in human embryonic stem cells.
    Ayad NME, Lakins JN, Ghagre A, Ehrlicher AJ, Weaver VM| | PubMed
  19. A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer.
    Stashko C, Hayward MK, Northey JJ, Pearson N, Ironside AJ, Lakins JN, Oria R, Goyette MA, Mayo L, Russnes HG, Hwang ES, Kutys ML, Polyak K, Weaver VM| | PubMed
  20. Uptake of tumor-derived microparticles induces metabolic reprogramming of macrophages in the early metastatic lung.
    Kersten K, You R, Liang S, Tharp KM, Pollack J, Weaver VM, Krummel MF, Headley MB| | PubMed
  21. Stiff matrix induces exosome secretion to promote tumour growth.
    Wu B, Liu DA, Guan L, Myint PK, Chin L, Dang H, Xu Y, Ren J, Li T, Yu Z, Jabban S, Mills GB, Nukpezah J, Chen YH, Furth EE, Gimotty PA, Wells RG, Weaver VM, Radhakrishnan R, Wang XW, Guo W| | PubMed
  22. Programming the Self-Organization of Endothelial Cells into Perfusable Microvasculature.
    Cabral KA, Srivastava V, Graham AJ, Coyle MC, Stashko C, Weaver V, Gartner ZJ| | PubMed
  23. Extracellular Matrix Glycation and Crosslinking in Mammary Tumor Progression.
    Northey JJ, Weaver VM| | PubMed
  24. Novel cryo-tomography workflow reveals nanometer-scale responses of epithelial cells to matrix stiffness and dimensionality.
    Gaietta G, Kai F, Swift MF, Weaver VM, Volkmann N, Hanein D| | PubMed
  25. Mechanosensitive Steroid Hormone Signaling and Cell Fate.
    Northey JJ, Weaver VM| | PubMed
  26. Low lamin A levels enhance confined cell migration and metastatic capacity in breast cancer.
    Bell ES, Shah P, Zuela-Sopilniak N, Kim D, Varlet AA, Morival JLP, McGregor AL, Isermann P, Davidson PM, Elacqua JJ, Lakins JN, Vahdat L, Weaver VM, Smolka MB, Span PN, Lammerding J| | PubMed
  27. ECM dimensionality tunes actin tension to modulate endoplasmic reticulum function and spheroid phenotypes of mammary epithelial cells.
    Kai F, Ou G, Tourdot RW, Stashko C, Gaietta G, Swift MF, Volkmann N, Long AF, Han Y, Huang HH, Northey JJ, Leidal AM, Viasnoff V, Bryant DM, Guo W, Wiita AP, Guo M, Dumont S, Hanein D, Radhakrishnan R, Weaver VM| | PubMed
  28. Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity.
    Tsai KK, Huang SS, Northey JJ, Liao WY, Hsu CC, Cheng LH, Werner ME, Chuu CP, Chatterjee C, Lakins JN, Weaver VM| | PubMed
  29. Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression.
    Metcalf KJ, Hayward MK, Berens E, Ironside AJ, Stashko C, Hwang ES, Weaver VM| | PubMed
  30. NCI's publication affiliation conundrum: Reframing innovation to incentivize an equitable path for advocate representation.
    Samson S, Northey JJ, Acerbi I, Goga A, Flink CL, Weaver VM, LaBarge MA| | PubMed
  31. Mechanobiology: forcing the second act.
    Weaver VM| | PubMed
  32. Autophagy in stromal fibroblasts promotes tumor desmoplasia and mammary tumorigenesis.
    Rudnick JA, Monkkonen T, Mar FA, Barnes JM, Starobinets H, Goldsmith J, Roy S, Bustamante Eguiguren S, Weaver VM, Debnath J| | PubMed
  33. Tissue mechanics in stem cell fate, development, and cancer.
    Hayward MK, Muncie JM, Weaver VM| | PubMed
  34. EPH/EPHRIN regulates cellular organization by actomyosin contractility effects on cell contacts.
    Kindberg AA, Srivastava V, Muncie JM, Weaver VM, Gartner ZJ, Bush JO| | PubMed
  35. Adhesion-mediated mechanosignaling forces mitohormesis.
    Tharp KM, Higuchi-Sanabria R, Timblin GA, Ford B, Garzon-Coral C, Schneider C, Muncie JM, Stashko C, Daniele JR, Moore AS, Frankino PA, Homentcovschi S, Manoli SS, Shao H, Richards AL, Chen KH, Hoeve JT, Ku GM, Hellerstein M, Nomura DK, Saijo K, Gestwicki J, Dunn AR, Krogan NJ, Swaney DL, Dillin A, Weaver VM| | PubMed
  36. Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree.
    Hendley AM, Rao AA, Leonhardt L, Ashe S, Smith JA, Giacometti S, Peng XL, Jiang H, Berrios DI, Pawlak M, Li LY, Lee J, Collisson EA, Anderson MS, Fragiadakis GK, Yeh JJ, Ye CJ, Kim GE, Weaver VM, Hebrok M| | PubMed
  37. Matrix compliance permits NF-κB activation to drive therapy resistance in breast cancer.
    Drain AP, Zahir N, Northey JJ, Zhang H, Huang PJ, Maller O, Lakins JN, Yu X, Leight JL, Alston-Mills BP, Hwang ES, Chen YY, Park CC, Weaver VM| | PubMed
  38. Improving DCIS diagnosis and predictive outcome by applying artificial intelligence.
    Hayward MK, Weaver VM| | PubMed
  39. Leveraging microenvironmental synthetic lethalities to treat cancer.
    Metcalf KJ, Alazzeh A, Werb Z, Weaver VM| | PubMed
  40. Membrane Tension Locks In Pluripotency.
    Muncie JM, Weaver VM| | PubMed
  41. Derivation of a nuclear heterogeneity image index to grade DCIS.
    Hayward MK, Louise Jones J, Hall A, King L, Ironside AJ, Nelson AC, Shelley Hwang E, Weaver VM| | PubMed
  42. Proteoglycans as Mediators of Cancer Tissue Mechanics.
    Barkovskaya A, Buffone A, Žídek M, Weaver VM| | PubMed
  43. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression.
    Maller O, Drain AP, Barrett AS, Borgquist S, Ruffell B, Zakharevich I, Pham TT, Gruosso T, Kuasne H, Lakins JN, Acerbi I, Barnes JM, Nemkov T, Chauhan A, Gruenberg J, Nasir A, Bjarnadottir O, Werb Z, Kabos P, Chen YY, Hwang ES, Park M, Coussens LM, Nelson AC, Hansen KC, Weaver VM| | PubMed
  44. Mechanical Tension Promotes Formation of Gastrulation-like Nodes and Patterns Mesoderm Specification in Human Embryonic Stem Cells.
    Muncie JM, Ayad NME, Lakins JN, Xue X, Fu J, Weaver VM| | PubMed
  45. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    Northey JJ, Barrett AS, Acerbi I, Hayward MK, Talamantes S, Dean IS, Mouw JK, Ponik SM, Lakins JN, Huang PJ, Wu J, Shi Q, Samson S, Keely PJ, Mukhtar RA, Liphardt JT, Shepherd JA, Hwang ES, Chen YY, Hansen KC, Littlepage LE, Weaver VM| | PubMed
  46. Zena Werb (1945-2020): Mourning the loss of a tissue microenvironment icon.
    Weaver VM, Bissell MJ| | PubMed
  47. In Memoriam - Zena Werb 1945-2020.
    Barcellos-Hoff MH, Weaver VM| | PubMed
  48. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.
    Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA| | PubMed
  49. Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice.
    Alsamman S, Christenson SA, Yu A, Ayad NME, Mooring MS, Segal JM, Hu JK, Schaub JR, Ho SS, Rao V, Marlow MM, Turner SM, Sedki M, Pantano L, Ghoshal S, Ferreira DDS, Ma HY, Duwaerts CC, Espanol-Suner R, Wei L, Newcomb B, Mileva I, Canals D, Hannun YA, Chung RT, Mattis AN, Fuchs BC, Tager AM, Yimlamai D, Weaver VM, Mullen AC, Sheppard D, Chen JY| | PubMed
  50. Zena Werb 1945-2020.
    Egeblad M, Coussens LM, Weaver VM| | PubMed
  51. Fibrosis and cancer: A strained relationship.
    Piersma B, Hayward MK, Weaver VM| | PubMed
  52. Tension in tumour cells keeps metabolism high.
    Ayad NME, Weaver VM| | PubMed
  53. A framework for advancing our understanding of cancer-associated fibroblasts.
    Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO, Jain RK, Janowitz T, Jorgensen C, Kimmelman AC, Kolonin MG, Maki RG, Powers RS, Puré E, Ramirez DC, Scherz-Shouval R, Sherman MH, Stewart S, Tlsty TD, Tuveson DA, Watt FM, Weaver V, Weeraratna AT, Werb Z| | PubMed
  54. Don't sugarcoat it: How glycocalyx composition influences cancer progression.
    Buffone A, Weaver VM| | PubMed
  55. Patterning the Geometry of Human Embryonic Stem Cell Colonies on Compliant Substrates to Control Tissue-Level Mechanics.
    Muncie JM, Falcón-Banchs R, Lakins JN, Sohn LL, Weaver VM| | PubMed
  56. Controlled modelling of human epiblast and amnion development using stem cells.
    Zheng Y, Xue X, Shao Y, Wang S, Esfahani SN, Li Z, Muncie JM, Lakins JN, Weaver VM, Gumucio DL, Fu J| | PubMed
  57. Wnt4 from the Niche Controls the Mechano-Properties and Quiescent State of Muscle Stem Cells.
    Eliazer S, Muncie JM, Christensen J, Sun X, D'Urso RS, Weaver VM, Brack AS| | PubMed
  58. Tissue mechanics, an important regulator of development and disease.
    Ayad NME, Kaushik S, Weaver VM| | PubMed
  59. The Extracellular Matrix Modulates the Metastatic Journey.
    Kai F, Drain AP, Weaver VM| | PubMed
  60. Spatiotemporal mosaic self-patterning of pluripotent stem cells using CRISPR interference.
    Libby AR, Joy DA, So PL, Mandegar MA, Muncie JM, Mendoza-Camacho FN, Weaver VM, Conklin BR, McDevitt TC| | PubMed
  61. A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma.
    Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai F, Przybyla L, Lee M, Lee HW, Tung JC, Maller O, Barrett AS, Lu KV, Lakins JN, Hansen KC, Obernier K, Alvarez-Buylla A, Bergers G, Phillips JJ, Nam DH, Bertozzi CR, Weaver VM| | PubMed
  62. Modeling Tissue Polarity in Context.
    Tharp KM, Weaver VM| | PubMed
  63. Fibronectin rescues estrogen receptor α from lysosomal degradation in breast cancer cells.
    Sampayo RG, Toscani AM, Rubashkin MG, Thi K, Masullo LA, Violi IL, Lakins JN, Cáceres A, Hines WC, Coluccio Leskow F, Stefani FD, Chialvo DR, Bissell MJ, Weaver VM, Simian M| | PubMed
  64. Compartment resolved proteomics reveals a dynamic matrisome in a biomechanically driven model of pancreatic ductal adenocarcinoma.
    Barrett AS, Maller O, Pickup MW, Weaver VM, Hansen KC| | PubMed
  65. The Physical and Biochemical Properties of the Extracellular Matrix Regulate Cell Fate.
    Muncie JM, Weaver VM| | PubMed
  66. New Horizons in Advocacy Engaged Physical Sciences and Oncology Research.
    Samson S, Northey JJ, Plaks V, Baas C, Dean I, LaBarge MA, Goga A, Van't Veer LJ, Weaver VM| | PubMed
  67. Feeling Stress: The Mechanics of Cancer Progression and Aggression.
    Northcott JM, Dean IS, Mouw JK, Weaver VM| | PubMed
  68. Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma.
    Ilkhanizadeh S, Sabelström H, Miroshnikova YA, Frantz A, Zhu W, Idilli A, Lakins JN, Schmidt C, Quigley DA, Fenster T, Yuan E, Trzeciak JR, Saxena S, Lindberg OR, Mouw JK, Burdick JA, Magnitsky S, Berger MS, Phillips JJ, Arosio D, Sun D, Weaver VM, Weiss WA, Persson AI| | PubMed
  69. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers.
    Takai K, Drain AP, Lawson DA, Littlepage LE, Karpuj M, Kessenbrock K, Le A, Inoue K, Weaver VM, Werb Z| | PubMed
  70. Excess area dependent scaling behavior of nano-sized membrane tethers.
    Ramakrishnan N, Sreeja KK, Roychoudhury A, Eckmann DM, Ayyaswamy PS, Baumgart T, Pucadyil T, Patil S, Weaver VM, Radhakrishnan R| | PubMed
  71. A bulky glycocalyx fosters metastasis formation by promoting G1 cell cycle progression.
    Woods EC, Kai F, Barnes JM, Pedram K, Pickup MW, Hollander MJ, Weaver VM, Bertozzi CR| | PubMed
  72. Tissue Force Programs Cell Fate and Tumor Aggression.
    Northey JJ, Przybyla L, Weaver VM| | PubMed
  73. α5β1-Integrin promotes tension-dependent mammary epithelial cell invasion by engaging the fibronectin synergy site.
    Miroshnikova YA, Rozenberg GI, Cassereau L, Pickup M, Mouw JK, Ou G, Templeman KL, Hannachi EI, Gooch KJ, Sarang-Sieminski AL, García AJ, Weaver VM| | PubMed
  74. Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.
    Pickup MW, Owens P, Gorska AE, Chytil A, Ye F, Shi C, Weaver VM, Kalluri R, Moses HL, Novitskiy SV| | PubMed
  75. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.
    Salvador F, Martin A, López-Menéndez C, Moreno-Bueno G, Santos V, Vázquez-Naharro A, Santamaria PG, Morales S, Dubus PR, Muinelo-Romay L, López-López R, Tung JC, Weaver VM, Portillo F, Cano A| | PubMed
  76. Cell and tissue mechanics: the new cell biology frontier.
    Weaver VM| | PubMed
  77. Visualizing dynamic microvillar search and stabilization during ligand detection by T cells.
    Cai E, Marchuk K, Beemiller P, Beppler C, Rubashkin MG, Weaver VM, Gérard A, Liu TL, Chen BC, Betzig E, Bartumeus F, Krummel MF| | PubMed
  78. Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis.
    Oudin MJ, Weaver VM| | PubMed
  79. Comprehensive characterization of DNA methylation changes in Fuchs endothelial corneal dystrophy.
    Khuc E, Bainer R, Wolf M, Clay SM, Weisenberger DJ, Kemmer J, Weaver VM, Hwang DG, Chan MF| | PubMed
  80. Integrin-mediated traction force enhances paxillin molecular associations and adhesion dynamics that increase the invasiveness of tumor cells into a three-dimensional extracellular matrix.
    Mekhdjian AH, Kai F, Rubashkin MG, Prahl LS, Przybyla LM, McGregor AL, Bell ES, Barnes JM, DuFort CC, Ou G, Chang AC, Cassereau L, Tan SJ, Pickup MW, Lakins JN, Ye X, Davidson MW, Lammerding J, Odde DJ, Dunn AR, Weaver VM| | PubMed
  81. Tissue mechanics regulate brain development, homeostasis and disease.
    Barnes JM, Przybyla L, Weaver VM| | PubMed
  82. Force-dependent breaching of the basement membrane.
    Chang TT, Thakar D, Weaver VM| | PubMed
  83. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K, Le A, Weaver VM, Werb Z| | PubMed
  84. From transformation to metastasis: deconstructing the extracellular matrix in breast cancer.
    Kaushik S, Pickup MW, Weaver VM| | PubMed
  85. Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells.
    Chan TS, Hsu CC, Pai VC, Liao WY, Huang SS, Tan KT, Yen CJ, Hsu SC, Chen WY, Shan YS, Li CR, Lee MT, Jiang KY, Chu JM, Lien GS, Weaver VM, Tsai KK| | PubMed
  86. Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression.
    Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins JN, Kim Y, Lobo K, Persson AI, Reis GF, McKnight TR, Holland EC, Phillips JJ, Weaver VM| | PubMed
  87. Cellular adaptation to biomechanical stress across length scales in tissue homeostasis and disease.
    Gilbert PM, Weaver VM| | PubMed
  88. Tissue Mechanics Orchestrate Wnt-Dependent Human Embryonic Stem Cell Differentiation.
    Przybyla L, Lakins JN, Weaver VM| | PubMed
  89. Visualizing mechanical modulation of nanoscale organization of cell-matrix adhesions.
    Ou G, Thakar D, Tung JC, Miroshnikova YA, Dufort CC, Gutierrez E, Groisman A, Weaver VM| | PubMed
  90. Mechanical Control of Epithelial-to-Mesenchymal Transitions in Development and Cancer.
    Przybyla L, Muncie JM, Weaver VM| | PubMed
  91. Site-Specific Modulation of Charge Controls the Structure and Stimulus Responsiveness of Intrinsically Disordered Peptide Brushes.
    Bhagawati M, Rubashkin MG, Lee JP, Ananthanarayanan B, Weaver VM, Kumar S| | PubMed
  92. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.
    Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM| | PubMed
  93. Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease.
    Kai F, Laklai H, Weaver VM| | PubMed
  94. Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness.
    Le LT, Cazares O, Mouw JK, Chatterjee S, Macias H, Moran A, Ramos J, Keely PJ, Weaver VM, Hinck L| | PubMed
  95. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha.
    Desai SS, Tung JC, Zhou VX, Grenert JP, Malato Y, Rezvani M, Español-Suñer R, Willenbring H, Weaver VM, Chang TT| | PubMed
  96. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.
    Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R| | PubMed
  97. Tumor-induced solid stress activates β-catenin signaling to drive malignant behavior in normal, tumor-adjacent cells.
    Ou G, Weaver VM| | PubMed
  98. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.
    Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA| | PubMed
  99. Monitoring developmental force distributions in reconstituted embryonic epithelia.
    Przybyla L, Lakins JN, Sunyer R, Trepat X, Weaver VM| | PubMed
  100. STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.
    Lau J, Ilkhanizadeh S, Wang S, Miroshnikova YA, Salvatierra NA, Wong RA, Schmidt C, Weaver VM, Weiss WA, Persson AI| | PubMed
  101. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration.
    Acerbi I, Cassereau L, Dean I, Shi Q, Au A, Park C, Chen YY, Liphardt J, Hwang ES, Weaver VM| | PubMed
  102. Fighting the force: Potential of homeobox genes for tumor microenvironment regulation.
    Northcott JM, Northey JJ, Barnes JM, Weaver VM| | PubMed
  103. Tumor mechanics and metabolic dysfunction.
    Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, Eliceiri KW, Keely PJ, Seewaldt VL, Weaver VM| | PubMed
  104. A 3D tension bioreactor platform to study the interplay between ECM stiffness and tumor phenotype.
    Cassereau L, Miroshnikova YA, Ou G, Lakins J, Weaver VM| | PubMed
  105. The extracellular matrix modulates the hallmarks of cancer.
    Pickup MW, Mouw JK, Weaver VM| | PubMed
  106. Extracellular matrix assembly: a multiscale deconstruction.
    Mouw JK, Ou G, Weaver VM| | PubMed
  107. The microenvironment matters.
    Weaver VM| | PubMed
  108. Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate.
    Rubashkin MG, Cassereau L, Bainer R, DuFort CC, Yui Y, Ou G, Paszek MJ, Davidson MW, Chen YY, Weaver VM| | PubMed
  109. Multicellular architecture of malignant breast epithelia influences mechanics.
    Venugopalan G, Camarillo DB, Webster KD, Reber CD, Sethian JA, Weaver VM, Fletcher DA, El-Samad H, Rycroft CH| | PubMed
  110. The cancer glycocalyx mechanically primes integrin-mediated growth and survival.
    Paszek MJ, DuFort CC, Rossier O, Bainer R, Mouw JK, Godula K, Hudak JE, Lakins JN, Wijekoon AC, Cassereau L, Rubashkin MG, Magbanua MJ, Thorn KS, Davidson MW, Rugo HS, Park JW, Hammer DA, Giannone G, Bertozzi CR, Weaver VM| | PubMed
  111. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.
    Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R| | PubMed
  112. Understanding tissue context influences on intratumour heterogeneity.
    Michor F, Weaver VM| | PubMed
  113. Deconstructing signaling in three dimensions.
    Rubashkin MG, Ou G, Weaver VM| | PubMed
  114. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression.
    Mouw JK, Yui Y, Damiano L, Bainer RO, Lakins JN, Acerbi I, Ou G, Wijekoon AC, Levental KR, Gilbert PM, Hwang ES, Chen YY, Weaver VM| | PubMed
  115. Rapid disorganization of mechanically interacting systems of mammary acini.
    Shi Q, Ghosh RP, Engelke H, Rycroft CH, Cassereau L, Sethian JA, Weaver VM, Liphardt JT| | PubMed
  116. Cell biology. Strength under tension.
    Bainer R, Weaver V| | PubMed
  117. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.
    Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL| | PubMed
  118. Collagen architecture in pregnancy-induced protection from breast cancer.
    Maller O, Hansen KC, Lyons TR, Acerbi I, Weaver VM, Prekeris R, Tan AC, Schedin P| | PubMed
  119. Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin.
    Damiano L, Stewart KM, Cohet N, Mouw JK, Lakins JN, Debnath J, Reisman D, Nickerson JA, Imbalzano AN, Weaver VM| | PubMed
  120. YAP forces fibroblasts to feel the tension.
    Maller O, DuFort CC, Weaver VM| | PubMed
  121. MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis.
    Tang Y, Rowe RG, Botvinick EL, Kurup A, Putnam AJ, Seiki M, Weaver VM, Keller ET, Goldstein S, Dai J, Begun D, Saunders T, Weiss SJ| | PubMed
  122. A physical sciences network characterization of non-tumorigenic and metastatic cells.
    Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH| | PubMed
  123. Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer.
    Li CR, Su JJ, Wang WY, Lee MT, Wang TY, Jiang KY, Li CF, Hsu JM, Chen CK, Chen M, Jiang SS, Weaver VM, Tsai KK| | PubMed
  124. Scanning angle interference microscopy reveals cell dynamics at the nanoscale.
    Paszek MJ, DuFort CC, Rubashkin MG, Davidson MW, Thorn KS, Liphardt JT, Weaver VM| | PubMed
  125. Morphogenesis: Laying down the tracks.
    Cassereau L, DuFort CC, Weaver VM| | PubMed
  126. The extracellular matrix: a dynamic niche in cancer progression.
    Lu P, Weaver VM, Werb Z| | PubMed
  127. Exploring the link between human embryonic stem cell organization and fate using tension-calibrated extracellular matrix functionalized polyacrylamide gels.
    Lakins JN, Chin AR, Weaver VM| | PubMed
  128. Extracellular matrix degradation and remodeling in development and disease.
    Lu P, Takai K, Weaver VM, Werb Z| | PubMed
  129. In situ force mapping of mammary gland transformation.
    Lopez JI, Kang I, You WK, McDonald DM, Weaver VM| | PubMed
  130. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth.
    Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, Munro J, Schröder E, Zhou J, Brunton VG, Barker N, Clevers H, Sansom OJ, Anderson KI, Weaver VM, Olson MF| | PubMed
  131. Valerie Weaver: overcoming cancer's stiff resistance. Interview by Caitlin Sedwick.
    Weaver V| | PubMed
  132. Balancing forces: architectural control of mechanotransduction.
    DuFort CC, Paszek MJ, Weaver VM| | PubMed
  133. Tumor microenvironment and progression.
    Dvorak HF, Weaver VM, Tlsty TD, Bergers G| | PubMed
  134. Engineering strategies to recapitulate epithelial morphogenesis within synthetic three-dimensional extracellular matrix with tunable mechanical properties.
    Miroshnikova YA, Jorgens DM, Spirio L, Auer M, Sarang-Sieminski AL, Weaver VM| | PubMed
  135. The extracellular matrix at a glance.
    Frantz C, Stewart KM, Weaver VM| | PubMed
  136. Effect of substrate stiffness and PDGF on the behavior of vascular smooth muscle cells: implications for atherosclerosis.
    Brown XQ, Bartolak-Suki E, Williams C, Walker ML, Weaver VM, Wong JY| | PubMed
  137. Forcing form and function: biomechanical regulation of tumor evolution.
    Yu H, Mouw JK, Weaver VM| | PubMed
  138. Dynamic interplay between the collagen scaffold and tumor evolution.
    Egeblad M, Rasch MG, Weaver VM| | PubMed
  139. SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells.
    Cohet N, Stewart KM, Mudhasani R, Asirvatham AJ, Mallappa C, Imbalzano KM, Weaver VM, Imbalzano AN, Nickerson JA| | PubMed
  140. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.
    Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver VM| | PubMed
  141. Biophysics. Enforcing order on signaling.
    Paszek M, Weaver V| | PubMed
  142. Integrin clustering is driven by mechanical resistance from the glycocalyx and the substrate.
    Paszek MJ, Boettiger D, Weaver VM, Hammer DA| | PubMed
  143. Matrix crosslinking forces tumor progression by enhancing integrin signaling.
    Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL, Weaver VM| | PubMed
  144. Mechanics, malignancy, and metastasis: the force journey of a tumor cell.
    Kumar S, Weaver VM| | PubMed
  145. Filamin A-beta1 integrin complex tunes epithelial cell response to matrix tension.
    Gehler S, Baldassarre M, Lad Y, Leight JL, Wozniak MA, Riching KM, Eliceiri KW, Weaver VM, Calderwood DA, Keely PJ| | PubMed
  146. The tissue diagnostic instrument.
    Hansma P, Yu H, Schultz D, Rodriguez A, Yurtsev EA, Orr J, Tang S, Miller J, Wallace J, Zok F, Li C, Souza R, Proctor A, Brimer D, Nogues-Solan X, Mellbovsky L, Peña MJ, Diez-Ferrer O, Mathews P, Randall C, Kuo A, Chen C, Peters M, Kohn D, Buckley J, Li X, Pruitt L, Diez-Perez A, Alliston T, Weaver V, Lotz J| | PubMed
  147. Multiscale modeling of form and function.
    Engler AJ, Humbert PO, Wehrle-Haller B, Weaver VM| | PubMed
  148. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis.
    Vasilatos SN, Broadwater G, Barry WT, Baker JC, Lem S, Dietze EC, Bean GR, Bryson AD, Pilie PG, Goldenberg V, Skaar D, Paisie C, Torres-Hernandez A, Grant TL, Wilke LG, Ibarra-Drendall C, Ostrander JH, D'Amato NC, Zalles C, Jirtle R, Weaver VM, Seewaldt VL| | PubMed
  149. A tense situation: forcing tumour progression.
    Butcher DT, Alliston T, Weaver VM| | PubMed
  150. Biomechanical regulation of cell orientation and fate.
    Lopez JI, Mouw JK, Weaver VM| | PubMed
  151. Three-dimensional context regulation of metastasis.
    Erler JT, Weaver VM| | PubMed
  152. A human breast cell model of preinvasive to invasive transition.
    Rizki A, Weaver VM, Lee SY, Rozenberg GI, Chin K, Myers CA, Bascom JL, Mott JD, Semeiks JR, Grate LR, Mian IS, Borowsky AD, Jensen RA, Idowu MO, Chen F, Chen DJ, Petersen OW, Gray JW, Bissell MJ| | PubMed
  153. Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion.
    Fournier AK, Campbell LE, Castagnino P, Liu WF, Chung BM, Weaver VM, Chen CS, Assoian RK| | PubMed
  154. Integrin-mediated signalling through the MAP-kinase pathway.
    Yee KL, Weaver VM, Hammer DA| | PubMed
  155. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures.
    Hebner C, Weaver VM, Debnath J| | PubMed
  156. alpha6beta4 integrin activates Rac-dependent p21-activated kinase 1 to drive NF-kappaB-dependent resistance to apoptosis in 3D mammary acini.
    Friedland JC, Lakins JN, Kazanietz MG, Chernoff J, Boettiger D, Weaver VM| | PubMed
  157. G'rab'bing the microenvironment for invasion.
    Weaver V, Werb Z| | PubMed
  158. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis.
    Kass L, Erler JT, Dembo M, Weaver VM| | PubMed
  159. Demystifying the effects of a three-dimensional microenvironment in tissue morphogenesis.
    Johnson KR, Leight JL, Weaver VM| | PubMed
  160. The ultrastructure of MCF-10A acini.
    Underwood JM, Imbalzano KM, Weaver VM, Fischer AH, Imbalzano AN, Nickerson JA| | PubMed
  161. Forcing the third dimension.
    Boudreau N, Weaver V| | PubMed
  162. Analysis of protein expression during oxidative stress in breast epithelial cells using a stable isotope labeled proteome internal standard.
    Yan Y, Weaver VM, Blair IA| | PubMed
  163. Tensional homeostasis and the malignant phenotype.
    Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM| | PubMed
  164. Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin.
    Yang C, Liu Y, Leskow FC, Weaver VM, Kazanietz MG| | PubMed
  165. Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression.
    Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC| | PubMed
  166. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion.
    Yeung T, Georges PC, Flanagan LA, Marg B, Ortiz M, Funaki M, Zahir N, Ming W, Weaver V, Janmey PA| | PubMed
  167. The tension mounts: mechanics meets morphogenesis and malignancy.
    Paszek MJ, Weaver VM| | PubMed
  168. Watch thy neighbor: cancer is a communal affair.
    Weaver VM, Gilbert P| | PubMed
  169. Death in the third dimension: apoptosis regulation and tissue architecture.
    Zahir N, Weaver VM| | PubMed
  170. Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors.
    Zahir N, Lakins JN, Russell A, Ming W, Chatterjee C, Rozenberg GI, Marinkovich MP, Weaver VM| | PubMed
  171. Alpha 6 beta 4 integrin regulates keratinocyte chemotaxis through differential GTPase activation and antagonism of alpha 3 beta 1 integrin.
    Russell AJ, Fincher EF, Millman L, Smith R, Vela V, Waterman EA, Dey CN, Guide S, Weaver VM, Marinkovich MP| | PubMed
  172. The tissue microenvironment as an epigenetic tumor modifier.
    Unger M, Weaver VM| | PubMed
  173. The organizing principle: microenvironmental influences in the normal and malignant breast.
    Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW| | PubMed
  174. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.
    Weaver VM, Lelièvre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ| | PubMed
  175. Membrane-associated MMP regulators: novel cell adhesion tumor suppressor proteins?
    Weaver VM| | PubMed
  176. Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation.
    Chrenek MA, Wong P, Weaver VM| | PubMed
  177. Lack of specificity of trans,trans-muconic acid as a benzene biomarker after ingestion of sorbic acid-preserved foods.
    Weaver VM, Buckley T, Groopman JD| | PubMed
  178. E7-transduced human breast epithelial cells show partial differentiation in three-dimensional culture.
    Spancake KM, Anderson CB, Weaver VM, Matsunami N, Bissell MJ, White RL| | PubMed
  179. Constitutive expression of Heregulin induces apoptosis in an erbB-2 overexpressing breast cancer cell line SKBr-3.
    Guerra-Vladusic FK, Scott G, Weaver V, Vladusic EA, Tsai MS, Benz CC, Lupu R| | PubMed
  180. Functional culture models to study mechanisms governing apoptosis in normal and malignant mammary epithelial cells.
    Weaver VM, Bissell MJ| | PubMed
  181. Tissue structure, nuclear organization, and gene expression in normal and malignant breast.
    Bissell MJ, Weaver VM, Lelièvre SA, Wang F, Petersen OW, Schmeichel KL| | PubMed
  182. Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology.
    Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, Bissell MJ| | PubMed
  183. Tissue phenotype depends on reciprocal interactions between the extracellular matrix and the structural organization of the nucleus.
    Lelièvre SA, Weaver VM, Nickerson JA, Larabell CA, Bhaumik A, Petersen OW, Bissell MJ| | PubMed
  184. Structural cues from the tissue microenvironment are essential determinants of the human mammary epithelial cell phenotype.
    Schmeichel KL, Weaver VM, Bissell MJ| | PubMed
  185. Differentiation and cancer in the mammary gland: shedding light on an old dichotomy.
    Petersen OW, Rønnov-Jessen L, Weaver VM, Bissell MJ| | PubMed
  186. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.
    Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ| | PubMed
  187. Extracellular matrix: the central regulator of cell and tissue homeostasis.
    Weaver VM, Roskelley CD| | PubMed
  188. Degradation of nuclear matrix and DNA cleavage in apoptotic thymocytes.
    Weaver VM, Carson CE, Walker PR, Chaly N, Lach B, Raymond Y, Brown DL, Sikorska M| | PubMed
  189. Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation.
    Lelièvre S, Weaver VM, Bissell MJ| | PubMed
  190. The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay.
    Weaver VM, Fischer AH, Peterson OW, Bissell MJ| | PubMed
  191. The development of a functionally relevant cell culture model of progressive human breast cancer.
    Weaver VM, Howlett AR, Langton-Webster B, Petersen OW, Bissell MJ| | PubMed
  192. Role of proteolysis in apoptosis: involvement of serine proteases in internucleosomal DNA fragmentation in immature thymocytes.
    Weaver VM, Lach B, Walker PR, Sikorska M| | PubMed
View Lab Site
yauchristina
Christina Yau, PhD

Professor of Surgery
Division of Surgical Oncology

Section:
Breast Surgery
Research Interests

Bioinformatics methods for evaluating clinical outcomes and biomarker discovery for personalized therapies in breast cancer

Research Type:
Basic Biomedical and Translational
Disease focus:
Bioinformatics approaches for personalized breast cancer therapy
View Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 118
  1. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, Brabham C, Yau C, Rosenbluth JM, Hirst GL, Campbell MJ, Borowsky A, Hylton N, Esserman LJ, Basu A| | PubMed
  2. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
    Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  3. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
    Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ| | PubMed
  4. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, Brown-Swigart L, Yau C, O'Grady N, Basu A, Lu R, Campbell MJ, Magbanua MJ, Coppé JP, I-SPY 2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Pohlmann PR, Hirst GL, Esserman LJ, van 't Veer LJ, Petricoin EF| | PubMed
  5. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM, Forero-Torres A, Pusztai L, Ellis ED, Albain KS, Blaes AH, Haley BB, Boughey JC, Elias AD, Clark AS, Isaacs CJ, Nanda R, Han HS, Yung RL, Tripathy D, Edmiston KK, Viscusi RK, Northfelt DW, Khan QJ, Asare SM, Wilson A, Hirst GL, Lu R, Symmans WF, Yee D, DeMichele AM, van 't Veer LJ, Esserman LJ, Olopade OI| | PubMed
  6. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, Li W, Price ER, Joe BN, Kornak J, Esserman LJ, Newitt DC, Hylton NM, I-SPY 2 Imaging Working Group, I-SPY 2 Investigator Network| | PubMed
  7. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.
    Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M| | PubMed
  8. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    Mukhtar RA, Yau C, Esserman LJ| | PubMed
  9. Development and testing of a polygenic risk score for breast cancer aggressiveness.
    Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer LV, Esserman LJ, Ziv E| | PubMed
  10. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ| | PubMed
  11. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ| | PubMed
  12. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.
    Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A| | PubMed
  13. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, Yau C, Wolf D, Park J, Parker BA, Chien AJ, Wallace AM, Murthy R, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Yung RL, Isaacs C, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Stringer-Reasor E, Price E, Joe B, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Buxton M, Clennell JL, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Melisko M, Perlmutter J, Rugo HS, Symmans WF, van 't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  14. Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A| | PubMed
  15. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA| | PubMed
  16. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
    Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS| | PubMed
  17. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.
    Lee JV, Housley F, Yau C, Nakagawa R, Winkler J, Anttila JM, Munne PM, Savelius M, Houlahan KE, Van de Mark D, Hemmati G, Hernandez GA, Zhang Y, Samson S, Baas C, Kok M, Esserman LJ, van 't Veer LJ, Rugo HS, Curtis C, Klefström J, Matloubian M, Goga A| | PubMed
  18. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ| | PubMed
  19. Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Marczyk M, Mrukwa A, Yau C, Wolf D, Chen YY, Balassanian R, Nanda R, Parker BA, Krings G, Sattar H, Zeck JC, Albain KS, Boughey JC, Liu MC, Elias AD, Clark AS, Venters SJ, Shad S, Basu A, Asare SM, Buxton M, Asare AL, Rugo HS, Perlmutter J, DeMichele AM, Yee D, Berry DA, Veer LV, Symmans WF, Esserman L, Pusztai L, I-SPY Consortium| | PubMed
  20. Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
    Johansson A, Yu NY, Iftimi A, Tobin NP, van 't Veer L, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, Esserman LJ, Yau C, Lindström LS| | PubMed
  21. Survivorship after neoadjuvant chemotherapy - Authors' reply.
    Yau C, Osdoit M, Esserman LJ, Symmans WF| | PubMed
  22. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF| | PubMed
  23. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
    Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM| | PubMed
  24. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A| | PubMed
  25. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ| | PubMed
  26. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ| | PubMed
  27. The WISDOM study: a new approach to screening can and should be tested.
    Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M| | PubMed
  28. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
    Onishi N, Li W, Newitt DC, Harnish RJ, Strand F, Nguyen AA, Arasu VA, Gibbs J, Jones EF, Wilmes LJ, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard S, Umphrey HR, Nelson MT, Church AL, Bolan PJ, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez Paniagua D, Hardesty L, Brandt KR, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane E, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica LA, Niell B, Drukteinis J, Newell MS, Giurescu ME, Berman E, Lehman CD, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau SH, Chenevert T, Yau C, DeMichele A, Berry DA, Esserman LJ, Hylton NM| | PubMed
  29. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
    Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ| | PubMed
  30. PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.
    O'Grady N, Gibbs DL, Abdilleh K, Asare A, Asare S, Venters S, Brown-Swigart L, Hirst GL, Wolf D, Yau C, van 't Veer LJ, Esserman L, Basu A| | PubMed
  31. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS| | PubMed
  32. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
    Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, Newitt DC, Gibbs J, Delson AL, Kalashnikova E, Aleshin A, Zimmermann B, Chien AJ, Tripathy D, Esserman L, Hylton N, van 't Veer L| | PubMed
  33. Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.
    Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, June-Koo Lee J, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N, TCGA Research Network, Meyerson M, Govindan R, Imielinski M| | PubMed
  34. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy.
    Du L, Yau C, Brown-Swigart L, Gould R, Krings G, Hirst GL, Bedrosian I, Layman RM, Carter JM, Klein M, Venters S, Shad S, van der Noordaa M, Chien AJ, Haddad T, Isaacs C, Pusztai L, Albain K, Nanda R, Tripathy D, Liu MC, Boughey J, Schwab R, Hylton N, DeMichele A, Perlmutter J, Yee D, Berry D, Van't Veer L, Valero V, Esserman LJ, Symmans WF| | PubMed
  35. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway.
    Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, Lee JJ, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N, TCGA Research Network, Meyerson M, Govindan R, Imielinski M| | PubMed
  36. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
    Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, Strand F, Onishi N, Nguyen AA, Kornak J, Joe BN, Price ER, Ojeda-Fournier H, Eghtedari M, Zamora KW, Woodard SA, Umphrey H, Bernreuter W, Nelson M, Church AL, Bolan P, Kuritza T, Ward K, Morley K, Wolverton D, Fountain K, Lopez-Paniagua D, Hardesty L, Brandt K, McDonald ES, Rosen M, Kontos D, Abe H, Sheth D, Crane EP, Dillis C, Sheth P, Hovanessian-Larsen L, Bang DH, Porter B, Oh KY, Jafarian N, Tudorica A, Niell BL, Drukteinis J, Newell MS, Cohen MA, Giurescu M, Berman E, Lehman C, Partridge SC, Fitzpatrick KA, Borders MH, Yang WT, Dogan B, Goudreau S, Chenevert T, Yau C, DeMichele A, Berry D, Esserman LJ, Hylton NM| | PubMed
  37. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, Tin A, Salari R, Shchegrova S, Pawar H, Delson AL, DeMichele A, Liu MC, Chien AJ, Tripathy D, Asare S, Lin CJ, Billings P, Aleshin A, Sethi H, Louie M, Zimmermann B, Esserman LJ, van 't Veer LJ| | PubMed
  38. Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.
    Hyland CJ, Varghese F, Yau C, Beckwith H, Khoury K, Varnado W, Hirst GL, Flavell RR, Chien AJ, Yee D, Isaacs CJ, Forero-Torres A, Esserman LJ, Melisko ME| | PubMed
  39. The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
    Basu A, Philip EJ, Dewitt B, Hanmer J, Chattopadhyay A, Yau C, Melisko ME, Esserman LJ| | PubMed
  40. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Magbanua MJM, O'Grady N, Hirst G, I-SPY 2 TRIAL Investigators, Asare S, Tripathy D, Berry D, Esserman L, Chien AJ, Petricoin EF, van 't Veer L| | PubMed
  41. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA| | PubMed
  42. A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population.
    Kang T, Yau C, Wong CK, Sanborn JZ, Newton Y, Vaske C, Benz SC, Krings G, Camarda R, Henry JE, Stuart J, Powell M, Benz CC| | PubMed
  43. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer.
    Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, Frampton GM, Han S, Hoadley KA, Kemal A, Laird PW, Lazar AJ, Le X, Oak N, Shen H, Wong CK, Zenklusen JC, Ziv E, Cancer Genome Atlas Analysis Network, Cherniack AD, Beroukhim R| | PubMed
  44. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ| | PubMed
  45. Response to Carter et al.
    Eklund M, Broglio K, Yau C, Connor JT, Fiscalini AS, Esserman LJ| | PubMed
  46. Androgen receptor gene expression in primary breast cancer.
    Vidula N, Yau C, Wolf D, Rugo HS| | PubMed
  47. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
    Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS| | PubMed
  48. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
    Yu K, Chen B, Aran D, Charalel J, Yau C, Wolf DM, van 't Veer LJ, Butte AJ, Goldstein T, Sirota M| | PubMed
  49. Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.
    Scott GK, Yau C, Becker BC, Khateeb S, Mahoney S, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC| | PubMed
  50. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
    Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ| | PubMed
  51. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
    Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, Bowlby-Yoder E, Hwang ES, Alvarado M, Ewing CA, Delson AL, Van't Veer LJ, Esserman L, Park JW| | PubMed
  52. A response to "Personalised medicine and population health: breast and ovarian cancer".
    Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E| | PubMed
  53. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ, I-SPY 2 Consortium| | PubMed
  54. The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches.
    Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscalini A, Esserman LJ| | PubMed
  55. Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.
    Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton N, Symmans F, Yee D, Esserman L, Berry D, Liu M, Park JW, Wessels LFA, Van't Veer L, Petricoin EF| | PubMed
  56. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ, STO Trialists Group| | PubMed
  57. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.
    Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM, Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW| | PubMed
  58. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
    Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I, Cancer Genome Atlas Research Network, Monnat RJ, Xiao Y, Wang C| | PubMed
  59. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.
    Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK, Cancer Genome Atlas Research Network, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C| | PubMed
  60. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
    Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R| | PubMed
  61. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
    Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE| | PubMed
  62. Discovery of internalizing antibodies to basal breast cancer cells.
    Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD| | PubMed
  63. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.
    Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF, Hylton N, Park CC| | PubMed
  64. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
    Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS| | PubMed
  65. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L| | PubMed
  66. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L| | PubMed
  67. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
    Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, TCGA Research Network, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE| | PubMed
  68. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS| | PubMed
  69. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY| | PubMed
  70. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).
    Vidula N, Yau C, Li J, Esserman LJ, Rugo HS| | PubMed
  71. Integrated genomic and molecular characterization of cervical cancer.
    Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center &Research Institute at Christiana Care Health Services, HudsonAlpha Institute for Biotechnology, ILSbio, LLC, Indiana University School of Medicine, Institute of Human Virology, Institute for Systems Biology, International Genomics Consortium, Leidos Biomedical, Massachusetts General Hospital, McDonnell Genome Institute at Washington University, Medical College of Wisconsin, Medical University of South Carolina, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NantOmics, National Cancer Institute, National Hospital, Abuja, Nigeria, National Human Genome Research Institute, National Institute of Environmental Health Sciences, National Institute on Deafness &Other Communication Disorders, Ontario Tumour Bank, London Health Sciences Centre, Ontario Tumour Bank, Ontario Institute for Cancer Research, Ontario Tumour Bank, The Ottawa Hospital, Oregon Health &Science University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SRA International, St Joseph's Candler Health System, Eli &Edythe L. Broad Institute of Massachusetts Institute of Technology &Harvard University, Research Institute at Nationwide Children's Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of Bergen, University of Texas MD Anderson Cancer Center, University of Abuja Teaching Hospital, University of Alabama at Birmingham, University of California, Irvine, University of California Santa Cruz, University of Kansas Medical Center, University of Lausanne, University of New Mexico Health Sciences Center, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, University of Pittsburgh, University of São Paulo, Ribeir ão Preto Medical School, University of Southern California, University of Washington, University of Wisconsin School of Medicine &Public Health, Van Andel Research Institute, Washington University in St Louis| | PubMed
  72. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C| | PubMed
  73. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
    Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, Corella AN, Eyob H, Kessenbrock K, Lawson DA, Marsh LA, Anderton BN, Rohrberg J, Kunder R, Bazarov AV, Yaswen P, McManus MT, Rugo HS, Werb Z, Goga A| | PubMed
  74. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA, I-SPY 2 Investigators| | PubMed
  75. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ, I-SPY 2 Investigators| | PubMed
  76. DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas.
    Troester MA, Hoadley KA, D'Arcy M, Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen H, Wilkerson MD, Sandhu R, Johnson NB, Allison KH, Beck AH, Yau C, Bowen J, Sheth M, Hwang ES, Perou CM, Laird PW, Ding L, Benz CC| | PubMed
  77. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
    Si H, Lu H, Yang X, Mattox A, Jang M, Bian Y, Sano E, Viadiu H, Yan B, Yau C, Ng S, Lee SK, Romano RA, Davis S, Walker RL, Xiao W, Sun H, Wei L, Sinha S, Benz CC, Stuart JM, Meltzer PS, Van Waes C, Chen Z| | PubMed
  78. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply.
    Esserman L, Yau C| | PubMed
  79. An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.
    Olow A, Chen Z, Niedner RH, Wolf DM, Yau C, Pankov A, Lee EP, Brown-Swigart L, van 't Veer LJ, Coppé JP| | PubMed
  80. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
    Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN| | PubMed
  81. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
    Yau C, Meyer L, Benz S, Vaske C, Scott G, Egan B, Labhart P, Pourmand N, Benz CC| | PubMed
  82. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
    Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, TCGA Research Network, Perou CM| | PubMed
  83. Rethinking the Standard for Ductal Carcinoma In Situ Treatment.
    Esserman L, Yau C| | PubMed
  84. DGCR8 is essential for tumor progression following PTEN loss in the prostate.
    Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R| | PubMed
  85. First Pregnancy Characteristics, Postmenopausal Breast Density, and Salivary Sex Hormone Levels in a Population at High Risk for Breast Cancer.
    Mockus M, Prebil L, Ereman R, Dollbaum C, Powell M, Yau C, Benz CC| | PubMed
  86. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.
    Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, I-SPY 1 TRIAL Investigators, Esserman L, Park JW, van 't Veer LJ| | PubMed
  87. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
    DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ| | PubMed
  88. Comprehensive genomic characterization of head and neck squamous cell carcinomas.
    Cancer Genome Atlas Network| | PubMed
  89. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.
    Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S| | PubMed
  90. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.
    Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MDM, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van't Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research Network, Benz CC, Perou CM, Stuart JM| | PubMed
  91. RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth.
    Wilson-Edell KA, Kehasse A, Scott GK, Yau C, Rothschild DE, Schilling B, Gabriel BS, Yevtushenko MA, Hanson IM, Held JM, Gibson BW, Benz CC| | PubMed
  92. Comprehensive molecular profiling of lung adenocarcinoma.
    Cancer Genome Atlas Research Network| | PubMed
  93. Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).
    Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ| | PubMed
  94. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.
    Wolf DM, Lenburg ME, Yau C, Boudreau A, van 't Veer LJ| | PubMed
  95. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ| | PubMed
  96. Comprehensive molecular characterization of clear cell renal cell carcinoma.
    Cancer Genome Atlas Research Network| | PubMed
  97. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ| | PubMed
  98. Integrated genomic characterization of endometrial carcinoma.
    Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA| | PubMed
  99. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.
    Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC| | PubMed
  100. Comprehensive molecular portraits of human breast tumours.
    Cancer Genome Atlas Network| | PubMed
  101. Comprehensive genomic characterization of squamous cell lung cancers.
    Cancer Genome Atlas Research Network| | PubMed
  102. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E, I-SPY TRIAL Investigators| | PubMed
  103. Comprehensive molecular characterization of human colon and rectal cancer.
    Cancer Genome Atlas Network| | PubMed
  104. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N| | PubMed
  105. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N, I-SPY 1 TRIAL Investigators| | PubMed
  106. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ, I-SPY TRIAL Investigators| | PubMed
  107. Integrated genomic analyses of ovarian carcinoma.
    Cancer Genome Atlas Research Network| | PubMed
  108. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC| | PubMed
  109. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
    Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH| | PubMed
  110. Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers.
    Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC| | PubMed
  111. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC| | PubMed
  112. Ageing, oxidative stress and cancer: paradigms in parallax.
    Benz CC, Yau C| | PubMed
  113. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C, Benz CC| | PubMed
  114. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
    Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC| | PubMed
  115. Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.
    Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC| | PubMed
  116. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
    Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC| | PubMed
  117. Novel pathways associated with quinone-induced stress in breast cancer cells.
    Benz CC, Atsriku C, Yau C, Britton D, Schilling B, Gibson BW, Baldwin MA, Scott GK| | PubMed
  118. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.
    Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC| | PubMed